{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4",
      "authorship_tag": "ABX9TyOSMieKzMUBcgQw8i7jAigh"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "collapsed": true,
        "id": "dxqrpxxw2lGL",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "448b79bd-906b-4a96-a6c8-158d6aa94b05"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/86.0 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[91m━━━━━━━━━━━━━━\u001b[0m\u001b[90m╺\u001b[0m\u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m30.7/86.0 kB\u001b[0m \u001b[31m773.8 kB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K     \u001b[91m━━━━━━━━━━━━━━━━━━━\u001b[0m\u001b[90m╺\u001b[0m\u001b[90m━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m41.0/86.0 kB\u001b[0m \u001b[31m739.1 kB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m86.0/86.0 kB\u001b[0m \u001b[31m918.4 kB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m21.3/21.3 MB\u001b[0m \u001b[31m23.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Building wheel for sentence-transformers (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m15.8/15.8 MB\u001b[0m \u001b[31m42.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m75.6/75.6 kB\u001b[0m \u001b[31m8.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m327.5/327.5 kB\u001b[0m \u001b[31m29.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.1/1.1 MB\u001b[0m \u001b[31m50.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m77.9/77.9 kB\u001b[0m \u001b[31m9.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m6.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m49.2/49.2 kB\u001b[0m \u001b[31m4.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m60.0/60.0 kB\u001b[0m \u001b[31m223.4 kB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h"
          ]
        }
      ],
      "source": [
        " #visualization tool for displaying long load/processing times\n",
        "!pip install tqdm --quiet\n",
        "#data processing\n",
        "!pip install pandas --quiet\n",
        "#workhorse for converting text into embeddings/vectors\n",
        "!pip install sentence-transformers==2.2.2 --quiet\n",
        "#data framework for LLM applications\n",
        "!pip install llama-index==0.9.29  --quiet\n",
        "#logging output\n",
        "!pip install loguru==0.7.0 --quiet\n",
        "#convenient pretty printing library\n",
        "!pip install rich --quiet\n",
        "#openai Tokenizer library\n",
        "!pip install tiktoken --quiet"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!curl -o Data_Med.json https://raw.githubusercontent.com/paramjeetn/Doctor_Copilot_V1/main/Data/Data_Med.json\n"
      ],
      "metadata": {
        "id": "TVNiZqzzJu_r",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "2426df10-010c-4f4a-eb19-cd8c1019fa93"
      },
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
            "                                 Dload  Upload   Total   Spent    Left  Speed\n",
            "100  101k  100  101k    0     0   443k      0 --:--:-- --:--:-- --:--:--  442k\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%load_ext autoreload\n",
        "%autoreload 2\n",
        "\n",
        "#standard libraries\n",
        "import sys\n",
        "sys.path.append('../')\n",
        "\n",
        "import json\n",
        "import os\n",
        "import time\n",
        "from typing import List, Tuple\n",
        "from math import ceil\n",
        "\n",
        "#external libraries\n",
        "import pandas as pd\n",
        "import numpy as np\n",
        "from rich import print\n",
        "from rich.pretty import pprint #nifty library for pretty printing\n",
        "from torch import cuda\n",
        "from tqdm import tqdm\n",
        "\n"
      ],
      "metadata": {
        "id": "rVxDl7MJKs6A",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "7541947c-95fe-4086-c55d-992d27dcbb3f"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The autoreload extension is already loaded. To reload it, use:\n",
            "  %reload_ext autoreload\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#root folder on Google Colab is: /content/\n",
        "root_folder = '/content/'  #'../data'\n",
        "data_file = 'Data_Med.json'\n",
        "data_path = os.path.join(root_folder, data_file)\n"
      ],
      "metadata": {
        "id": "-Y9k7OPOK1Px"
      },
      "execution_count": 17,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def load_json(file_path: str) -> list[dict]:\n",
        "  with open(file_path) as f:\n",
        "    data = json.load(f)\n",
        "  return data\n",
        "\n",
        "data = load_json(data_path)\n",
        "print(f'Total # of papers: {len(data)}')"
      ],
      "metadata": {
        "id": "WtQfbJ9dK70E",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 33
        },
        "outputId": "030810e4-bc4a-4191-95be-e2373bfc45cb"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Total # of papers: \u001b[1;36m14\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\">Total # of papers: <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">14</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(data[0])"
      ],
      "metadata": {
        "id": "4T02-Ng3LCEN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "contents = [d['content'] for d in data]\n",
        "content_lengths = [len(content.split()) for content in contents]\n",
        "df = pd.DataFrame(content_lengths, columns=['# Words'])\n",
        "df.describe()"
      ],
      "metadata": {
        "id": "wlsV5sHQNjJ5",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 300
        },
        "outputId": "b3094c28-ce27-4b89-9682-ef746604cae7"
      },
      "execution_count": 19,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "           # Words\n",
              "count    14.000000\n",
              "mean    862.285714\n",
              "std     423.422580\n",
              "min     362.000000\n",
              "25%     639.000000\n",
              "50%     789.500000\n",
              "75%    1025.750000\n",
              "max    2116.000000"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d1f11b83-4e0e-46ee-9e94-7d06914d5de5\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th># Words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>14.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>862.285714</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>423.422580</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>362.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>639.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>789.500000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>1025.750000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>2116.000000</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d1f11b83-4e0e-46ee-9e94-7d06914d5de5')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-d1f11b83-4e0e-46ee-9e94-7d06914d5de5 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-d1f11b83-4e0e-46ee-9e94-7d06914d5de5');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-b1308209-2446-4ec2-b988-166a73292e46\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b1308209-2446-4ec2-b988-166a73292e46')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-b1308209-2446-4ec2-b988-166a73292e46 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 8,\n  \"fields\": [\n    {\n      \"column\": \"# Words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 627.9957488534548,\n        \"min\": 14.0,\n        \"max\": 2116.0,\n        \"num_unique_values\": 8,\n        \"samples\": [\n          862.2857142857143,\n          789.5,\n          14.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 19
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(contents[:2])"
      ],
      "metadata": {
        "collapsed": true,
        "id": "GoKYZ7LZaL_I"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Tokenisation not needed for chroma\n",
        "from llama_index.text_splitter import SentenceSplitter #one of the best on the market\n",
        "\n",
        "#set chunk size and instantiate your SentenceSplitter\n",
        "chunk_size = 256\n",
        "gpt35_txt_splitter = SentenceSplitter(chunk_size=chunk_size, chunk_overlap=0)\n"
      ],
      "metadata": {
        "id": "UcczfWPfQker"
      },
      "execution_count": 21,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def split_contents(corpus: list[dict],\n",
        "                   text_splitter: SentenceSplitter,\n",
        "                   content_field: str='content'\n",
        "                   ) -> list[list[str]]:\n",
        "\n",
        "    return [text_splitter.split_text(d[content_field]) for d in corpus]\n"
      ],
      "metadata": {
        "id": "jf7-DAXIazSa"
      },
      "execution_count": 22,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "content_splits = split_contents(data, gpt35_txt_splitter,'content')\n",
        "print(content_splits[0])"
      ],
      "metadata": {
        "id": "xF0uG_AHa00U",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 865
        },
        "collapsed": true,
        "outputId": "4045efe5-7d62-4c35-9c78-d3709b7188db"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m[\u001b[0m\n",
              "    \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: 5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47\u001b[0m\n",
              "\u001b[32mmmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose tolerance test \u001b[0m\n",
              "\u001b[32mPrediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma glucose \u001b[0m\n",
              "\u001b[32mPrediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with classic\u001b[0m\n",
              "\u001b[32mhyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient evidence \u001b[0m\n",
              "\u001b[32mto support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'\u001b[0m,\n",
              "    \u001b[32m'• In the absence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2 diabetes \u001b[0m\n",
              "\u001b[32mrequires confirmatory testing, which can be a different test on the same day or the same test on a different day. •\u001b[0m\n",
              "\u001b[32mMarked discordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes type is not always \u001b[0m\n",
              "\u001b[32mstraightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or autoimmune β-cell \u001b[0m\n",
              "\u001b[32mdestruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin secretion frequently on\u001b[0m\n",
              "\u001b[32mthe background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at \u001b[0m\n",
              "\u001b[32m24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or \u001b[0m\n",
              "\u001b[32mchemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and\u001b[0m\n",
              "\u001b[32mtype 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a \u001b[0m\n",
              "\u001b[32mvalidated risk calculator.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 years of age ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople \u001b[0m\n",
              "\u001b[32mwith prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk medicines, or a history of \u001b[0m\n",
              "\u001b[32mpancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23 kg/m2 in Asian American \u001b[0m\n",
              "\u001b[32mindividuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ High-risk \u001b[0m\n",
              "\u001b[32mrace/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on therapy for hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ \u001b[0m\n",
              "\u001b[32mPolycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or trigylcerides >250 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>\u001b[0m\u001b[32m2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ\u001b[0m\n",
              "\u001b[32mPhysical inactivity ʜ Other clinical conditions associated with insulin resistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical Notes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results\u001b[0m\n",
              "\u001b[32mare normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those with prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or sooner with symptoms \u001b[0m\n",
              "\u001b[32mor changes in risk.'\u001b[0m,\n",
              "    \u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 diabetes should be considered after the onset of puberty or\u001b[0m\n",
              "\u001b[32mafter 10 years of age, whichever occurs earlier, in children and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mor obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: An altered \u001b[0m\n",
              "\u001b[32mrelationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: A mismatch between A1C and glycemia could be caused by \u001b[0m\n",
              "\u001b[32msome hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third trimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, glucose-6-phosphate \u001b[0m\n",
              "\u001b[32mdehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or erythropoietin therapy. \u001b[0m\n",
              "\u001b[32mPeople with HIV should be screened for diabetes and prediabetes before and 3–6 months after starting or changing \u001b[0m\n",
              "\u001b[32mantiretroviral therapy and annually if initial results are normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting plasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mcondition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for diabetes 3-6 months after an episode of acute \u001b[0m\n",
              "\u001b[32mpancreatitis and annually thereafter.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard test for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical \u001b[0m\n",
              "\u001b[32mtips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not previously \u001b[0m\n",
              "\u001b[32mdiagnosed with cystic fibrosis-related diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: \u001b[0m\n",
              "\u001b[32mPosttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for hyperglycemia after organ transplantation. \u001b[0m\n",
              "\u001b[32mPosttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive \u001b[0m\n",
              "\u001b[32mtherapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible \u001b[0m\n",
              "\u001b[32mmonogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 \u001b[0m\n",
              "\u001b[32mmonths of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who \u001b[0m\n",
              "\u001b[32moften have a family history of diabetes in successive generations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of \u001b[0m\n",
              "\u001b[32minheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.'\u001b[0m,\n",
              "    \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: \u001b[0m\n",
              "\u001b[32mTherapy with certain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Consider screening people for prediabetes or diabetes if they \u001b[0m\n",
              "\u001b[32mare on certain medications known to increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, \u001b[0m\n",
              "\u001b[32msome HIV medications, and second-generation antipsychotic medications. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test test for \u001b[0m\n",
              "\u001b[32mdiagnosing diabetes'\u001b[0m\n",
              "\u001b[1m]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">[</span>\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: 5.7–6.4% (39–47</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose tolerance test </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with classic</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient evidence </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'• In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2 diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">requires confirmatory testing, which can be a different test on the same day or the same test on a different day. •</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Marked discordance between A1C and repeated blood (B) Classification Classification of diabetes type is not always </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or autoimmune β-cell </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin secretion frequently on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes mellitus (GDM; detected at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">24–28 weeks of gestation in individuals without previously identified diabetes or high-risk glucose metabolism) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the exocrine pancreas, and drug- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 Diabetes: Screening for prediabetes and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes should be performed in asymptomatic adults with an informal assessment of risk factors or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">validated risk calculator.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 years of age ii)People </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk medicines, or a history of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian American </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals) who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ High-risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on therapy for hypertension) ʜ </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or trigylcerides &gt;250 mg/dL (&gt;2.8 mmol/L) ʜ</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Physical inactivity ʜ Other clinical conditions associated with insulin resistance (E) Clinical Notes i) If results</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are normal, repeat screening at least every 3 years (annually for those with prediabetes), or sooner with symptoms </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or changes in risk.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'ii) Risk-based screening for prediabetes or type 2 diabetes should be considered after the onset of puberty or</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after 10 years of age, whichever occurs earlier, in children and adolescents with overweight (BMI ≥85th percentile)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or obesity (BMI ≥95th percentile) who have one or more risk factors for diabetes. (F) i) (a) condition: An altered </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">relationship between A1C and glycemia (b) clinical tips: A mismatch between A1C and glycemia could be caused by </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">some hemoglobin variants, pregnancy (second and third trimesters and the postpartum period), glucose-6-phosphate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or erythropoietin therapy. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">People with HIV should be screened for diabetes and prediabetes before and 3–6 months after starting or changing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">antiretroviral therapy and annually if initial results are normal. (c) best test:Fasting plasmaglucose ii) (a) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: Acute pancreatitis (b) clinical tips: Screen for diabetes 3-6 months after an episode of acute </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pancreatitis and annually thereafter.'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test: Any standard test for diagnosing diabetes iii) (a) condition: Cystic fibrosis (b) clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not previously </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed with cystic fibrosis-related diabetes (c) best test: Oral glucose tolerance test iv) (a) condition: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation status (b) clinical tips: Screen for hyperglycemia after organ transplantation. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy and free of acute infections. (c) best test: Oral glucose tolerance test v) (a) condition: Possible </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monogenic diabetes (b) clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">months of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">often have a family history of diabetes in successive generations (suggestive of an autosomal dominant pattern of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inheritance).'</span>,\n",
              "    <span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi) (a) condition: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Therapy with certain medications (b) clinical tips: Consider screening people for prediabetes or diabetes if they </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are on certain medications known to increase diabetes risk, such as glucocorticoids, statins, thiazide diuretics, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">some HIV medications, and second-generation antipsychotic medications. (c) best test:Any standard test test for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosing diabetes'</span>\n",
              "<span style=\"font-weight: bold\">]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#helper function to capture the lengths of each split\n",
        "\n",
        "def get_split_lengths(splits: List[List[str]], column_name: str='Split Lengths') -> pd.DataFrame:\n",
        "    '''\n",
        "    Given a list of text splits, returns the length of each split\n",
        "    in a pandas DataFrame.\n",
        "    '''\n",
        "    lengths = list(map(len, splits))\n",
        "    return pd.DataFrame(lengths, columns=[column_name])"
      ],
      "metadata": {
        "id": "ny70umHJa3TY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import matplotlib.ticker as ticker\n",
        "\n",
        "column_name = 'Split Lengths'\n",
        "\n",
        "# replace None with the output from the split_contents function\n",
        "df = get_split_lengths(content_splits , column_name=column_name)\n",
        "df['Split Lengths'] = df['Split Lengths'] * chunk_size\n",
        "\n",
        "# reverse the order of the episode # to correctly show left to right chronological order\n",
        "df.index = sorted(list(df.index), reverse=True)\n",
        "# create plot\n",
        "ax = df.iloc[::-1].plot.bar(y='Split Lengths', xlabel='Papers #', ylabel='Approx. Length in Tokens', title='Paper Length (in tokens) over Time', figsize=(20,8))\n",
        "ax.xaxis.set_major_locator(ticker.MultipleLocator(1))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 722
        },
        "id": "1erANCxRa44T",
        "outputId": "e27677d5-2002-4f8c-d216-76b1383d11c0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x800 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def join_metadata(data: list[dict], content_splits: list[list[str]]) -> list[dict]:\n",
        "\n",
        "    joined_documents = []\n",
        "\n",
        "    for i, episode in enumerate(data):\n",
        "        for j, text in enumerate(content_splits[i]):\n",
        "            new_doc = {}\n",
        "            new_doc[\"doc_id\"] = data[i][\"doc_id\"]\n",
        "            new_doc[\"content_id\"] = data[i][\"doc_id\"] + \"_cont_\" + str(j+1)\n",
        "            new_doc[\"doc_name\"] = data[i][\"doc_name\"]\n",
        "            new_doc[\"summary\"] = data[i][\"Summary\"]\n",
        "            new_doc[\"content\"] = text\n",
        "            joined_documents.append(new_doc)\n",
        "\n",
        "    return joined_documents"
      ],
      "metadata": {
        "collapsed": true,
        "id": "IrAjZjAha6h6"
      },
      "execution_count": 28,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "docs = join_metadata(data, content_splits )\n",
        "print(docs)"
      ],
      "metadata": {
        "id": "Cu7LGJxUgpTK",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "outputId": "a691bb61-b17b-4fcd-9567-a4049cfc9345"
      },
      "execution_count": 29,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1m[\u001b[0m\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_1'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic Tests for Diabetes: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mA1C Prediabetes: \u001b[0m\n",
              "\u001b[32m5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47 mmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2-hour glucose value during a 75-g oral glucose \u001b[0m\n",
              "\u001b[32mtolerance test Prediabetes: 140–199 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mFasting plasma \u001b[0m\n",
              "\u001b[32mglucose Prediabetes: 100–125 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetes: ≥126 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥7.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mRandom glucose value with\u001b[0m\n",
              "\u001b[32mclassic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • There is insufficient \u001b[0m\n",
              "\u001b[32mevidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_2'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'• In the absence of unequivocal hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hyperglycemic crisis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, diagnosis of type 2\u001b[0m\n",
              "\u001b[32mdiabetes requires confirmatory testing, which can be a different test on the same day or the same test on a \u001b[0m\n",
              "\u001b[32mdifferent day. • Marked discordance between A1C and repeated blood \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification Classification of diabetes \u001b[0m\n",
              "\u001b[32mtype is not always straightforward at presentation, and misdiagnosis is common. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32midiopathic or \u001b[0m\n",
              "\u001b[32mautoimmune β-cell destruction\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mType 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnon-autoimmune progressive loss of adequate β-cell insulin \u001b[0m\n",
              "\u001b[32msecretion frequently on the background of insulin resistance and metabolic syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mGestational diabetes \u001b[0m\n",
              "\u001b[32mmellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM; detected at 24–28 weeks of gestation in individuals without previously identified diabetes or \u001b[0m\n",
              "\u001b[32mhigh-risk glucose metabolism\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDiabetes from other causes \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., monogenic diabetes syndromes, diseases of the \u001b[0m\n",
              "\u001b[32mexocrine pancreas, and drug- or chemical-induced diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32mScreening Criteria for Prediabetes and Type 2 \u001b[0m\n",
              "\u001b[32mDiabetes: Screening for prediabetes and type 2 diabetes should be performed in asymptomatic adults with an informal\u001b[0m\n",
              "\u001b[32massessment of risk factors or a validated risk calculator.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_1'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_1_cont_3'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32mInformal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Everyone ≥35 years of\u001b[0m\n",
              "\u001b[32mage ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with prior GDM iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mHistory of prediabetes iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32mPeople with HIV, exposure to high-risk medicines, or a \u001b[0m\n",
              "\u001b[32mhistory of pancreatitis. Adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥18 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with overweight or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥25 kg/m2 or ≥23 kg/m2 in Asian \u001b[0m\n",
              "\u001b[32mAmerican individuals\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ \u001b[0m\n",
              "\u001b[32mHigh-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥130/80 mmHg or on therapy for \u001b[0m\n",
              "\u001b[32mhypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Polycystic ovary syndrome ʜ HDL cholestorol \u001b[0m\u001b[32m<\u001b[0m\u001b[32m35\u001b[0m\u001b[32m mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<0.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or trigylcerides >250 mg/dL\u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m>2.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m ʜ Physical inactivity ʜ Other clinical conditions associated with insulin resistance \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical \u001b[0m\n",
              "\u001b[32mNotes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If results are normal, repeat screening at least every 3 years \u001b[0m\u001b[32m(\u001b[0m\u001b[32mannually for those with prediabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or \u001b[0m\n",
              "\u001b[32msooner with symptoms or changes in risk.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk-based screening for prediabetes or type 2 diabetes should be considered after the \u001b[0m\n",
              "\u001b[32monset of puberty or after 10 years of age, whichever occurs earlier, in children and adolescents with overweight \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have one or more risk factors for diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mcondition: An altered relationship between A1C and glycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: A mismatch between A1C and glycemia \u001b[0m\n",
              "\u001b[32mcould be caused by some hemoglobin variants, pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32msecond and third trimesters and the postpartum period\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, \u001b[0m\n",
              "\u001b[32mglucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or \u001b[0m\n",
              "\u001b[32merythropoietin therapy. People with HIV should be screened for diabetes and prediabetes before and 3–6 months after\u001b[0m\n",
              "\u001b[32mstarting or changing antiretroviral therapy and annually if initial results are normal. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Fasting \u001b[0m\n",
              "\u001b[32mplasmaglucose ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Acute pancreatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for diabetes 3-6 months after an \u001b[0m\n",
              "\u001b[32mepisode of acute pancreatitis and annually thereafter.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Any standard test for diagnosing diabetes iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Cystic fibrosis \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not \u001b[0m\n",
              "\u001b[32mpreviously diagnosed with cystic fibrosis-related diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mcondition: Posttransplantation status \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Screen for hyperglycemia after organ transplantation. \u001b[0m\n",
              "\u001b[32mPosttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive \u001b[0m\n",
              "\u001b[32mtherapy and free of acute infections. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test: Oral glucose tolerance test v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Possible \u001b[0m\n",
              "\u001b[32mmonogenic diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 \u001b[0m\n",
              "\u001b[32mmonths of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who \u001b[0m\n",
              "\u001b[32moften have a family history of diabetes in successive generations \u001b[0m\u001b[32m(\u001b[0m\u001b[32msuggestive of an autosomal dominant pattern of \u001b[0m\n",
              "\u001b[32minheritance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_1_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diagnosis and Classification of Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing \u001b[0m\n",
              "\u001b[32mvarious tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral \u001b[0m\n",
              "\u001b[32mglucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is \u001b[0m\n",
              "\u001b[32mdiagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of \u001b[0m\n",
              "\u001b[32msymptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the\u001b[0m\n",
              "\u001b[32mnecessity for confirmatory testing in ambiguous cases. The classification section details different types of \u001b[0m\n",
              "\u001b[32mdiabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is \u001b[0m\n",
              "\u001b[32mrecommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior \u001b[0m\n",
              "\u001b[32mgestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for \u001b[0m\n",
              "\u001b[32mnormal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like \u001b[0m\n",
              "\u001b[32mhemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended\u001b[0m\n",
              "\u001b[32mbased on the individual's condition and risk factors.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m condition: Therapy with certain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m clinical tips: Consider screening people for prediabetes or \u001b[0m\n",
              "\u001b[32mdiabetes if they are on certain medications known to increase diabetes risk, such as glucocorticoids, statins, \u001b[0m\n",
              "\u001b[32mthiazide diuretics, some HIV medications, and second-generation antipsychotic medications. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m best test:Any \u001b[0m\n",
              "\u001b[32mstandard test test for diagnosing diabetes'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening for Type 2 Diabetes \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Why Screen? • Lab testing is safe and cost- effective. • Screening presents an opportunity to address \u001b[0m\n",
              "\u001b[32mcardiovascular risk factors \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hypertension and dyslipidemia\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2. How to Screen • Conduct an informal \u001b[0m\n",
              "\u001b[32massessment of risk factors. –or– • Use an assessment tool such as the ADA risk test. • Consider diagnostic testing \u001b[0m\n",
              "\u001b[32mbased on assessment results. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When to Screen • Monitor people with prediabetes at least annually. • In those \u001b[0m\n",
              "\u001b[32mwithout prediabetes who have normal results, repeat screening at least every 3 years. • Screen after the onset of \u001b[0m\n",
              "\u001b[32mpuberty or after the age of 10 years in children and adolescents with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m who have at least one risk factor.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Symptoms suggestive of diabetes or changes in risk \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diet and Physical Activity \u001b[0m\n",
              "\u001b[32mRecommendations for Adults at Risk for Type 2 Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Follow a Healthy Eating Pattern • Emphasize whole \u001b[0m\n",
              "\u001b[32mgrains, legumes, nuts, fruits, and vegetables and minimize refined and processed foods • A variety of healthy \u001b[0m\n",
              "\u001b[32meating patterns include: » Mediterranean-style » Low-carbohydrate » Vegetarian or plant-based » DASH \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDietary \u001b[0m\n",
              "\u001b[32mApproaches to Stop Hypertension\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Get Regular Physical Activity • ≥150 min/week of moderate-intensity physical \u001b[0m\n",
              "\u001b[32mactivity, such as brisk walking • May include resistance or strength training • Break up prolonged sedentary time \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Where to Refer: • Refer adults with overweight or obesity who are at high risk for type 2 diabetes to a \u001b[0m\n",
              "\u001b[32mrecognized diabetes prevention lifestyle change program \u001b[0m\u001b[32m(\u001b[0m\u001b[32mcdc.gov/diabetes/prevention/find-a-program.html\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mWhat is the Diabetes Prevention Program? • The Diabetes Prevention Program \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDPP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m study demonstrated that intensive \u001b[0m\n",
              "\u001b[32mlifestyle intervention could reduce the risk of type diabetes by 58% over 3 years.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The two major goals of the DPP intensive lifestyle intervention were to achieve and maintain \u001b[0m\n",
              "\u001b[32m≥7% weight loss and ≥150 min of moderate-intensity physical activity, such as brisk walking, per week. \u001b[0m\n",
              "\u001b[32mTechnology-assisted programs using smartphones, web apps, and telehealth platforms can effectively deliver the DPP \u001b[0m\n",
              "\u001b[32mlifestyle change program, overcoming barriers, especially for low-income and rural individuals. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Person-Centered\u001b[0m\n",
              "\u001b[32mCare Goals for Individuals at Risk of Type 2 Diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m It is important to weight the individualized risks and \u001b[0m\n",
              "\u001b[32mbenefits of interventions. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Facilitate weight management in those with overweight/obesity. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Minimize \u001b[0m\n",
              "\u001b[32mprogression of hyperglycemia. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Reduce cardiovascular risk. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Consider more intensive approaches for \u001b[0m\n",
              "\u001b[32mindividuals at high risk of progression to diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m BMI ≥35 kg/m2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Higher glucose levels \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., fasting plasma glucose 110–125 mg/dL \u001b[0m\n",
              "\u001b[32m[\u001b[0m\u001b[32m6.1–6.9 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m, 2–h post-challenge glucose 173 199 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m9.6–11 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m, and A1C ≥6.0% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m42 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mHistory of gestational diabetes mellitus What medications can be prescribed to adults to prevent type 2 diabetes? \u001b[0m\n",
              "\u001b[32mThe U.S. Food and Drug Administration has not approved any drugs for diabetes prevention. Metformin has the \u001b[0m\n",
              "\u001b[32mstrongest evidence base for diabetes prevention. Who should be considered for metformin therapy to prevent type 2 \u001b[0m\n",
              "\u001b[32mdiabetes? i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Adults aged 25–59 years with a BMI ≥35 kg/m2 ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Individuals with higher fasting plasma glucose \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g.,\u001b[0m\n",
              "\u001b[32m≥110 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m≥ 6 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Those with higher A1C \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., ≥6.0% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m≥42 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Individuals with a history of \u001b[0m\n",
              "\u001b[32mgestational diabetes mellitus What parameters should be monitoring in people on metformin therapy?'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Vitamin B12 should be measured periodically, especially in those with anemia or peripheral \u001b[0m\n",
              "\u001b[32mneuropathy. Screening for type 1 diabetes? 1. Screen using autoantibodies 2. In people with preclinical type 1 \u001b[0m\n",
              "\u001b[32mdiabetes, monitor for disease progression using A1C approximately every 6 months and 75-g oral glucose tolerance \u001b[0m\n",
              "\u001b[32mtest \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi.e., fasting and 2-h plasma glucose\u001b[0m\u001b[32m)\u001b[0m\u001b[32m annually; modify frequency of monitoring based on individual risk \u001b[0m\n",
              "\u001b[32massessment based on age, number and type of autoantibodies, and glycemic metrics. Medication to delay the onset of \u001b[0m\n",
              "\u001b[32mtype 1 diabetes Teplizumab-mzwv infusion to delay the onset of symptomatic type 1 diabetes should be considered in \u001b[0m\n",
              "\u001b[32mselected individuals who are ≥8 years of age and have stage 2 type 1 diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Staging of type 1 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage 1 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: • Autoimmunity • Normoglycemia • \u001b[0m\n",
              "\u001b[32mPresymptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic criteria : • Multiple islet autoantibodies • No IGT or IFG \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage 2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mCharacteristics: • Autoimmunity • Dysglycemia • Presymptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic criteria : • Islet autoantibodies \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32musually multiple\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Dysglycemia: IFG and/or IGT • FPG 100–125 mg/dl \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–6.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • 2-h PG 140–199 mg/dl \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m7.8–11.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • A1C 5.7–6.4% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m39–47 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or ≥10% increase in A1C \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stage 3 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: • \u001b[0m\n",
              "\u001b[32mAutoimmunity • Overt hyperglycemia • Symptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnostic criteria : • Autoantibodies may become absent • \u001b[0m\n",
              "\u001b[32mDiabetes by Does statin therapy increase the risk of developing type 2 diabetes?'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_2_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Prevention or Delay of Diabetes and Associated Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'This text outlines strategies for the prevention and management of diabetes and associated \u001b[0m\n",
              "\u001b[32mcomorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is \u001b[0m\n",
              "\u001b[32mrecommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others \u001b[0m\n",
              "\u001b[32mevery three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy \u001b[0m\n",
              "\u001b[32meating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet \u001b[0m\n",
              "\u001b[32mstyles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at \u001b[0m\n",
              "\u001b[32mleast 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. \u001b[0m\n",
              "\u001b[32mMetformin is noted as the most supported pharmacological prevention for high-risk individuals, although not \u001b[0m\n",
              "\u001b[32mFDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic \u001b[0m\n",
              "\u001b[32mmetrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the \u001b[0m\n",
              "\u001b[32muse of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Statin therapy may slightly elevate type 2 diabetes risk in high-risk individuals. • In \u001b[0m\n",
              "\u001b[32mprimary and secondary prevention of cardiovascular disease, statin benefits outweigh diabetes risk. • Discontinuing\u001b[0m\n",
              "\u001b[32mstatins based on concerns about increased diabetes risk is not advised. Does pioglitazone have a role in secondary \u001b[0m\n",
              "\u001b[32mcardiovascular prevention in people at risk for type 2 diabetes? Pioglitazone could reduce stroke and myocardial \u001b[0m\n",
              "\u001b[32minfarction risks in people with a history of stroke and evidence of insulin resistance or prediabetes. However, the\u001b[0m\n",
              "\u001b[32mbenefit must be weighed against potential weight gain, edema, and increased fracture risk. Lower doses may lessen \u001b[0m\n",
              "\u001b[32mthese adverse effects.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and Adolescents'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and \u001b[0m\n",
              "\u001b[32mdevelopmentally appropriate diabetes self-management education for children and adolescents, which should be \u001b[0m\n",
              "\u001b[32mprovided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff\u001b[0m\n",
              "\u001b[32mtraining to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in \u001b[0m\n",
              "\u001b[32myouth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting \u001b[0m\n",
              "\u001b[32mplasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to \u001b[0m\n",
              "\u001b[32mrule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 \u001b[0m\n",
              "\u001b[32minhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, \u001b[0m\n",
              "\u001b[32mretinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia\u001b[0m\n",
              "\u001b[32mis crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and \u001b[0m\n",
              "\u001b[32mpharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without \u001b[0m\n",
              "\u001b[32macidosis or ketosis.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and adolescents with diabetes and their parents/caregivers should receive culturally \u001b[0m\n",
              "\u001b[32msensitive and developmentally appropriate individualized diabetes self-management education and support according \u001b[0m\n",
              "\u001b[32mto national standards at diagnosis and routinely thereafter. Recommendations for managing Type 1 diabetes are \u001b[0m\n",
              "\u001b[32mcomprehensively addressed in the ADA Standards of Care in Diabetes—2024 document. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m School and Child Care \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mYouth spend significant time in school/day care, necessitating personnel training for optimal diabetes care. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mProper care ensures optimal diabetes management and safe access to all school- or day care– sponsored \u001b[0m\n",
              "\u001b[32mopportunities. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Federal and state laws require schools, day care facilities, and other entities to provide \u001b[0m\n",
              "\u001b[32mneeded diabetes care to enable the children to safely access the school or day care environment. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Type 2 \u001b[0m\n",
              "\u001b[32mDiabetes in Youth and Adolescents \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening • Risk-based screening should be considered after the onset of \u001b[0m\n",
              "\u001b[32mpuberty or ≥10 years of age, whichever occurs earlier, in youth with overweight \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBMI ≥85th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or obesity \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mBMI ≥95th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and who have one or more additional risk factors for diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and Adolescents'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and \u001b[0m\n",
              "\u001b[32mdevelopmentally appropriate diabetes self-management education for children and adolescents, which should be \u001b[0m\n",
              "\u001b[32mprovided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff\u001b[0m\n",
              "\u001b[32mtraining to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in \u001b[0m\n",
              "\u001b[32myouth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting \u001b[0m\n",
              "\u001b[32mplasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to \u001b[0m\n",
              "\u001b[32mrule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 \u001b[0m\n",
              "\u001b[32minhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, \u001b[0m\n",
              "\u001b[32mretinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia\u001b[0m\n",
              "\u001b[32mis crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and \u001b[0m\n",
              "\u001b[32mpharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without \u001b[0m\n",
              "\u001b[32macidosis or ketosis.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diagnosis • Fasting plasma glucose, 2-h plasma glucose during a 75-g oral glucose \u001b[0m\n",
              "\u001b[32mtolerance test, and A1C can be used to diagnose prediabetes or diabetes in children and adolescents. • In those in \u001b[0m\n",
              "\u001b[32mwhom a diagnosis of type 2 diabetes is being considered, a panel of pancreatic autoantibodies should be tested to \u001b[0m\n",
              "\u001b[32mexclude the possibility of autoimmune type 1 diabetes. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Treatment • Treatment of type 2 diabetes in youth may \u001b[0m\n",
              "\u001b[32minclude: metformin, insulin, a glucaogon-like peptide 1 \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGLP-1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m receptor agonist approved for use in youth with \u001b[0m\n",
              "\u001b[32mtype 2 diabetes, and/or the sodium–glucose cotransporter 2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32mSGLT2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m inhibitor empagliflozin. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mSee figure on the next\u001b[0m\n",
              "\u001b[32mpage.\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Complications • Blood pressure should be measured at every clinic visit and treated if found to be \u001b[0m\n",
              "\u001b[32melevated on three separate measurements. • Urine albumin-to-creatinine ratio and estimated glomerular filtration \u001b[0m\n",
              "\u001b[32mrate should be obtained at the time of diagnosis then annually. • Neuropathy screening by foot exam should be done \u001b[0m\n",
              "\u001b[32mat diagnosis and then annually.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and Adolescents'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and \u001b[0m\n",
              "\u001b[32mdevelopmentally appropriate diabetes self-management education for children and adolescents, which should be \u001b[0m\n",
              "\u001b[32mprovided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff\u001b[0m\n",
              "\u001b[32mtraining to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in \u001b[0m\n",
              "\u001b[32myouth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting \u001b[0m\n",
              "\u001b[32mplasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to \u001b[0m\n",
              "\u001b[32mrule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 \u001b[0m\n",
              "\u001b[32minhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, \u001b[0m\n",
              "\u001b[32mretinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia\u001b[0m\n",
              "\u001b[32mis crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and \u001b[0m\n",
              "\u001b[32mpharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without \u001b[0m\n",
              "\u001b[32macidosis or ketosis.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Retinopathy screening by dilated fundoscopy should be done at diagnosis and then annually. • \u001b[0m\n",
              "\u001b[32mEvaluation for nonalcoholic fatty liver disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mby measuring AST and ALT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m should be done at diagnosis and then \u001b[0m\n",
              "\u001b[32mannually. • Screening for symptoms of obstructive sleep apnea should be done at each visit. • Evaluate for \u001b[0m\n",
              "\u001b[32mpolycystic ovary syndrome in female adolescents when indicated. • Lipid screening should be done after optimizing \u001b[0m\n",
              "\u001b[32mglycemia and then annually. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Addressing Probable New Cases of Type 2 Diabetes in Youth New-Onset Diabetes \u001b[0m\n",
              "\u001b[32mManagement in Youth With Overweight or Obesity and Suspected Type 2 Diabetes Initial Management: Initiate lifestyle\u001b[0m\n",
              "\u001b[32mmanagement and diabetes education for all new cases. Determine Hemoglobin A1C Levels: If A1C < 8.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32mwith no \u001b[0m\n",
              "\u001b[32macidosis or ketosis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Start treatment with Metformin, titrating up to 2,000 mg per day as tolerated. If A1C ≥ 8.5% \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mwith no acidosis or ketosis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Begin treatment with Metformin, titrating up to 2,000 mg per day as tolerated.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and Adolescents'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and \u001b[0m\n",
              "\u001b[32mdevelopmentally appropriate diabetes self-management education for children and adolescents, which should be \u001b[0m\n",
              "\u001b[32mprovided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff\u001b[0m\n",
              "\u001b[32mtraining to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in \u001b[0m\n",
              "\u001b[32myouth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting \u001b[0m\n",
              "\u001b[32mplasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to \u001b[0m\n",
              "\u001b[32mrule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 \u001b[0m\n",
              "\u001b[32minhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, \u001b[0m\n",
              "\u001b[32mretinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia\u001b[0m\n",
              "\u001b[32mis crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and \u001b[0m\n",
              "\u001b[32mpharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without \u001b[0m\n",
              "\u001b[32macidosis or ketosis.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Add long-acting insulin, starting at 0.5 units/kg/day, with titration every 2-3 days based on \u001b[0m\n",
              "\u001b[32mblood glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. For Acidosis or DKA \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDiabetic Ketoacidosis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or HHNK \u001b[0m\u001b[32m(\u001b[0m\u001b[32mHyperglycemic Hyperosmolar \u001b[0m\n",
              "\u001b[32mNonketotic Syndrome\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Manage with intravenous \u001b[0m\u001b[32m(\u001b[0m\u001b[32mIV\u001b[0m\u001b[32m)\u001b[0m\u001b[32m insulin until acidosis resolves. Transition to subcutaneous \u001b[0m\n",
              "\u001b[32minsulin following resolution, adjusting treatment as identified by the type of diabetes once antibodies are known. \u001b[0m\n",
              "\u001b[32mPancreatic Autoantibodies Testing: Negative Result: Continue or start Metformin. If using insulin, titrate dosage \u001b[0m\n",
              "\u001b[32mbased on glucose values. If A1C goals are not met: Continue Metformin. Consider adding a GLP-1 receptor agonist or \u001b[0m\n",
              "\u001b[32man SGLT2 inhibitor approved for youth with type 2 diabetes. Initiate or adjust insulin therapy. If using \u001b[0m\n",
              "\u001b[32mlong-acting insulin only and glycemic targets are not met with escalating doses, consider adding prandial insulin. \u001b[0m\n",
              "\u001b[32mTotal daily insulin dose may exceed 1 unit/kg/day. Positive Result: Continue or initiate multiple daily injections \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mMDI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m of insulin or pump therapy, as appropriate for type 1 diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_3_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Children and Adolescents'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and \u001b[0m\n",
              "\u001b[32mdevelopmentally appropriate diabetes self-management education for children and adolescents, which should be \u001b[0m\n",
              "\u001b[32mprovided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff\u001b[0m\n",
              "\u001b[32mtraining to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in \u001b[0m\n",
              "\u001b[32myouth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting \u001b[0m\n",
              "\u001b[32mplasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to \u001b[0m\n",
              "\u001b[32mrule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 \u001b[0m\n",
              "\u001b[32minhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, \u001b[0m\n",
              "\u001b[32mretinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia\u001b[0m\n",
              "\u001b[32mis crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and \u001b[0m\n",
              "\u001b[32mpharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without \u001b[0m\n",
              "\u001b[32macidosis or ketosis.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Discontinue Metformin.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes A holistic \u001b[0m\n",
              "\u001b[32mapproach to obesity management is essential, encompassing nutrition counseling, regular exercise, behavioral \u001b[0m\n",
              "\u001b[32mstrategies, and diabetes self-management education to ensure effective and sustainable results. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Management of \u001b[0m\n",
              "\u001b[32mOverweight and Obesity In people with type 2 diabetes and overweight or obesity, weight management should represent\u001b[0m\n",
              "\u001b[32ma primary goal of treatment along with glycemic management. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Weight management is crucially important because \u001b[0m\n",
              "\u001b[32mit: • Delays progression from prediabetes to type 2 diabetes • Is highly beneficial in treating type 2 diabetes • \u001b[0m\n",
              "\u001b[32mImproves glycemia and reduces the need for glucose-lowering medications • Reduces cardiovascular risk factors, \u001b[0m\n",
              "\u001b[32mlowering long-term cardiovascular and mortality risks • Reduces other obesity-related health risks iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When \u001b[0m\n",
              "\u001b[32maddressing weight management: • Use person-centered, nonjudgmental, person-first language \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., “person with \u001b[0m\n",
              "\u001b[32mdiabetes” rather than diabetic person” and “person with obesity” rather than “obese person”\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. • Calculate BMI and \u001b[0m\n",
              "\u001b[32mperform measures body fat distribution \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., waist circumference, waist-to-hip ratio, and/or waist-to-height \u001b[0m\n",
              "\u001b[32mratio\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. • Monitor obesity-related parameters at least annually to guide treatment decisions.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'LIFESTYLE MODIFICATIONS plus ANTI-OBESITY MEDICATION / METABOLIC SURGERY is PERSON-CENTERED \u001b[0m\n",
              "\u001b[32mAPPROACH \u001b[0m\u001b[32m(\u001b[0m\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Person-Centered Treatment Options for Overweight and Obesity in Type 2 Diabetes BMI Categories: \u001b[0m\n",
              "\u001b[32m25.0-26.9 kg/m² \u001b[0m\u001b[32m(\u001b[0m\u001b[32mor 23.0-24.9\u001b[0m\u001b[32m)\u001b[0m\u001b[32m* 27.0-29.9 kg/m² \u001b[0m\u001b[32m(\u001b[0m\u001b[32mor 25.0-27.4\u001b[0m\u001b[32m)\u001b[0m\u001b[32m* ≥30.0 kg/m² \u001b[0m\u001b[32m(\u001b[0m\u001b[32mor ≥27.5\u001b[0m\u001b[32m)\u001b[0m\u001b[32m* Treatment Options: \u001b[0m\n",
              "\u001b[32mIntensive Behavioral Counseling: Recommended for individuals with a BMI of: 25.0-26.9 kg/m² 27.0-29.9 kg/m² ≥30.0 \u001b[0m\n",
              "\u001b[32mkg/m² Obesity Pharmacotherapy: Recommended for individuals with a BMI of: 27.0-29.9 kg/m² ≥30.0 kg/m² Metabolic \u001b[0m\n",
              "\u001b[32mSurgery: Recommended for individuals with a BMI of ≥30.0 kg/m². Notes: The alternative BMI thresholds \u001b[0m\u001b[32m(\u001b[0m\u001b[32min \u001b[0m\n",
              "\u001b[32mparentheses\u001b[0m\u001b[32m)\u001b[0m\u001b[32m indicate adjusted values for specific populations or conditions, suggesting a more tailored approach \u001b[0m\n",
              "\u001b[32mto treatment.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The table visually indicates these recommendations with green checkmarks, confirming the \u001b[0m\n",
              "\u001b[32mappropriateness of each treatment option for each BMI category. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Recommendations Nutrition, physical activity, \u001b[0m\n",
              "\u001b[32mand behavioral therapy to achieve and maintain ≥5% weight loss are recommended for people with type 2 diabetes and \u001b[0m\n",
              "\u001b[32moverweight or obesity. Frequent counseling \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥16 sessions in 6 months\u001b[0m\u001b[32m)\u001b[0m\u001b[32m focusing on nutrition, exercise, and \u001b[0m\n",
              "\u001b[32mbehavioral strategies to achieve a 500–750 kcal/day energy deficit, is beneficial for weight loss and recommended \u001b[0m\n",
              "\u001b[32mif available. Long-term \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥1 year\u001b[0m\u001b[32m)\u001b[0m\u001b[32m weight maintenance programs are advised for those meeting weight loss goals, \u001b[0m\n",
              "\u001b[32moffering monthly support, weekly body weight monitoring, self-monitoring strategies, and regular physical activity \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m200–300 min/week\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Short-term, structured very-low-calorie diets \u001b[0m\u001b[32m(\u001b[0m\u001b[32m800–1,000 kcal/day\u001b[0m\u001b[32m)\u001b[0m\u001b[32m should be reserved for \u001b[0m\n",
              "\u001b[32mselect individuals, prescribed by trained practitioners in medical settings with close monitoring, and include \u001b[0m\n",
              "\u001b[32mcounseling for long-term weight maintenance. When developing a plan of care, consider systemic, structural, and \u001b[0m\n",
              "\u001b[32msocioeconomic factors that may affect nutrition patterns and food choices, such as food insecurity and hunger, \u001b[0m\n",
              "\u001b[32maccess to healthful food options, cultural circumstances, and other social determinants of health.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mvi\u001b[0m\u001b[32m)\u001b[0m\u001b[32mDrugs Approved for the Treatment of Obesity 1. Medication: Phentermine \u001b[0m\u001b[32m(\u001b[0m\u001b[32mSymphathomimetic \u001b[0m\n",
              "\u001b[32mamine anorectic\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Duration: Short-term treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32m12 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects: Dry mouth, insomnia, dizziness, \u001b[0m\n",
              "\u001b[32mirritability, increased blood pressure, and elevated heart rate. Possible Safety Concerns/Considerations: • \u001b[0m\n",
              "\u001b[32mContraindicated for use in combination with monoamine oxidase inhibitors 2. Medication: Orlistat \u001b[0m\u001b[32m(\u001b[0m\u001b[32mLipase inhibitor\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mDuration: Long-term treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects: Abdominal pain, flatulence, and fecal urgency. \u001b[0m\n",
              "\u001b[32mPossible Safety Concerns/Considerations: • Potential malabsorption of fat-soluble vitamins \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA, D, E and K\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and of \u001b[0m\n",
              "\u001b[32mcertain medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., cyclosporine, thyroid hormone, and anticonvulsants\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Rare cases of severe liver injury \u001b[0m\n",
              "\u001b[32mreported • Cholelithiasis • Nephrolithiasis 3.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Medication: Phentermine / Topiramate ER \u001b[0m\u001b[32m(\u001b[0m\u001b[32mSymphathomimetic amine anorectic/antiepileptic\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mDuration: Long-term treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects: Constipation, paresthesia, insomnia, \u001b[0m\n",
              "\u001b[32mnasopharyngitis, xerostomia, and increased blood pressure Possible Safety Concerns/Considerations: \\ue08c \u001b[0m\n",
              "\u001b[32mContraindicated for use in combination with monoamine oxidase inhibitors \\ue08c Birth defects \\ue08c Cognitive \u001b[0m\n",
              "\u001b[32mimpairment \\ue08c Acute angle-closure glaucoma \\ue08c Nephrolithiasis 4.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Medication: Naltrexone/bupropion ER \u001b[0m\u001b[32m(\u001b[0m\u001b[32mOpioid antagonist/antidepressant combination\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Duration: \u001b[0m\n",
              "\u001b[32mLong-term treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects:Constipation, nausea, headache,xerostomia, insomnia, and \u001b[0m\n",
              "\u001b[32melevated heart rate and blood pressure Possible Safety Concerns/Considerations: • Contraindicated in people with \u001b[0m\n",
              "\u001b[32munmanaged hypertension and/or seizure disorders • Contraindicated for use with chronic opioid therapy • Acute \u001b[0m\n",
              "\u001b[32mangle-closure glaucoma \\ue08c BLACK BOX WARNING: Risk of suicidal behavior/ideation in people <24 years of age who \u001b[0m\n",
              "\u001b[32mhave depression 5. Medication: Liraglutide \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGlucagon-like peptide 1 receptor agonist\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Duration: Long-term treatment\u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects: Possible Safety Concerns/Consideration: 6.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Medication:Semaglutide \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGlucagon-like peptide 1 receptor agonist\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Duration: Long-term treatment\u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects:Gastrointestinal side effects \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnausea, vomiting, diarrhea, and esophageal \u001b[0m\n",
              "\u001b[32mreflux\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, injection site reactions, elevated heart rate, hypoglycemia Possible Safety Concerns/Consideration: • \u001b[0m\n",
              "\u001b[32mPancreatitis has been reported in clinical trials, but causality has not been established. Discontinue if \u001b[0m\n",
              "\u001b[32mpancreatitis is suspected. • Use caution in people with kidney disease when initiating or increasing dose due to \u001b[0m\n",
              "\u001b[32mpotential risk of acute kidney injury. • May cause cholelithiasis and gallstone-related complications • \u001b[0m\n",
              "\u001b[32mGastrointestinal disorders \u001b[0m\u001b[32m(\u001b[0m\u001b[32msevere constipation and small bowel obstruction/ileus progression\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Monitor for \u001b[0m\n",
              "\u001b[32mpotential consequences of delayed absorption of oral medications. \\ue08c BLACK BOX WARNING: Risk of thyroid C-cell \u001b[0m\n",
              "\u001b[32mtumors in rodents; human relevance not determined 7.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Medication: Tirzepatide \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDual glucose-dependent insulinotropic polypeptide and glucagon-like \u001b[0m\n",
              "\u001b[32mpeptide 1 receptor agonist\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Duration: Long-term treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32m52 or 56 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Common Side Effects: Gastrointestinal \u001b[0m\n",
              "\u001b[32mside effects \u001b[0m\u001b[32m(\u001b[0m\u001b[32mnausea, vomiting, diarrhea, and esophageal reflux\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, injection site reactions, elevated heart rate, \u001b[0m\n",
              "\u001b[32mhypoglycemia Possible Safety Concerns/Consideration: • Pancreatitis has been reported in clinical trials, but \u001b[0m\n",
              "\u001b[32mcausality has not been established. Discontinue if pancreatitis is suspected. • Use caution in people with kidney \u001b[0m\n",
              "\u001b[32mdisease when initiating or increasing dose due to potential risk of acute kidney injury. • May cause cholelithiasis\u001b[0m\n",
              "\u001b[32mand gallstone-related complications. • Gastrointestinal disorders \u001b[0m\u001b[32m(\u001b[0m\u001b[32msevere constipation and small bowel \u001b[0m\n",
              "\u001b[32mobstruction/ileus progression\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Monitor effects of oral medications with narrow therapeutic index \u001b[0m\u001b[32m(\u001b[0m\u001b[32mwarfarin\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or \u001b[0m\n",
              "\u001b[32mwhose efficacy is dependent on threshold concentration. • Advise those using oral hormonal contraception to use or \u001b[0m\n",
              "\u001b[32madd a nonoral contraception method for 4 weeks after initiation and dose escalations.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_4_cont_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes \u001b[0m\n",
              "\u001b[32mnutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is \u001b[0m\n",
              "\u001b[32mpivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,\u001b[0m\n",
              "\u001b[32mreducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach \u001b[0m\n",
              "\u001b[32mis advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are \u001b[0m\n",
              "\u001b[32mtailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity \u001b[0m\n",
              "\u001b[32mpharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are \u001b[0m\n",
              "\u001b[32madvised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for \u001b[0m\n",
              "\u001b[32mobesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and \u001b[0m\n",
              "\u001b[32msafety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and \u001b[0m\n",
              "\u001b[32madjustments are made based on efficacy and tolerability.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\\ue08c BLACK BOX WARNING: Risk of thyroid C-cell tumors in rodents; human relevance not \u001b[0m\n",
              "\u001b[32mdetermined \u001b[0m\u001b[32m(\u001b[0m\u001b[32mvii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Weight Loss Efficacy of Glucose-Lowering Medications \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m VERY HIGH: Semaglutide \u001b[0m\u001b[32m(\u001b[0m\u001b[32minjectable\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, \u001b[0m\n",
              "\u001b[32mtirzepatide \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m INTERMEDIATE : Dulaglutide, liraglutide \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m NEUTRAL : Dipeptidyl peptidase 4 inhibitors, metformin \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mvii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose-Lowering Medications • Consider weight when choosing glucose-lowering medications for individuals \u001b[0m\n",
              "\u001b[32mwith type 2 diabetes and overweight or obesity.  When possible, avoid prescribing medications that cause weight \u001b[0m\n",
              "\u001b[32mgain to treat comorbid conditions.  Obesity pharmacotherapy should be considered for people with diabetes and \u001b[0m\n",
              "\u001b[32moverweight or obesity along with lifestyle changes. Potential benefits and risks must be considered. • Continue \u001b[0m\n",
              "\u001b[32mobesity pharmacotherapy if it is effective \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>5% weight loss after 3 months\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. • Consider changing or stopping \u001b[0m\n",
              "\u001b[32mtreatment if weight loss is <5% after 3 months or if significant safety/tolerability issues arise'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Retinopathy, Neuropathy, and Foot Care'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing\u001b[0m\n",
              "\u001b[32mthe progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For\u001b[0m\n",
              "\u001b[32mdiabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, \u001b[0m\n",
              "\u001b[32mwith more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis \u001b[0m\n",
              "\u001b[32mfor Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for \u001b[0m\n",
              "\u001b[32mdiabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care \u001b[0m\n",
              "\u001b[32mrecommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses \u001b[0m\n",
              "\u001b[32mto prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like \u001b[0m\n",
              "\u001b[32mloss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging \u001b[0m\n",
              "\u001b[32mfrom annually to every 1-3 months for those at highest risk.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Retinopathy, Neuropathy, and Foot Care Optimizing the management of glycemia, blood pressure, \u001b[0m\n",
              "\u001b[32mand lipids can reduce or slow the progression of microvascular complications of diabetes. i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Optimize Glucose \u001b[0m\n",
              "\u001b[32mControl ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Optimize Blood Pressure iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Control Optimize Lipid Control \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Diabetic Retinopathy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening \u001b[0m\n",
              "\u001b[32mRecommended DR screenings can allow for timely treatment to prevent or reverse vision loss. 1. How: Dilated \u001b[0m\n",
              "\u001b[32mcomprehensive eye exam: This type of eye examination involves dilating the pupils to better examine the retina and \u001b[0m\n",
              "\u001b[32mother eye structures for signs of damage. Retinal photography: This process captures detailed images of the retina \u001b[0m\n",
              "\u001b[32mto detect changes over time and monitor the progression of diabetic retinopathy. 2. When: For individuals with Type\u001b[0m\n",
              "\u001b[32m1 diabetes, a dilated comprehensive eye exam is recommended within five years after the onset of diabetes. For \u001b[0m\n",
              "\u001b[32mindividuals with Type 2 diabetes, it is advised to undergo retinal photography at the time of diabetes diagnosis. \u001b[0m\n",
              "\u001b[32mFollow-Up Eye Exam Schedule: 3. Annual exams are recommended for patients with any level of retinopathy.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Retinopathy, Neuropathy, and Foot Care'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing\u001b[0m\n",
              "\u001b[32mthe progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For\u001b[0m\n",
              "\u001b[32mdiabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, \u001b[0m\n",
              "\u001b[32mwith more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis \u001b[0m\n",
              "\u001b[32mfor Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for \u001b[0m\n",
              "\u001b[32mdiabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care \u001b[0m\n",
              "\u001b[32mrecommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses \u001b[0m\n",
              "\u001b[32mto prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like \u001b[0m\n",
              "\u001b[32mloss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging \u001b[0m\n",
              "\u001b[32mfrom annually to every 1-3 months for those at highest risk.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Exams should be conducted every 1-2 years for those without retinopathy and who have had one or\u001b[0m\n",
              "\u001b[32mmore annual exams showing well-managed glycemia. Patients with progressing or sight-threatening retinopathy need \u001b[0m\n",
              "\u001b[32mmore frequent examinations to monitor and manage their condition effectively. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Neuropathy i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening All \u001b[0m\n",
              "\u001b[32mpeople with diabetes should be assessed for diabetic peripheral neuropathy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDPN\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Қ Starting at the diagnosis of \u001b[0m\n",
              "\u001b[32mtype 2 diabetes Қ 5 years after the diagnosis of type 1 diabetes Қ At least annually thereafter Symptoms and signs \u001b[0m\n",
              "\u001b[32mof autonomic neuropathy should be assessed: Қ Starting at the diagnosis of type 2 diabetes Қ 5 years after the \u001b[0m\n",
              "\u001b[32mdiagnosis of type 1 diabetes Қ At least annually thereafter Қ With evidence of other microvascular complications, \u001b[0m\n",
              "\u001b[32mparticularly kidney disease and DPN Treatment • Various drugs may reduce pain from DPN, and both drug and non-drug \u001b[0m\n",
              "\u001b[32mstrategies may ease symptoms of DPN and autonomic neuropathy. • The safest and most evidence-based pharmacologic \u001b[0m\n",
              "\u001b[32moptions for DPN include gabapentinoids, serotonin- norepinephrine reuptake inhibitors, tricyclic antidepressants, \u001b[0m\n",
              "\u001b[32mand sodium channel blockers.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Retinopathy, Neuropathy, and Foot Care'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing\u001b[0m\n",
              "\u001b[32mthe progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For\u001b[0m\n",
              "\u001b[32mdiabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, \u001b[0m\n",
              "\u001b[32mwith more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis \u001b[0m\n",
              "\u001b[32mfor Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for \u001b[0m\n",
              "\u001b[32mdiabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care \u001b[0m\n",
              "\u001b[32mrecommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses \u001b[0m\n",
              "\u001b[32mto prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like \u001b[0m\n",
              "\u001b[32mloss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging \u001b[0m\n",
              "\u001b[32mfrom annually to every 1-3 months for those at highest risk.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Refer to a neurologist or pain specialist when pain control is not achieved within the scope \u001b[0m\n",
              "\u001b[32mof practice of the treating clinician. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Foot Care Initial treatment recommendations should include: • Daily foot\u001b[0m\n",
              "\u001b[32minspection • Use of moisturizers for dry, scaly skin and avoidance of self-care of ingrown nails and calluses • \u001b[0m\n",
              "\u001b[32mWell-fitted athletic or walking shoes with customized pressure-relieving orthoses for people with increased plantar\u001b[0m\n",
              "\u001b[32mpressures \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., with plantar calluses\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk Stratification and Screening Frequency Category 0: Very Low Ulcer\u001b[0m\n",
              "\u001b[32mRisk Characteristics: No loss of protective sensation \u001b[0m\u001b[32m(\u001b[0m\u001b[32mLOPS\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and no peripheral arterial disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mPAD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Examination \u001b[0m\n",
              "\u001b[32mFrequency: Annually. Category 1: Low Ulcer Risk Characteristics: Either LOPS or PAD. Examination Frequency: Every \u001b[0m\n",
              "\u001b[32m6–12 months. Category 2: Moderate Ulcer Risk Characteristics: Either LOPS and PAD, or LOPS/PAD combined with foot \u001b[0m\n",
              "\u001b[32mdeformity. Examination Frequency: Every 3–6 months. Category 3: High Ulcer Risk Characteristics: LOPS or PAD, and \u001b[0m\n",
              "\u001b[32mone or more of the following: History of foot ulcer. Amputation \u001b[0m\u001b[32m(\u001b[0m\u001b[32mminor or major\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. End-stage renal disease.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_5_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Retinopathy, Neuropathy, and Foot Care'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing\u001b[0m\n",
              "\u001b[32mthe progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For\u001b[0m\n",
              "\u001b[32mdiabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, \u001b[0m\n",
              "\u001b[32mwith more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis \u001b[0m\n",
              "\u001b[32mfor Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for \u001b[0m\n",
              "\u001b[32mdiabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care \u001b[0m\n",
              "\u001b[32mrecommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses \u001b[0m\n",
              "\u001b[32mto prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like \u001b[0m\n",
              "\u001b[32mloss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging \u001b[0m\n",
              "\u001b[32mfrom annually to every 1-3 months for those at highest risk.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Examination Frequency: Every 1–3 months.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"Cardiovascular Disease and Risk Management Atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, \u001b[0m\n",
              "\u001b[32mencompassing coronary heart disease, cerebrovascular disease, and peripheral artery disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mPAD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m presumed to be of\u001b[0m\n",
              "\u001b[32matherosclerotic origin, is the primary cause of morbidity and mortality in individuals with diabetes, leading to \u001b[0m\n",
              "\u001b[32msignificant health care costs. Managing multiple risk factors simultaneously can prevent or slow the progression of\u001b[0m\n",
              "\u001b[32mASCVD. Heart failure is another major cause of morbidity and mortality from cardiovascular disease. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mRecommendations for the Treatment of Confirmed Hypertension in Nonpregnant People With Diabetes management of \u001b[0m\n",
              "\u001b[32mconfirmed hypertension in nonpregnant people with diabetes. It offers guidelines based on initial blood pressure \u001b[0m\n",
              "\u001b[32mreadings and the presence of albuminuria or coronary artery disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCAD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Here's a structured text description \u001b[0m\n",
              "\u001b[32mmaintaining the correct flow and context: Initial Assessment and Treatment Decision Based on Blood Pressure \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mLevels: Initial BP >130/80 & <150/90 mmHg: Treatment Initiation: Start one agent.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Assess for Albuminuria or CAD: No: Start one drug from ACEi \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAngiotensin-Converting Enzyme \u001b[0m\n",
              "\u001b[32minhibitors\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, ARB \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAngiotensin II Receptor Blockers\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or CCB \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCalcium Channel Blockers\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or Diuretic. Yes: Start one\u001b[0m\n",
              "\u001b[32mdrug, either ACEi or ARB. Follow-up: If treatment is tolerated and target BP is achieved, continue therapy. If \u001b[0m\n",
              "\u001b[32mtarget is not met on two agents, continue therapy if treatment is tolerated. Initial BP ≥150/90 mmHg: Treatment \u001b[0m\n",
              "\u001b[32mInitiation: Start two agents. Assess for Albuminuria or CAD: No: Start drugs from two of three options: ACEi, ARB, \u001b[0m\n",
              "\u001b[32mCCB, or Diuretic. Yes: Start both ACEi or ARB, and either CCB or Diuretic. Follow-up: If adverse effects occur, \u001b[0m\n",
              "\u001b[32mconsider switching to an alternative medication \u001b[0m\u001b[32m(\u001b[0m\u001b[32mACEi, ARB, CCB, Diuretic\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. If BP not meeting target or adverse \u001b[0m\n",
              "\u001b[32meffects occur using a drug from each of the three classes, consider the addition of a mineralocorticoid receptor \u001b[0m\n",
              "\u001b[32mantagonist and refer to a specialist with expertise in BP management.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Ongoing Management: Assess BP Control and Adverse Effects Regularly: Adjust treatment based on \u001b[0m\n",
              "\u001b[32mefficacy and tolerance. Addition of Complementary Drug Class: If the target is not met, add an agent from a \u001b[0m\n",
              "\u001b[32mcomplementary drug class. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening for Asymptomatic Cardiovascular Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 1. Coronary Artery Disease \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mCAD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Who to Screen: Routine screening is not recommended for asymptomatic individuals. Additional Guidelines: If \u001b[0m\n",
              "\u001b[32matypical cardiac symptoms, signs or symptoms of associated vascular disease, or electrocardiogram abnormalities are\u001b[0m\n",
              "\u001b[32mpresent, screening should be conducted using routine methods. 2. Heart Failure \u001b[0m\u001b[32m(\u001b[0m\u001b[32mHF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Who to Screen: All adults with \u001b[0m\n",
              "\u001b[32mdiabetes, as diabetes increases risks for asymptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32mstage B\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and symptomatic \u001b[0m\u001b[32m(\u001b[0m\u001b[32mstage\u001b[0m\u001b[32m)\u001b[0m\u001b[32m HF. Screening Methods: \u001b[0m\n",
              "\u001b[32mMeasure B-type natriuretic peptide \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBNP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or N-terminal pro-BNP. Echocardiography is recommended for those with \u001b[0m\n",
              "\u001b[32mabnormal BNP levels. 3. Peripheral Artery Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mPAD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Who to Screen: Individuals with diabetes aged ≥50 years, \u001b[0m\n",
              "\u001b[32mthose with any microvascular disease, foot complications, or end-stage organ damage from diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Duration Consideration: Consider screening anyone with a diabetes duration of ≥10 years. \u001b[0m\n",
              "\u001b[32mScreening Method: Ankle-brachial index testing. Treatment of Stage B HF in People With Diabetes 1. General \u001b[0m\n",
              "\u001b[32mTreatment Recommendation Risk Reduction: To reduce the risk of progression to stage C HF, treatment with ACE \u001b[0m\n",
              "\u001b[32minhibitors \u001b[0m\u001b[32m(\u001b[0m\u001b[32mACEi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or Angiotensin II Receptor Blockers \u001b[0m\u001b[32m(\u001b[0m\u001b[32mARB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and a beta-blocker is recommended. 2. Treatment Based \u001b[0m\n",
              "\u001b[32mon Specific Risks If high risk for or established CVD: Use SGLT2 inhibitors \u001b[0m\u001b[32m(\u001b[0m\u001b[32mcanagliflozin, dapagliflozin, or \u001b[0m\n",
              "\u001b[32mempagliflozin\u001b[0m\u001b[32m)\u001b[0m\u001b[32m to reduce the risk of HF hospitalization. If diabetic kidney disease: Consider using finerenone. If \u001b[0m\n",
              "\u001b[32mspecific SGLT2i consideration: Use SGLT2i like sotagliflozin. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m How often should you check lipids? • For people \u001b[0m\n",
              "\u001b[32mwith prediabetes or diabetes not on lipid-lowering therapy, check at diagnosis and at least annually thereafter. • \u001b[0m\n",
              "\u001b[32mCheck lipids at initiation of lipid- lowering therapy, 4–12 weeks after initiation or dose changes, and annually \u001b[0m\n",
              "\u001b[32mthereafter.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'High-intensity Statin Therapy Objective: Lowers LDL cholesterol by ≥50% Medications and \u001b[0m\n",
              "\u001b[32mDosages: Atorvastatin: 40-80 mg Rosuvastatin: 20-40 mg Moderate-intensity Statin Therapy Objective: Lowers LDL \u001b[0m\n",
              "\u001b[32mcholesterol by 30-49% Medications and Dosages: Atorvastatin: 10-20 mg Rosuvastatin: 5-10 mg Simvastatin: 20-40 mg \u001b[0m\n",
              "\u001b[32mPravastatin: 40-80 mg Lovastatin: 40 mg Fluvastatin XL: 80 mg \u001b[0m\u001b[32m(\u001b[0m\u001b[32mextended release\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Pitavastatin: 1-4 mg Additional \u001b[0m\n",
              "\u001b[32mInformation: Administration: All listed statins are taken once daily. Fluvastatin XL is specified as an \u001b[0m\n",
              "\u001b[32mextended-release formulation, which may offer benefits in terms of steady medication levels throughout the day. \u001b[0m\n",
              "\u001b[32mThis list provides a detailed guide for prescribing statins, helping healthcare providers to choose the appropriate\u001b[0m\n",
              "\u001b[32mintensity of statin therapy based on individual patient needs and treatment goals. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Lipid Management for Primary\u001b[0m\n",
              "\u001b[32mPrevention of ASCVD Events in People with Diabetes 1. Age Group 20-39 Years Treatment Strategy: Lifestyle therapy \u001b[0m\n",
              "\u001b[32mis recommended.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Additional Measures: Consider statin therapy if there are additional ASCVD risk factors. 2. Age\u001b[0m\n",
              "\u001b[32mGroup 40-75 Years Treatment Strategy: Lifestyle therapy. Statin Usage: Use a moderate-intensity statin in those \u001b[0m\n",
              "\u001b[32mwithout ASCVD. Use a high-intensity statin in those with ≥1 ASCVD risk factor, aiming for an LDL cholesterol <70 \u001b[0m\n",
              "\u001b[32mmg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<1.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. 3. Age Group >75 Years Treatment Strategy: Lifestyle therapy. Statin Usage: Continue current \u001b[0m\n",
              "\u001b[32mstatin therapy or consider initiating a moderate-intensity statin after weighing benefits and risks. Lipid \u001b[0m\n",
              "\u001b[32mManagement for Secondary Prevention of ASCVD Events in People With Diabetes of All Ages 1. Treatment Strategy \u001b[0m\n",
              "\u001b[32mStatin Usage: Use high-intensity statin therapy to reduce LDL cholesterol by ≥50% from baseline to a target of <55 \u001b[0m\n",
              "\u001b[32mmg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<1.4 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Additional Medications: Add ezetimibe or a PCSK9 inhibitor if LDL cholesterol goals are not \u001b[0m\n",
              "\u001b[32mmet on maximum tolerated statin therapy. Alternatives for Statin Intolerance: Use bempedoic acid for those who are \u001b[0m\n",
              "\u001b[32mstatin intolerant.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_6_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Cardiovascular Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The guidelines emphasize comprehensive management strategies for individuals with diabetes to \u001b[0m\n",
              "\u001b[32mmitigate the risk of atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, heart failure, and other cardiovascular \u001b[0m\n",
              "\u001b[32mcomplications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. \u001b[0m\n",
              "\u001b[32mInitial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other\u001b[0m\n",
              "\u001b[32msuitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on \u001b[0m\n",
              "\u001b[32mblood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart \u001b[0m\n",
              "\u001b[32mfailure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and \u001b[0m\n",
              "\u001b[32mankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid \u001b[0m\n",
              "\u001b[32mmanagement, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, \u001b[0m\n",
              "\u001b[32mcomplemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or \u001b[0m\n",
              "\u001b[32mPCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'It may be reasonable to add ezetimibe or a PCSK9 inhibitor to maximum tolerated statin therapy.\u001b[0m\n",
              "\u001b[32mFor severe statin intolerance, consider alternative lipid-lowering treatments such as PCSK9 inhibitor with \u001b[0m\n",
              "\u001b[32mmonoclonal antibody treatment, bempedoic acid, or PCSK9 inhibitor with siRNA inclisiran.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Screening for Chronic Kidney Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Who? Everyone with type 2 diabetes Everyone with \u001b[0m\n",
              "\u001b[32mtype 1 diabetes for ≥5 years How? Urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Estimated glomerular filtration rate \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m How often? Annually Monitoring Established CKD How? UACR and eGFR. Use the CKD Epidemiology Collaboration’s \u001b[0m\n",
              "\u001b[32mCKD-EPI Refit equation, which eliminates race as a variable, for all individuals. How often? One to four times per \u001b[0m\n",
              "\u001b[32myear, depending on the stage of the disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Classification of Chronic Kidney Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m CKD is classified \u001b[0m\n",
              "\u001b[32mbased on: Cause \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m GFR \u001b[0m\u001b[32m(\u001b[0m\u001b[32mG\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Albuminuria \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m GFR Categories: G1: Normal or high; GFR ≥90 mL/min/1.73 m² - Low risk \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mif no other markers of kidney disease, no CKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m G2: Mildly decreased; GFR 60-89 mL/min/1.73 m² - Low risk G3a: \u001b[0m\n",
              "\u001b[32mMildly to moderately decreased; GFR 45-59 mL/min/1.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'73 m² - Moderately increased risk G3b: Moderately to severely decreased; GFR 30-44 mL/min/1.73 \u001b[0m\n",
              "\u001b[32mm² - High risk G4: Severely decreased; GFR 15-29 mL/min/1.73 m² - Very high risk G5: Kidney failure; GFR <15 \u001b[0m\n",
              "\u001b[32mmL/min/1.73 m² - Very high risk Albuminuria Categories: A1: Normal to mildly increased; <30 mg/g \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<3 mg/mmol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m A2: \u001b[0m\n",
              "\u001b[32mModerately increased; 30-299 mg/g \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3-29 mg/mmol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m A3: Severely increased; ≥300 mg/g \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥30 mg/mmol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Recommended \u001b[0m\n",
              "\u001b[32mActions Based on GFR and Albuminuria Levels: For G1-G2: A1: Screen 1 A2: Screen 1;'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Treat 1 A3: Treat and refer 3 For G3a: A1: Treat 1 A2: Treat 1 A3: Treat and refer 3 For G3b: \u001b[0m\n",
              "\u001b[32mA1: Treat 2 A2: Treat and refer 3 A3: Treat and refer 3 For G4: A1: Treat and refer 3 A2: Treat and refer 3 A3: \u001b[0m\n",
              "\u001b[32mTreat and refer 4+ For G5: A1: Treat and refer 4+ A2: Treat and refer 4+ A3: Treat and refer 4+ Risk Levels Low \u001b[0m\n",
              "\u001b[32mrisk: Indicates GFR categories G1 and G2 when there are no other markers of kidney disease. Moderately increased \u001b[0m\n",
              "\u001b[32mrisk: Assigned to G3a, suggesting more attention is needed. High risk: Associated with G3b, indicating advanced and\u001b[0m\n",
              "\u001b[32mnoticeable decline in kidney function. Very high risk: Applies to G4 and G5, highlighting severe impairment or \u001b[0m\n",
              "\u001b[32mfailure of kidney function. Why Manage CKD?'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Decreases risk of CKD progression ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Reduces cardiovascular risk \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Holistic Approach to \u001b[0m\n",
              "\u001b[32mImproving Outcomes in People With Diabetes and CKD Lifestyle Modifications: Healthy Diet Physical Activity Smoking \u001b[0m\n",
              "\u001b[32mCessation Weight Management First-line Drug Therapy: SGLT2i: Initiate if eGFR ≥20; continue until dialysis or \u001b[0m\n",
              "\u001b[32mtransplant. Metformin: Initiate if eGFR ≥30. RAS Inhibitor: Use at maximum tolerated dose if hypertension is \u001b[0m\n",
              "\u001b[32mpresent. Regular Reassessment Every 3-6 Months: Assess glycemia, albuminuria, blood pressure \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cardiovascular \u001b[0m\n",
              "\u001b[32mdisease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m risk, and lipids. Additional Risk-based Therapy: GLP-1 RA: If needed to achieve individualized \u001b[0m\n",
              "\u001b[32mglycemic targets. Nonsteroidal MRA: If albuminuria \u001b[0m\u001b[32m(\u001b[0m\u001b[32mACR ≥30 mg/g\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and normal potassium levels. Dihydropyridine CCB \u001b[0m\n",
              "\u001b[32mand/or Diuretic: If needed to achieve individualized BP targets. Steroidal MRA: For resistant hypertension if eGFR \u001b[0m\n",
              "\u001b[32m≥45. Antiplatelet Agents: For clinical atherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Ezetimibe, PCSK9i, or Icosapent Ethyl: If indicated based on ASCVD risk and lipids. Moderate- \u001b[0m\n",
              "\u001b[32mor High-intensity Statin Therapy: Depending on individual risk factors and overall health. Further Interventions: \u001b[0m\n",
              "\u001b[32mOther Glucose-lowering Drugs: If needed to further achieve individualized glycemic targets. Color-coded Key Green: \u001b[0m\n",
              "\u001b[32mIndicates therapies and actions applicable to all patients \u001b[0m\u001b[32m(\u001b[0m\u001b[32mboth type 1 and type 2 diabetes\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Blue: Indicates \u001b[0m\n",
              "\u001b[32mactions or therapies specifically for type 2 diabetes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mT2D\u001b[0m\u001b[32m)\u001b[0m\u001b[32m only. This flowchart provides a comprehensive guide for\u001b[0m\n",
              "\u001b[32mmanaging diabetes and CKD, emphasizing a multi-faceted approach involving lifestyle changes, medication, and \u001b[0m\n",
              "\u001b[32mregular monitoring to adapt treatment as needed based on individual patient risk factors and disease progression. \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Clinical Tips Periodically check serum creatinine and potassium levels when ACE inhibitor, angiotensin receptor\u001b[0m\n",
              "\u001b[32mblocker \u001b[0m\u001b[32m(\u001b[0m\u001b[32mARB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, or nonsteroidal mineralcorticoid receptor antagonist is used. Do not discontinue ACE inhibitor or \u001b[0m\n",
              "\u001b[32mARB therapy for increases ≤30% increases in serum creatinine in the absence of volume depletion.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_7_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Chronic Kidney Disease and Risk Management'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The guidelines for managing chronic kidney disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m in individuals with diabetes emphasize\u001b[0m\n",
              "\u001b[32mregular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves \u001b[0m\n",
              "\u001b[32mmeasuring the urinary albumin-to-creatinine ratio \u001b[0m\u001b[32m(\u001b[0m\u001b[32mUACR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the estimated glomerular filtration rate \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, using\u001b[0m\n",
              "\u001b[32mtools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels \u001b[0m\n",
              "\u001b[32mof albuminuria, each dictating specific management strategies from routine screening to immediate referral for \u001b[0m\n",
              "\u001b[32madvanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy \u001b[0m\n",
              "\u001b[32mwith drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and \u001b[0m\n",
              "\u001b[32mcardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions \u001b[0m\n",
              "\u001b[32madjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle \u001b[0m\n",
              "\u001b[32mand medical therapies to address the multifactorial aspects of diabetes and CKD management.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Aim for a urinary albumin reduction ≥30% in people with CKD and urinary albumin ≥300 mg/g to \u001b[0m\n",
              "\u001b[32mslow CKD progression.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities Diabetes treatment goals aim \u001b[0m\n",
              "\u001b[32mto prevent or delay complications and optimize quality of life. These goals should be developed collaboratively \u001b[0m\n",
              "\u001b[32mwith people with diabetes to honor their preferences and values. Comprehensive diabetes care should be provided by \u001b[0m\n",
              "\u001b[32man interprofessional team which may include but is not limited to diabetes care and education specialists, primary \u001b[0m\n",
              "\u001b[32mcare and subspecialty clinicians, nurses, registered dietitian nutritionists, exercise specialists, pharmacists, \u001b[0m\n",
              "\u001b[32mdentists, podiatrists, behavioral health professionals, and community partners such as community health workers and\u001b[0m\n",
              "\u001b[32mcommunity paramedics. Ongoing treatment necessitates regular follow-up and the active engagement of people with \u001b[0m\n",
              "\u001b[32mdiabetes and their care partners. Comprehensive medical evaluations \u001b[0m\u001b[32m(\u001b[0m\u001b[32mdescribed in the table below\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and the \u001b[0m\n",
              "\u001b[32mprovision of all recommended vaccinations \u001b[0m\u001b[32m(\u001b[0m\u001b[32mcdc.gov/vaccines\u001b[0m\u001b[32m)\u001b[0m\u001b[32m are essential components of ongoing diabetes care. \u001b[0m\n",
              "\u001b[32mAssessment of Comorbidities Q\u001b[0m\u001b[32m)\u001b[0m\u001b[32m What autoimmune conditions should people with type 1 diabetes be screened for?'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Ans: People with type 1 diabetes should be screened soon after diagnosis and periodically \u001b[0m\n",
              "\u001b[32mthereafter for: Autoimmune thyroid disease Other autoimmune conditions, if suggestive signs and symptoms are \u001b[0m\n",
              "\u001b[32mpresent Autoimmune Conditions Associated With Type 1 Diabetes Celiac disease Autoimmune liver disease Collagen \u001b[0m\n",
              "\u001b[32mvascular diseases Autoimmune thyroid disease Pernicious anemia Primary adrenal insufficiency Myasthenia gravis Q\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mHow does diabetes affect bone health? Ans: People with type 1 or type 2 diabetes have a higher fracture risk than \u001b[0m\n",
              "\u001b[32mthose without diabetes. This risk escalates with longer diabetes duration and poor glycemic control. People with \u001b[0m\n",
              "\u001b[32mtype 2 diabetes on thiazolidinediones, insulin, or a sulfonylurea have an even higher fracture risk. Optimizing \u001b[0m\n",
              "\u001b[32mBone Health in People With Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening: In older adults \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>65 years of age\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and high-risk young adults \u001b[0m\n",
              "\u001b[32mDual-energy X-ray absorptiometry every 2–3 years ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Nutrition and Activity : Calcium and vitamin D Aerobic and \u001b[0m\n",
              "\u001b[32mweight-bearing physical activity Fall precautions iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Pharmacotherapy Choose glucose-lowering medications with safe\u001b[0m\n",
              "\u001b[32mprofiles for bone health and low hypoglycemia risk to prevent falls.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Consider antiresorptive and osteo-anabolic agents for those with aT-score ≤−2.0 or previous \u001b[0m\n",
              "\u001b[32mfragility fractures. Question: Are people with diabetes at increased risk for cancer? Ans: Diabetes is associated \u001b[0m\n",
              "\u001b[32mwith increased risk of cancers of the liver, pancreas, endometrium, colon/rectum, breast, and bladder. \u001b[0m\n",
              "\u001b[32mNevertheless, cancer screening recommendations are the same for people with diabetes as for those without diabetes.\u001b[0m\n",
              "\u001b[32mQuestion: How prevalent is nonalcoholic fatty liver disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mNAFLD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m? Who should be screened for it and how? Ans: i\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mPrevalence Approximately 70% of people with type 2 diabetes have NAFLD.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening Goals To identify individuals at risk for complications from nonalcoholic \u001b[0m\n",
              "\u001b[32msteatohepatitis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mNASH\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, such as cirrhosis and hepatocellular carcinoma To prevent death from liver disease iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mHigh-Risk individuals People with central obesity and cardiometabolic risks or insulin resistance Individuals >50 \u001b[0m\n",
              "\u001b[32myears of age Those with persistent high plasma aminotransferase levels \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAST/ALT >30 units/L for >6 months\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mScreening Tool \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Proposed Algorithm for Risk Stratification in Individuals with NAFLD or NASH. Noninvasive \u001b[0m\n",
              "\u001b[32mTesting for Fibrosis \u001b[0m\u001b[32m(\u001b[0m\u001b[32mFIB-4\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Initial Step: Perform FIB-4 test to assess the risk of fibrosis. Risk Categories: Low \u001b[0m\n",
              "\u001b[32mRisk: Individuals categorized under low risk following the FIB-4 test. Indeterminate Risk: Individuals whose \u001b[0m\n",
              "\u001b[32mresults do not clearly categorize them as either low or high risk. High Risk: Individuals identified as high risk \u001b[0m\n",
              "\u001b[32mfor fibrosis based on the FIB-4 results. Subsequent Actions: Low Risk: Follow-up: Repeat the FIB-4 test in 2-3 \u001b[0m\n",
              "\u001b[32myears to monitor any changes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Indeterminate Risk: Further Testing: Proceed with vibration-controlled transient elastography \u001b[0m\n",
              "\u001b[32mor an ELF \u001b[0m\u001b[32m(\u001b[0m\u001b[32mEnhanced Liver Fibrosis\u001b[0m\u001b[32m)\u001b[0m\u001b[32m blood test to refine the risk assessment. After further testing: Low Risk: \u001b[0m\n",
              "\u001b[32mContinue to monitor with a repeat of the test in 2-3 years. High Risk: Refer to a gastroenterologist or \u001b[0m\n",
              "\u001b[32mhepatologist for further evaluation and management. High Risk: Immediate Referral: Refer directly to a \u001b[0m\n",
              "\u001b[32mgastroenterologist or hepatologist for advanced management and intervention. This flowchart provides a guideline on\u001b[0m\n",
              "\u001b[32mhow to proceed with fibrosis risk assessment in patients using initial noninvasive testing and determining the need\u001b[0m\n",
              "\u001b[32mfor further evaluation or routine monitoring based on risk levels. Management Weight loss with intensive lifestyle \u001b[0m\n",
              "\u001b[32mtherapy and/or metabolic surgery, as appropriate, is recommended. Pioglitazone and glucagon-like peptide 1 receptor\u001b[0m\n",
              "\u001b[32magonists are the preferred agents for treatment of hyperglycemia in adults with type 2 diabetes and NASH, unless \u001b[0m\n",
              "\u001b[32mdecompensated cirrhosis is present. People with type 2 diabetes and decompensated cirrhosis from NASH should be \u001b[0m\n",
              "\u001b[32mtreated with insulin. Statin therapy is safe in the setting of NAFLD.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Use with caution and close monitoring in people with decompensated cirrhosis. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Components of\u001b[0m\n",
              "\u001b[32mthe Comprehensive Diabetes Medical Evaluation Initial Visit, Every Follow-Up Visit, and Annual Visit Diabetes \u001b[0m\n",
              "\u001b[32mHistory Characteristics at onset \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., age, symptoms\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Review of previous treatment plans and response. Assess \u001b[0m\n",
              "\u001b[32mfrequency/cause/severity of past hospitalizations. Family History Family history of diabetes in a first-degree \u001b[0m\n",
              "\u001b[32mrelative. Family history of autoimmune disorder. Personal History of Complications and Common Comorbidities Common \u001b[0m\n",
              "\u001b[32mcomorbidities \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., obesity, OSA, NAFLD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. High blood pressure or abnormal lipids. Macrovascular and microvascular \u001b[0m\n",
              "\u001b[32mcomplications. Hypoglycemia: awareness/frequency/causes/timing of episodes. Presence of hemoglobinopathies or \u001b[0m\n",
              "\u001b[32manemias. Last dental visit. Last dilated eye exam. Visits to specialists. Disability assessment and use of \u001b[0m\n",
              "\u001b[32massistive devices. Personal history of autoimmune disease. Interval History Changes in medical/family history since\u001b[0m\n",
              "\u001b[32mlast visit. Eating patterns and weight history. Assess familiarity with carbohydrate counting. Physical activity \u001b[0m\n",
              "\u001b[32mand sleep behaviors. Tobacco, alcohol, and substance use.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Medications and Vaccinations Current medication plan. Medication-taking behavior. Medication \u001b[0m\n",
              "\u001b[32mintolerance or side effects. Complementary and alternative medicine use. Vaccination history and needs. Technology \u001b[0m\n",
              "\u001b[32mUse Access use of health apps/online education. Glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mmeter/CGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m results and data use. Review insulin\u001b[0m\n",
              "\u001b[32mpump settings and use. Social Life Assessment Identify existing social supports. Identify surrogate decision maker,\u001b[0m\n",
              "\u001b[32madvanced care plan. Identify social determinants of health. Assess daily routine and environment. Physical \u001b[0m\n",
              "\u001b[32mExamination Height, weight, and BMI. Blood pressure determination. Orthostatic blood pressure measures. Fundoscopic\u001b[0m\n",
              "\u001b[32mexamination. Thyroid palpation. Skin examination. Comprehensive foot examination. Screen for PAD \u001b[0m\u001b[32m(\u001b[0m\u001b[32mpedal \u001b[0m\n",
              "\u001b[32mpulses—refer for ABI if diminished\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Screen for depression, anxiety, diabetes distress. Consider assessment for \u001b[0m\n",
              "\u001b[32mcognitive performance. Consider assessment for functional performance. Consider assessment for bone pain. \u001b[0m\n",
              "\u001b[32mLaboratory Evaluation Lipid profile, liver function tests, spot urinary albumin-to-creatinine ratio. Serum \u001b[0m\n",
              "\u001b[32mcreatinine and estimated glomerular filtration rate. Thyroid-stimulating hormone in people with type 1 diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_8_cont_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Comprehensive Medical Evaluation and Assessment of Comorbidities'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"The comprehensive medical evaluation for diabetes management involves a holistic approach that \u001b[0m\n",
              "\u001b[32mprioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team \u001b[0m\n",
              "\u001b[32mincluding specialists from various medical and community fields supports ongoing care. Key components include \u001b[0m\n",
              "\u001b[32mregular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, \u001b[0m\n",
              "\u001b[32mparticularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes\u001b[0m\n",
              "\u001b[32mare screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2\u001b[0m\n",
              "\u001b[32mdiabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective \u001b[0m\n",
              "\u001b[32mmanagement incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular \u001b[0m\n",
              "\u001b[32mmonitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,\u001b[0m\n",
              "\u001b[32mfamily, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough \u001b[0m\n",
              "\u001b[32massessment and optimal management of diabetes and its associated conditions.\"\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Vitamin B12 if on metformin. Complete Blood Count \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCBC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with platelets. Serum potassium levels \u001b[0m\n",
              "\u001b[32min people with diabetes on ACE inhibitors, ARBs, or diuretics. Calcium, vitamin D, phosphorus for appropriate \u001b[0m\n",
              "\u001b[32mpatients. This comprehensive checklist ensures that all significant aspects of diabetes management are reviewed and\u001b[0m\n",
              "\u001b[32massessed regularly to provide the best possible care and outcomes for individuals with diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes Building \u001b[0m\n",
              "\u001b[32mpositive health behaviors and maintaining psychological well-being are foundational for achieving diabetes \u001b[0m\n",
              "\u001b[32mmanagement goals and maximizing quality of life. Essential tasks to help people with diabetes achieve their health \u001b[0m\n",
              "\u001b[32mgoals: Refer for diabetes self-management education andsupport \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Counsel on and support cessation of tobacco \u001b[0m\n",
              "\u001b[32mproducts and vaping Refer for medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Counsel on health behaviors Counsel on routine \u001b[0m\n",
              "\u001b[32mphysical activity Support and refer to behavior health professionals for psychosocial care \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m DSMES Is Critical \u001b[0m\n",
              "\u001b[32mPeople Who Benefit • All people with diabetes Advantages • Ensures informed decision-making • Promotes self-care \u001b[0m\n",
              "\u001b[32mbehaviors • Facilitates problem-solving • Improved collaboration with the health care team • Imparts knowledge and \u001b[0m\n",
              "\u001b[32mself-care skills • Incorporates needs, goals, and life experiences Times to Refer • Annually • At diagnosis • When \u001b[0m\n",
              "\u001b[32mnot meeting treatment goals • When complicating factors develop • When transitions in life and care occur \u001b[0m\n",
              "\u001b[32mAppropriate Settings • Group or individual visits • In-person, telehealth, or digital platforms Essential \u001b[0m\n",
              "\u001b[32mComponents • Provide culturally appropriate content • Be responsive to individual preferences, needs, and values • \u001b[0m\n",
              "\u001b[32mUse positive, strength-based language that puts people first.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Consider social determinants of health with a focus on health equity. Proven Outcomes • \u001b[0m\n",
              "\u001b[32mImproved diabetes knowledge, self-care, and quality of life • Lower A1C and self-reported weight reductions • \u001b[0m\n",
              "\u001b[32mReduced all-cause mortality risk, acute care and hospital services utilization, and lower health care costs • \u001b[0m\n",
              "\u001b[32mIncreased use of primary care and preventive services • Positive coping behavior \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Psychosocial Care for All \u001b[0m\n",
              "\u001b[32mPeople With Diabetes: Considerations and Recommendations \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screening ✓ Clinically significant mental health \u001b[0m\n",
              "\u001b[32mdiagnoses are considerably more prevalent in people with diabetes than in those without. ✓ Clinicians should \u001b[0m\n",
              "\u001b[32mimplement psychosocial screening protocols, including for diabetes distress. ✓ People with diabetes, caregivers, \u001b[0m\n",
              "\u001b[32mand family members should be screened at least annually or when changes in disease, treatment, or life \u001b[0m\n",
              "\u001b[32mcircumstances occur. ✓ Address both clinical and subclinical psychological symptoms,which can affect the ability to\u001b[0m\n",
              "\u001b[32mcarry out self-management, short-term glycemic stability, as well as mortality risk. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Interventions ✓ \u001b[0m\n",
              "\u001b[32mInterventions should be collaborative, person-centered, and culturally informed. ✓ Refer to behavioral health \u001b[0m\n",
              "\u001b[32mprofessionals or other trained health care professionals, ideally with experience in diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'✓ Consider individuals’ treatment burden, confidence and self-efficacy in management, and \u001b[0m\n",
              "\u001b[32msocial and family support Diabetes Distress The ongoing demands of diabetes self-care and the possibility or \u001b[0m\n",
              "\u001b[32mreality of disease progression are directly linked to reported diabetes distress. High levels of distress: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mSignificantly affect medication-taking behavior ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Are linked to higher A1C, lower self-efficacy, and less-optimal\u001b[0m\n",
              "\u001b[32meating\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and exercise behavior \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Medical Nutrition Therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m for Diabetes Management General Principles of \u001b[0m\n",
              "\u001b[32mMNT: Flexible, Realistic, and Sustainable: Successful MNT programs adapt to individual lifestyles and are designed \u001b[0m\n",
              "\u001b[32mto be maintained over the long term. Provided by a Registered Dietitian Nutritionist: Expert guidance ensures that \u001b[0m\n",
              "\u001b[32mdietary plans are tailored to meet the unique needs of each individual. Available to All: MNT is recommended for \u001b[0m\n",
              "\u001b[32mindividuals with type 1 or type 2 diabetes, prediabetes, and gestational diabetes mellitus.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"Key Nutrition Principles: Include: Nonstarchy vegetables Whole grains Nuts/seeds Low-fat dairy \u001b[0m\n",
              "\u001b[32mproducts Whole fruits Legumes Minimize: Meat Sugar-sweetened beverages Sweets Refined grains Ultra-processed foods \u001b[0m\n",
              "\u001b[32mScreening Recommendations: Screen for disordered eating, food insecurity, and a history of dieting to better tailor\u001b[0m\n",
              "\u001b[32mdietary interventions and support. Support for Positive Health Behavior: Motivational Interviewing: Engaging in \u001b[0m\n",
              "\u001b[32mconversations that strengthen an individual's motivation and commitment to change. Problem-solving: Developing \u001b[0m\n",
              "\u001b[32mstrategies to address barriers to healthy eating. Patient Activation: Empowering patients to take active roles in \u001b[0m\n",
              "\u001b[32mmanaging their health. Goal-setting and Action-planning: Establishing clear, achievable goals and steps to meet \u001b[0m\n",
              "\u001b[32mthem. Encouragement of Self-Monitoring: Promoting regular monitoring of health behaviors, with or without clinician\u001b[0m\n",
              "\u001b[32mfeedback. Social Support: Identifying and utilizing social resources to support dietary changes. Specific \u001b[0m\n",
              "\u001b[32mAdvisories to Stop: Cigarettes E-cigarettes/vapes All tobacco products This includes recommendations for counseling\u001b[0m\n",
              "\u001b[32mand/or pharmacologic treatment to support cessation. Additional Notes: Data do not support a specific distribution \u001b[0m\n",
              "\u001b[32mof macronutrients; instead, individuals with diabetes are encouraged to adopt healthy eating patterns tailored to \u001b[0m\n",
              "\u001b[32mtheir personal needs and preferences.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"This MNT framework provides a holistic approach to diabetes management through diet, \u001b[0m\n",
              "\u001b[32memphasizing flexibility, personalized care, and comprehensive support strategies to foster long-term health \u001b[0m\n",
              "\u001b[32mimprovements. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 24-Hour Physical Behaviors for Type 2 Diabetes 1. Sitting/Breaking Up Prolonged Sitting: \u001b[0m\n",
              "\u001b[32mRecommendation: Limit sitting by breaking up prolonged sitting every 30 minutes with short regular bouts of slow \u001b[0m\n",
              "\u001b[32mwalking/simple resistance exercises to improve glucose metabolism. 2. Stepping: Benefits: An increase of only 500 \u001b[0m\n",
              "\u001b[32msteps/day is associated with a 2-9% decreased risk of cardiovascular morbidity and all-cause mortality. A 5- to \u001b[0m\n",
              "\u001b[32m6-minute brisk, intense walk per day equates to ~4 years' greater life expectancy. 3. Sweating \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mModerate-to-Vigorous Activity\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Recommendation: Encourage ≥150 minutes/week of moderate-intensity physical \u001b[0m\n",
              "\u001b[32mactivity \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., use large muscle groups, rhythmic in nature\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or 75 minutes/week of vigorous-intensity spread over 2\u001b[0m\n",
              "\u001b[32mto 3 days/week, with no more than 2 consecutive days of inactivity. Supplement with two to three sessions involving\u001b[0m\n",
              "\u001b[32mresistance, flexibility, and/or balance. 4.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"Strengthening: Activities: Resistance exercise \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., any activity that uses the person's own \u001b[0m\n",
              "\u001b[32mbody weight or works against a resistance\u001b[0m\u001b[32m)\u001b[0m\u001b[32m also improves insulin sensitivity and glucose levels; activities like \u001b[0m\n",
              "\u001b[32mtai chi and yoga also enhance elements of flexibility and balance. 5. Physical Function/Frailty/Sarcopenia: \u001b[0m\n",
              "\u001b[32mConcern: The frailty phenotype in Type 2 diabetes is unique, often encompassing obesity alongside physical frailty \u001b[0m\n",
              "\u001b[32mat an earlier age. The ability to undertake simple functional exercises in middle age is similar to that in those \u001b[0m\n",
              "\u001b[32mover a decade older. 6. Sleep: Quality and Quantity: Aim for consistent, uninterrupted sleep, even on weekends. \u001b[0m\n",
              "\u001b[32mLong \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>8h\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and short \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<6h\u001b[0m\u001b[32m)\u001b[0m\u001b[32m sleep durations negatively impact A1C. Chronotype: Evening chronotypes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi.e., night owl;\u001b[0m\n",
              "\u001b[32mgo to bed late and get up late\u001b[0m\u001b[32m)\u001b[0m\u001b[32m may be more susceptible to poor glycemic levels vs. morning chronotypes \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi.e., \u001b[0m\n",
              "\u001b[32mearly bird; go to bed early and get up early\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_9_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes emphasizes fostering positive health behaviors and psychological \u001b[0m\n",
              "\u001b[32mwell-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management \u001b[0m\n",
              "\u001b[32meducation and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, medical nutrition therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mMNT\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, cessation of smoking and vaping, regular physical \u001b[0m\n",
              "\u001b[32mactivity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and \u001b[0m\n",
              "\u001b[32meffective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. \u001b[0m\n",
              "\u001b[32mPsychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and \u001b[0m\n",
              "\u001b[32mappropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized \u001b[0m\n",
              "\u001b[32meating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking \u001b[0m\n",
              "\u001b[32mup prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises\u001b[0m\n",
              "\u001b[32mto improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies \u001b[0m\n",
              "\u001b[32mare designed to support individuals with diabetes in achieving better health and managing the condition \u001b[0m\n",
              "\u001b[32meffectively.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Impact of Physical Behaviors on Cardiometabolic Health in Type 2 Diabetes Impact Table: \u001b[0m\n",
              "\u001b[32mDifferent physical behaviors such as sitting, stepping, moderate-to-vigorous activity, strengthening, sleep \u001b[0m\n",
              "\u001b[32mduration, sleep quality, and consistent timing \u001b[0m\u001b[32m(\u001b[0m\u001b[32mchronotype\u001b[0m\u001b[32m)\u001b[0m\u001b[32m have various effects on glucose/insulin levels, blood \u001b[0m\n",
              "\u001b[32mpressure, A1C, lipids, physical function, depression, and quality of life. The table categorizes the impact as: \u001b[0m\n",
              "\u001b[32mGreen arrows: strong evidence of higher levels/improvement. Yellow arrows: medium strength evidence. Red arrows: \u001b[0m\n",
              "\u001b[32mlimited evidence. Circle: no data available. This approach underscores a holistic view of managing Type 2 diabetes,\u001b[0m\n",
              "\u001b[32msuggesting that balanced daily physical activities and regulated sleep patterns are crucial for maintaining overall\u001b[0m\n",
              "\u001b[32mhealth and managing the disease effectively.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Assessment of Glycemic Status How to Assess A1C measurement Continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32musing appropriate metrics \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., time in range \u001b[0m\u001b[32m[\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m]\u001b[0m\u001b[32m and/or glucose management indicator \u001b[0m\u001b[32m[\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When to Assess How \u001b[0m\n",
              "\u001b[32mfrequently? In those meeting treatment goals = At least two times per year For individuals not meeting treatment \u001b[0m\n",
              "\u001b[32mgoals, with frequent or severe hypo- or hyperglycemia, changing health status, or growth and development in youth =\u001b[0m\n",
              "\u001b[32mAt least quarterly or more frequently as appropriate clinically Clinical Notes Limitations: Accuracy can be \u001b[0m\n",
              "\u001b[32maffected by conditions that affect red blood cell turnover \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hemolytic and other anemias, glucose-6-phosphate \u001b[0m\n",
              "\u001b[32mdehydrogenase deficiency, recent blood transfusion, use of drugs that stimulate erythropoiesis, end‐stage kidney \u001b[0m\n",
              "\u001b[32mdisease, and pregnancy\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Some hemoglobin variants can interfere with some A1C assays, although this problem has \u001b[0m\n",
              "\u001b[32mbeen minimized with newer assays. A1C does not assess glycemic variability or hypoglycemia. Consider alternative \u001b[0m\n",
              "\u001b[32mmeasures, such as fructosamine and glycated albumin, when necessary. Assess glycemic variability using a \u001b[0m\n",
              "\u001b[32mcombination of results from blood glucose monitoring/CGM and A1C.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glucose Assessment via CGM: The Ambulatory Glucose Profile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Report 1. Ensure sufficient \u001b[0m\n",
              "\u001b[32mdata for analysis; CGM active at least 70% of the time over 14 days is recommended. 2. Discuss individuals’ daily \u001b[0m\n",
              "\u001b[32mself-management routine. 3. Ask individuals to identify and explain what they observe on the report. 4. Check \u001b[0m\n",
              "\u001b[32moverall CGM metrics: i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Time below range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTBR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: percentage of readings and time with glucose <70 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<3.9 \u001b[0m\n",
              "\u001b[32mmmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m{\u001b[0m\u001b[32mAGP Report: Continuous Glucose Monitoring Overview 1. Time in Ranges: Very High \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>250 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 20% of the \u001b[0m\n",
              "\u001b[32mtime \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <5%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m High \u001b[0m\u001b[32m(\u001b[0m\u001b[32m180-250 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 24% of the time \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <25%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Target \u001b[0m\u001b[32m(\u001b[0m\u001b[32m70-180 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 46% of the time \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: \u001b[0m\n",
              "\u001b[32m>70%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m; notes that each 5% increase is clinically beneficial Low \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<70 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 10% of the time \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <4%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Very Low \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m<54 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 5% of the time \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <1%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 2.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Test Patient Information: DOB: January 1, 1970 Testing Period: 14 Days, from August 8 to August\u001b[0m\n",
              "\u001b[32m21, 2021 CGM Activation: 100% active during the testing period, ensuring reliable data collection. 3. Glucose \u001b[0m\n",
              "\u001b[32mMetrics: Average Glucose: 175 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <154 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: 7.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <7%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose\u001b[0m\n",
              "\u001b[32mVariability: 45.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGoal: <36%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m; defined as the percentage coefficient of variation, indicating the extent of \u001b[0m\n",
              "\u001b[32mfluctuations in glucose levels. Key Insights and Recommendations: Time in Target Range: The patient spent 46% of \u001b[0m\n",
              "\u001b[32mthe time within the target glucose range, which is below the goal of >70%. Efforts should be made to increase time \u001b[0m\n",
              "\u001b[32mwithin this range to improve overall glucose management. High and Very High Levels: Significant time was spent with\u001b[0m\n",
              "\u001b[32mglucose levels higher than recommended, suggesting a need for adjustments in treatment or lifestyle to better \u001b[0m\n",
              "\u001b[32mmanage glucose peaks. Low and Very Low Levels: The percentages here also exceed the goals, indicating potential \u001b[0m\n",
              "\u001b[32mrisks of hypoglycemia. This might require reevaluation of medication doses or meal planning.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glucose Variability: High variability indicates that glucose levels are fluctuating more than \u001b[0m\n",
              "\u001b[32mdesired, which can be a concern for overall metabolic stability. \u001b[0m\u001b[32m}\u001b[0m\u001b[32m ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m TIR: percentage of readings and time with \u001b[0m\n",
              "\u001b[32mglucose 70–180 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m3.9–10.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Time above range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTAR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: percentage of readings and time >250 mg/dL \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m>13.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Mean glucose v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose management indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: an estimate of A1C vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glycemic variability:\u001b[0m\n",
              "\u001b[32mexpressed as percent coefficient of variation; target ≤36% 5\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Identify any hypoglycemia first, and then look for \u001b[0m\n",
              "\u001b[32mhyperglycemia patterns. Review the time spent in these patterns on the overall profile and daily graphs. \u001b[0m\u001b[32m{\u001b[0m\u001b[32mOverview \u001b[0m\n",
              "\u001b[32mof the Ambulatory Glucose Profile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Graph 1. Graph Layout: The graph displays glucose levels over a 24-hour \u001b[0m\n",
              "\u001b[32mperiod, beginning and ending at midnight. It uses different colored bands to indicate the range of glucose values, \u001b[0m\n",
              "\u001b[32mfrom the 5th percentile to the 95th percentile. 2.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glucose Level Ranges: Red Line: Represents the median \u001b[0m\u001b[32m(\u001b[0m\u001b[32m50th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m glucose level, \u001b[0m\n",
              "\u001b[32mproviding a central trend line of the glucose readings throughout the day. Green Band: This area represents the \u001b[0m\n",
              "\u001b[32mtarget glucose range \u001b[0m\u001b[32m(\u001b[0m\u001b[32m70 to 180 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, where glucose levels are considered well-managed. Orange and Yellow Bands: \u001b[0m\n",
              "\u001b[32mThese bands show higher glucose levels, up to the 75th and 95th percentiles, respectively. Light Green and Light \u001b[0m\n",
              "\u001b[32mOrange Bands: Represent the lower \u001b[0m\u001b[32m(\u001b[0m\u001b[32m25th percentile\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and higher glucose ranges, respectively. 3. Key Points in \u001b[0m\n",
              "\u001b[32mGlucose Fluctuations: Overnight and Early Morning: The graph generally shows lower glucose levels, with the median \u001b[0m\n",
              "\u001b[32mline within or close to the target range. Postprandial Peaks: Noticeable increases in glucose levels can be seen \u001b[0m\n",
              "\u001b[32mduring typical meal times \u001b[0m\u001b[32m(\u001b[0m\u001b[32mbreakfast, lunch, and dinner\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, indicating postprandial glucose responses. Late Evening: \u001b[0m\n",
              "\u001b[32mGlucose levels tend to rise in the late evening, possibly due to dinner intake or lessened physical activity. 4. \u001b[0m\n",
              "\u001b[32mSignificance of Different Percentiles: 5% to 25% Percentiles \u001b[0m\u001b[32m(\u001b[0m\u001b[32mLight Green\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Show the lower fluctuations of glucose,\u001b[0m\n",
              "\u001b[32mindicating times when glucose levels might drop too low.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_6'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'75% to 95% Percentiles \u001b[0m\u001b[32m(\u001b[0m\u001b[32mOrange to Yellow\u001b[0m\u001b[32m)\u001b[0m\u001b[32m: Highlight times when glucose levels are \u001b[0m\n",
              "\u001b[32msignificantly above the target, suggesting hyperglycemia risks. Clinical Implications Target Range Maintenance: The\u001b[0m\n",
              "\u001b[32maim is to have the median line within the green band as much as possible, indicating good glucose control. \u001b[0m\n",
              "\u001b[32mManagement of Peaks: High peaks suggest a need for adjustments in diet, medication, or both to better manage \u001b[0m\n",
              "\u001b[32mglucose spikes. Addressing Hypoglycemia: Any part of the median line dipping below the target range especially if \u001b[0m\n",
              "\u001b[32mreaching the light green area, needs attention to prevent hypoglycemia. \u001b[0m\u001b[32m}\u001b[0m\u001b[32m 6\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Discuss identified patterns and ask \u001b[0m\n",
              "\u001b[32mindividuals to reflect on potential causes and possible solutions. \u001b[0m\u001b[32m{\u001b[0m\u001b[32mOverview of Daily Glucose Profiles Graph \u001b[0m\n",
              "\u001b[32mDetails: Each graph is labeled with the days of the week, from Sunday through Saturday. The glucose levels are \u001b[0m\n",
              "\u001b[32mplotted against time, marked at 12pm for clarity, showing the midday point. Glucose Level Guidelines: Target Range:\u001b[0m\n",
              "\u001b[32mThe target glucose range \u001b[0m\u001b[32m(\u001b[0m\u001b[32m70 to 180 mg/dL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m is highlighted by a green band that spans across each graph.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_7'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"Glucose Readings: The daily glucose readings are represented by a line that varies in height, \u001b[0m\n",
              "\u001b[32mindicating the fluctuations in glucose levels throughout each day. Analysis of the Daily Glucose Profiles General \u001b[0m\n",
              "\u001b[32mObservations: Variability: There's noticeable variability in glucose levels across the days. Some days show more \u001b[0m\n",
              "\u001b[32mstability with glucose levels staying within or near the target range, while other days exhibit significant spikes \u001b[0m\n",
              "\u001b[32mand drops. Patterns: Common patterns can be observed, such as potential spikes around typical meal times \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mbreakfast, lunch, and dinner\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. These spikes might suggest postprandial glucose responses. Specific Days Analysis: \u001b[0m\n",
              "\u001b[32mDays like Sunday and Wednesday show relatively good control with the glucose levels mostly staying within the \u001b[0m\n",
              "\u001b[32mtarget range. Other days, like Tuesday and Friday, exhibit more fluctuations with notable spikes that exceed 180 \u001b[0m\n",
              "\u001b[32mmg/dL and brief dips potentially going below 70 mg/dL. Clinical Implications Consistency and Control: The graph for\u001b[0m\n",
              "\u001b[32meach day provides insights into how well glucose levels are managed and how consistent the control is across \u001b[0m\n",
              "\u001b[32mdifferent days. Days with less fluctuation are indicative of more stable glucose control.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_8'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Adjustments Needed: Identifying days with high variability can help in targeting specific times\u001b[0m\n",
              "\u001b[32mfor intervention, such as adjusting meal plans, medication timing, or physical activity. Utility for Diabetes \u001b[0m\n",
              "\u001b[32mManagement: These daily profiles are crucial for patients and healthcare providers to assess and adjust diabetes \u001b[0m\n",
              "\u001b[32mmanagement plans. Understanding daily patterns helps in making informed decisions to optimize glucose control, \u001b[0m\n",
              "\u001b[32mpotentially adjusting dietary intake, medication dosages, or lifestyle changes to achieve better glycemic \u001b[0m\n",
              "\u001b[32moutcomes.\u001b[0m\u001b[32m}\u001b[0m\u001b[32m 7\u001b[0m\u001b[32m)\u001b[0m\u001b[32m If you use CGM metrics to assess glycemia, goals for nonpregnant adults or those with frailty will \u001b[0m\n",
              "\u001b[32mvary; set glycemic goals based on the general guidelines below. 8\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Use shared decision-making to develop an action \u001b[0m\n",
              "\u001b[32mplan. Correlation Between A1C and Estimated Average Glucose \u001b[0m\u001b[32m(\u001b[0m\u001b[32meAG\u001b[0m\u001b[32m)\u001b[0m\u001b[32m A calculator for converting A1C results into eAG,\u001b[0m\n",
              "\u001b[32min either mg/dL or mmol/L, is available at professional.diabetes.org/eAG. Data in parentheses are a 95% CI.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_9'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'A1C \u001b[0m\u001b[32m(\u001b[0m\u001b[32m%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m mg/dL mmol/L 5 97 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m76–120\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 5.4 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m4.2–6.7\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 6 126 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m100–152\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 7.0 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.5–8.5\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 7 154 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m123–185\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32m8.6 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m6.8–10.3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 8 183 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m147–217\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 10.2 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m8.1–12.1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 9 212 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m170–249\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 11.8 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m9.4–13.9\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 10 240 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m193–282\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 13.4 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m10.7–15.7\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 11\u001b[0m\n",
              "\u001b[32m269 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m217–314\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 14.9 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m12.0–17.5\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 12 298 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m240–347\u001b[0m\u001b[32m)\u001b[0m\u001b[32m 16.5 \u001b[0m\u001b[32m(\u001b[0m\u001b[32m13.3–19.3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Setting and Modifying Glycemic Goals Glycemic \u001b[0m\n",
              "\u001b[32mgoals should be individualized and periodically reevaluated. 1. Individualize based on key characteristics of the \u001b[0m\n",
              "\u001b[32mperson with diabetes. 2. Individualize in the context of shared decision-making \u001b[0m\u001b[32m(\u001b[0m\u001b[32mto address needs and preferences\u001b[0m\u001b[32m)\u001b[0m\u001b[32m.\u001b[0m\n",
              "\u001b[32m3.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Follow these general guidelines: Recommended glycemic goals for many nonpregnant adults with \u001b[0m\n",
              "\u001b[32mdiabetes without significant hypoglycemia: A1C <7.0% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<53 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Preprandial capillary plasma glucose: 80–130 \u001b[0m\n",
              "\u001b[32mmg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m4.4–7.2 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Peak postprandial capillary plasma glucose: <180 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<10.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m CGM metrics: TIR >70% \u001b[0m\n",
              "\u001b[32mwith TBR <4% and <1% of time with glucose <54 mg/dL A lower A1C goal may be acceptable and even beneficial if it \u001b[0m\n",
              "\u001b[32mcan be achieved safely without significant hypoglycemia or other adverse effects of treatment. A higher A1C goal \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32msuch as <8% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m64 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m may be appropriate for individuals with limited life expectancy or when the harms of \u001b[0m\n",
              "\u001b[32mtreatment are greater than the benefits. TIR >50% with <1% TBR is appropriate in those with frailty or at high risk\u001b[0m\n",
              "\u001b[32mof hypoglycemia. Deintensify glucose-lowering medications for those at high hypoglycemia risk or when treatment \u001b[0m\n",
              "\u001b[32mrisks or burdens outweigh the benefits.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Overview of the Table: Patient/Disease Features and A1C Target Stringency The table uses a \u001b[0m\n",
              "\u001b[32mcolor gradient to indicate the appropriateness of more stringent \u001b[0m\u001b[32m(\u001b[0m\u001b[32mtoward a lower A1C target, <7%\u001b[0m\u001b[32m)\u001b[0m\u001b[32m versus less \u001b[0m\n",
              "\u001b[32mstringent A1C targets based on specific patient or disease characteristics: 1. Risks Potentially Associated with \u001b[0m\n",
              "\u001b[32mHypoglycemia and Other Drug-Related Adverse Effects More Stringent: Low risk of adverse effects favors a more \u001b[0m\n",
              "\u001b[32mstringent A1C target. Less Stringent: High risk of adverse effects favors a less stringent A1C target. 2. Disease \u001b[0m\n",
              "\u001b[32mDuration More Stringent: Newly diagnosed patients may benefit more from stringent targets to potentially reverse \u001b[0m\n",
              "\u001b[32mdisease progression. Less Stringent: Long-standing diabetes where more stringent targets might not significantly \u001b[0m\n",
              "\u001b[32malter disease outcomes. 3. Life Expectancy More Stringent: Longer life expectancy supports aiming for a stricter \u001b[0m\n",
              "\u001b[32mA1C to reduce long-term complications. Less Stringent: Shorter life expectancy may prioritize comfort and quality \u001b[0m\n",
              "\u001b[32mof life over strict glucose control. 4. Important Comorbidities More Stringent: Absence of severe comorbidities \u001b[0m\n",
              "\u001b[32mmight allow for tighter glucose control without significant risks.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_12'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"Less Stringent: Presence of severe comorbidities where strict control may exacerbate or \u001b[0m\n",
              "\u001b[32mcomplicate conditions. 5. Established Vascular Complications More Stringent: Few or mild complications might \u001b[0m\n",
              "\u001b[32mencourage tighter control to prevent progression. Less Stringent: Severe complications may mean that the risks of \u001b[0m\n",
              "\u001b[32mstringent control outweigh the benefits. 6. Individual Needs and Preference More Stringent: Patients who are highly\u001b[0m\n",
              "\u001b[32mmotivated and have excellent self-care capabilities. Less Stringent: Patients who prefer less burdensome therapy \u001b[0m\n",
              "\u001b[32mdue to personal preferences or ability to manage complex regimens. 7. Resources and Support System More Stringent: \u001b[0m\n",
              "\u001b[32mReadily available resources and support systems enable stricter A1C targets. Less Stringent: Limited resources and \u001b[0m\n",
              "\u001b[32msupport may necessitate a less stringent approach to avoid overwhelming the patient. Summary This table effectively\u001b[0m\n",
              "\u001b[32mguides healthcare providers in personalizing diabetes treatment goals based on individual patient factors. It \u001b[0m\n",
              "\u001b[32memphasizes the importance of tailoring A1C targets to balance effective diabetes management with the patient's \u001b[0m\n",
              "\u001b[32moverall health status, lifestyle, and preferences, ensuring both safety and quality of life. Person and disease \u001b[0m\n",
              "\u001b[32mfactors used to determine optimal glycemic targets.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_13'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Characteristics and predicaments toward the left justify more stringent efforts to lower A1C; \u001b[0m\n",
              "\u001b[32mthose toward the right suggest less stringent efforts. A1C 7% = 53 mmol/mol. Hypoglycemia Assessment, Prevention, \u001b[0m\n",
              "\u001b[32mand Treatment Hypoglycemia is categorized into three levels based on blood glucose concentrations and symptom \u001b[0m\n",
              "\u001b[32mseverity. Level 1 is glucose <70 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<3.9 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m but ≥54 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m≥3.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Level 2 is glucose <54 mg/dL \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32m<3.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Level 3 is a severe event characterized by altered mental and/or physical status requiring \u001b[0m\n",
              "\u001b[32massistance for treatment of hypoglycemia, irrespective of glucose level. Assessment and medication selection i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mReview hypoglycemia history at every clinical encounter in all at-risk individuals. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Screen for impaired \u001b[0m\n",
              "\u001b[32mhypoglycemia awareness in all at-risk individuals. iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Consider hypoglycemia risk when selecting diabetes \u001b[0m\n",
              "\u001b[32mmedications and setting glycemic goals. Prevention and management of hypoglycemia i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Use CGM for individuals at \u001b[0m\n",
              "\u001b[32mhigh risk for hypoglycemia.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_10_cont_14'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic Goals and Hypoglycemia'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Glycemic status in diabetes management is assessed using A1C measurements and continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, which includes metrics like Time in Range \u001b[0m\u001b[32m(\u001b[0m\u001b[32mTIR\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Glucose Management Indicator \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGMI\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32mAssessments should occur at least twice a year for those meeting treatment goals and quarterly for those not \u001b[0m\n",
              "\u001b[32mmeeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red\u001b[0m\n",
              "\u001b[32mblood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine \u001b[0m\n",
              "\u001b[32mfor more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose \u001b[0m\n",
              "\u001b[32mProfile \u001b[0m\u001b[32m(\u001b[0m\u001b[32mAGP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, offering insights into daily glucose fluctuations and helping to identify periods of hypo- or \u001b[0m\n",
              "\u001b[32mhyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual \u001b[0m\n",
              "\u001b[32mneeds, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in \u001b[0m\n",
              "\u001b[32moptimizing diabetes management by addressing both short-term fluctuations and long-term health goals'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose is the preferred treatment for hypoglycemia in conscious individuals with glucose \u001b[0m\n",
              "\u001b[32mlevels <70 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<39 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, although any form of fast-acting carbohydrate can be used. Re-test and re-treat, if \u001b[0m\n",
              "\u001b[32mneeded, after 15 minutes. iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32mEnsure that glucagon is prescribed for all those taking insulin and those at high \u001b[0m\n",
              "\u001b[32mrisk for hypoglycemia, with education provided on its use and proper storage. iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Offer structured education on \u001b[0m\n",
              "\u001b[32mhypoglycemia prevention and treatment to all individuals taking insulin and those at high risk for hypoglycemia. v\u001b[0m\u001b[32m)\u001b[0m\n",
              "\u001b[32mUpon occurrence of one or more episodes of level 2 or level 3 hypoglycemia, promptly reevaluate the treatment plan,\u001b[0m\n",
              "\u001b[32mincluding considering whether to deintensify or switch medications. v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Refer individuals with impaired hypoglycemia\u001b[0m\n",
              "\u001b[32mawareness to a trained health care professional for evidence-based interventions to help reestablish awareness of \u001b[0m\n",
              "\u001b[32mhypoglycemia symptoms. vi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Conduct ongoing assessments of cognitive function, ensuring extra caution and support \u001b[0m\n",
              "\u001b[32mfor hypoglycemia if impaired or declining cognition is identified.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Older Adults'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The approach to managing diabetes in older adults is differentiated by their health status, \u001b[0m\n",
              "\u001b[32mranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For \u001b[0m\n",
              "\u001b[32mhealthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or \u001b[0m\n",
              "\u001b[32mcognitive impairments aim for less stringent targets like <8.0%. Treatment in skilled nursing facilities focuses on\u001b[0m\n",
              "\u001b[32mmaintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health \u001b[0m\n",
              "\u001b[32msituations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32memphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options\u001b[0m\n",
              "\u001b[32mto simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment \u001b[0m\n",
              "\u001b[32mgoals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside \u001b[0m\n",
              "\u001b[32mmedications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach \u001b[0m\n",
              "\u001b[32mprioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Individualization of Treatment Goals and Medication Plans for Older Adults With Diabetes \u001b[0m\n",
              "\u001b[32mCentral Panel: Patient Characteristics and Health Status i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Healthy Individuals: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: Few \u001b[0m\n",
              "\u001b[32mcoexisting chronic illnesses and intact cognitive and functional status. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Treatment Goal: A1C <7-7.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m53-58 \u001b[0m\n",
              "\u001b[32mmmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Complex/Intermediate Health: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: Multiple coexisting chronic illnesses or two or \u001b[0m\n",
              "\u001b[32mmore instrumental activities of daily living \u001b[0m\u001b[32m(\u001b[0m\u001b[32mIADL\u001b[0m\u001b[32m)\u001b[0m\u001b[32m impairments or mild to moderate cognitive impairments. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mTreatment Goal: A1C <8.0% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<64 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Community-dwelling Individuals in Skilled Nursing Facilities: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mCharacteristics: Receiving care in a skilled nursing facility for short-term rehabilitation. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Treatment Goal: \u001b[0m\n",
              "\u001b[32mFocus on glucose goals of 100–200 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.55–11.1 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m rather than strict A1C targets. iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Very Complex/Poor \u001b[0m\n",
              "\u001b[32mHealth: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Characteristics: Long-term care or end-stage chronic illnesses or moderate to severe cognitive \u001b[0m\n",
              "\u001b[32mimpairment or more ADL impairments.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Older Adults'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The approach to managing diabetes in older adults is differentiated by their health status, \u001b[0m\n",
              "\u001b[32mranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For \u001b[0m\n",
              "\u001b[32mhealthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or \u001b[0m\n",
              "\u001b[32mcognitive impairments aim for less stringent targets like <8.0%. Treatment in skilled nursing facilities focuses on\u001b[0m\n",
              "\u001b[32mmaintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health \u001b[0m\n",
              "\u001b[32msituations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32memphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options\u001b[0m\n",
              "\u001b[32mto simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment \u001b[0m\n",
              "\u001b[32mgoals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside \u001b[0m\n",
              "\u001b[32mmedications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach \u001b[0m\n",
              "\u001b[32mprioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32mTreatment Goal: Avoid reliance on A1C; focus on avoiding hypoglycemia and symptomatic \u001b[0m\n",
              "\u001b[32mhyperglycemia. v\u001b[0m\u001b[32m)\u001b[0m\u001b[32m At the End of Life: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Treatment Goal: Avoid hypoglycemia and symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32mfocusing on comfort. Left Panel: Medication Strategies for Maintenance Stay the Course if the person: Can \u001b[0m\n",
              "\u001b[32mmanage/perform tasks required. Has infrequent acute illnesses. Has support available, if needed. Right Panel: \u001b[0m\n",
              "\u001b[32mMedication Strategies for Simplification Deintensify or Simplify the Plan if the person: Has had severe or \u001b[0m\n",
              "\u001b[32mrecurrent hypoglycemia. Has experienced deterioration in health, cognitive, or functional status. Has had recent or\u001b[0m\n",
              "\u001b[32mfrequent acute illnesses or hospitalization. Is experiencing wide glycemic excursions. Has had significant changes \u001b[0m\n",
              "\u001b[32min social circumstances. Is dealingling with polypharmacy issues. Additional Considerations \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBottom Left\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Consider \u001b[0m\n",
              "\u001b[32musing continuous glucose monitoring and other technologies to reduce hypoglycemia. Include medications to reduce \u001b[0m\n",
              "\u001b[32mcardiovascular risk, irrespective of glycemia. Use available resources to reduce cost-related barriers to \u001b[0m\n",
              "\u001b[32mtreatment.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Older Adults'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The approach to managing diabetes in older adults is differentiated by their health status, \u001b[0m\n",
              "\u001b[32mranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For \u001b[0m\n",
              "\u001b[32mhealthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or \u001b[0m\n",
              "\u001b[32mcognitive impairments aim for less stringent targets like <8.0%. Treatment in skilled nursing facilities focuses on\u001b[0m\n",
              "\u001b[32mmaintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health \u001b[0m\n",
              "\u001b[32msituations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32memphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options\u001b[0m\n",
              "\u001b[32mto simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment \u001b[0m\n",
              "\u001b[32mgoals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside \u001b[0m\n",
              "\u001b[32mmedications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach \u001b[0m\n",
              "\u001b[32mprioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Summary This diagram effectively maps out a patient-centered approach to managing diabetes in \u001b[0m\n",
              "\u001b[32molder adults, taking into account the complexity of their health status and the practicalities of their daily \u001b[0m\n",
              "\u001b[32mlives. It emphasizes flexible treatment goals tailored to individual needs, capacities, and life stages, aiming to \u001b[0m\n",
              "\u001b[32mbalance effective glycemic control with quality of life and minimizing treatment burdens. Simplification of Complex\u001b[0m\n",
              "\u001b[32mInsulin Therapy 1. Individual on Basal \u001b[0m\u001b[32m(\u001b[0m\u001b[32mLong- or Intermediate-acting\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and/or Prandial \u001b[0m\u001b[32m(\u001b[0m\u001b[32mShort- or Rapid-acting\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mInsulins: Basal Insulin Adjustments: Change timing from bedtime to morning. Titrate dose of basal insulin based on \u001b[0m\n",
              "\u001b[32mfasting finger-stick glucose test results over a week: If fasting goal is 90-150 mg/dL, consider adjusting goals \u001b[0m\n",
              "\u001b[32mbased on overall health and goals of care. If 50% of fasting values are above goal, increase dose by 2 units. If 2+\u001b[0m\n",
              "\u001b[32mfasting values per week are <80 mg/dL, decrease dose by 2 units. Prandial Insulin Adjustments: If prandial insulin \u001b[0m\n",
              "\u001b[32m>10 units/dose, decrease dose by 50% and consider adding noninsulin agents.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Older Adults'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The approach to managing diabetes in older adults is differentiated by their health status, \u001b[0m\n",
              "\u001b[32mranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For \u001b[0m\n",
              "\u001b[32mhealthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or \u001b[0m\n",
              "\u001b[32mcognitive impairments aim for less stringent targets like <8.0%. Treatment in skilled nursing facilities focuses on\u001b[0m\n",
              "\u001b[32mmaintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health \u001b[0m\n",
              "\u001b[32msituations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32memphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options\u001b[0m\n",
              "\u001b[32mto simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment \u001b[0m\n",
              "\u001b[32mgoals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside \u001b[0m\n",
              "\u001b[32mmedications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach \u001b[0m\n",
              "\u001b[32mprioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Titrate prandial insulin doses down as noninsulin agent doses are increased with the aim to \u001b[0m\n",
              "\u001b[32mdiscontinue prandial insulin if feasible. 2. Individual on Premixed Insulin: Use 70% of the total dose as basal \u001b[0m\n",
              "\u001b[32minsulin only in the morning. If mealtime insulin ≤10 units/dose: Discontinue prandial insulin and add noninsulin \u001b[0m\n",
              "\u001b[32magent\u001b[0m\u001b[32m(\u001b[0m\u001b[32ms\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Additional Pathways and Tips: Adding Noninsulin Agents: If eGFR is ≥45 mg/dL, start metformin 500 mg \u001b[0m\n",
              "\u001b[32mdaily and increase dose every 2 weeks as tolerated. If eGFR is <45 mg/dL and patient is already taking metformin or\u001b[0m\n",
              "\u001b[32mmetformin is not tolerated, proceed to second-line agents. General Guidelines: Do not use rapid- and short-acting \u001b[0m\n",
              "\u001b[32minsulin at bedtime. Use a simplified sliding scale for adjusting prandial insulin based on premeal glucose levels. \u001b[0m\n",
              "\u001b[32mStop sliding scale when not needed daily. Additional Recommendations Based on Comprehensive Care Guidelines: Use \u001b[0m\n",
              "\u001b[32mindividual and drug characteristics to guide decision-making.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_11_cont_5'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Older Adults'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The approach to managing diabetes in older adults is differentiated by their health status, \u001b[0m\n",
              "\u001b[32mranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For \u001b[0m\n",
              "\u001b[32mhealthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or \u001b[0m\n",
              "\u001b[32mcognitive impairments aim for less stringent targets like <8.0%. Treatment in skilled nursing facilities focuses on\u001b[0m\n",
              "\u001b[32mmaintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health \u001b[0m\n",
              "\u001b[32msituations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, \u001b[0m\n",
              "\u001b[32memphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options\u001b[0m\n",
              "\u001b[32mto simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment \u001b[0m\n",
              "\u001b[32mgoals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside \u001b[0m\n",
              "\u001b[32mmedications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach \u001b[0m\n",
              "\u001b[32mprioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Adjust insulin dose and/or add glucose-lowering agents based on finger-stick glucose testing \u001b[0m\n",
              "\u001b[32mbefore meals and bedtime: Target for pre-meal glucose is 90-150 mg/dL. Increase dose if more than two finger-stick \u001b[0m\n",
              "\u001b[32mvalues per week are above the goal. Decrease dose if 2+ pre-meal finger-stick values/week are <90 mg/dL. Summary \u001b[0m\n",
              "\u001b[32mThis guide effectively outlines how to simplify complex insulin regimens for individuals with varying levels of \u001b[0m\n",
              "\u001b[32mblood glucose control and health statuses. It emphasizes personalized treatment adjustments to optimize efficacy, \u001b[0m\n",
              "\u001b[32mminimize hypoglycemia risks, and reduce the burden of diabetes management.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes Care in the Hospital'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize \u001b[0m\n",
              "\u001b[32mrisks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including \u001b[0m\n",
              "\u001b[32mmortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,\u001b[0m\n",
              "\u001b[32mand assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies \u001b[0m\n",
              "\u001b[32mmaintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in \u001b[0m\n",
              "\u001b[32mmedications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home \u001b[0m\n",
              "\u001b[32mrequires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling\u001b[0m\n",
              "\u001b[32mfollow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels \u001b[0m\n",
              "\u001b[32mwith insulin and implementing transitional care models are employed to further decrease the likelihood of \u001b[0m\n",
              "\u001b[32mreadmissions.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes Care in the Hospital \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glycemic Management During Hospitalization Carefully managing\u001b[0m\n",
              "\u001b[32mpeople with diabetes during hospitalization can reduce the risk of hyperglycemia, hypoglycemia,or extreme glucose \u001b[0m\n",
              "\u001b[32mvariability, which all lead to adverse outcomes, including death. Consult with a specialized diabetes or glucose \u001b[0m\n",
              "\u001b[32mmanagement team when possible. Hospital Care Delivery Standards Institute validated order sets for management of \u001b[0m\n",
              "\u001b[32mdysglycemia in the hospital. State the type of diabetes on the initial evaluation when it is known. Perform an A1C \u001b[0m\n",
              "\u001b[32mtest on all hospitalized people with diabetes or hyperglycemia \u001b[0m\u001b[32m(\u001b[0m\u001b[32mrandom blood glucose >140 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m7.8 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m if no\u001b[0m\n",
              "\u001b[32mA1C result is available from the prior 3 months. Assess diabetes self-management knowledge and behaviors on \u001b[0m\n",
              "\u001b[32madmission and provide self-management education,if available, when needed.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes Care in the Hospital'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize \u001b[0m\n",
              "\u001b[32mrisks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including \u001b[0m\n",
              "\u001b[32mmortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,\u001b[0m\n",
              "\u001b[32mand assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies \u001b[0m\n",
              "\u001b[32mmaintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in \u001b[0m\n",
              "\u001b[32mmedications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home \u001b[0m\n",
              "\u001b[32mrequires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling\u001b[0m\n",
              "\u001b[32mfollow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels \u001b[0m\n",
              "\u001b[32mwith insulin and implementing transitional care models are employed to further decrease the likelihood of \u001b[0m\n",
              "\u001b[32mreadmissions.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m\"\u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Perioperative Care \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m A1C and glucose goals : • Elective surgery A1C goal: <8% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m63.9 \u001b[0m\n",
              "\u001b[32mmmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m • Blood glucose goal within 4 hours of surgery: 100–180 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m5.6–10.0 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Medication \u001b[0m\n",
              "\u001b[32madjustments: • Hold metformin on the day of surgery. • Discontinue sodium–glucose cotransporter 2 inhibitors 3–4 \u001b[0m\n",
              "\u001b[32mdays before surgery. • Hold other oral glucose-lowering agents the morning of the surgery or procedure. Then either\u001b[0m\n",
              "\u001b[32mkeep the next bullet or follow my suggestion and delete it, since I can't find it anywhere in the full SOC. • \u001b[0m\n",
              "\u001b[32mIndividualize plan based on clinical scenario and procedure/surgery. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Insulin therapy adjustments: • Give half\u001b[0m\n",
              "\u001b[32mof NPH dose or 75–80% of long-acting analog insulin or adjust insulin pump basal rates based on diabetes type and \u001b[0m\n",
              "\u001b[32mclinical judgment. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Transition From the Hospital to the Ambulatory Setting Tailor a structured discharge plan to\u001b[0m\n",
              "\u001b[32mthe individual with diabetes: \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Provide diabetes self-management education before discharge. \u001b[0m\u001b[32m(\u001b[0m\u001b[32m2\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Ensure \u001b[0m\n",
              "\u001b[32mmedication reconciliation and access.\"\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'12_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes Care in the Hospital'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize \u001b[0m\n",
              "\u001b[32mrisks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including \u001b[0m\n",
              "\u001b[32mmortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,\u001b[0m\n",
              "\u001b[32mand assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies \u001b[0m\n",
              "\u001b[32mmaintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in \u001b[0m\n",
              "\u001b[32mmedications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home \u001b[0m\n",
              "\u001b[32mrequires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling\u001b[0m\n",
              "\u001b[32mfollow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels \u001b[0m\n",
              "\u001b[32mwith insulin and implementing transitional care models are employed to further decrease the likelihood of \u001b[0m\n",
              "\u001b[32mreadmissions.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32m3\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Arrange virtual or in-person follow-up visits post-discharge: \u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Schedule a visit with the\u001b[0m\n",
              "\u001b[32mprimary care clinician, endocrinologist, or diabetes specialist within 1 month of discharge. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Schedule earlier \u001b[0m\n",
              "\u001b[32mfollow-up \u001b[0m\u001b[32m(\u001b[0m\u001b[32m1–2 weeks\u001b[0m\u001b[32m)\u001b[0m\u001b[32m if medications change or glucose targets not met at discharge. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Strategies To Reduce \u001b[0m\n",
              "\u001b[32mReadmissions i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Identifying people with ketosis-prone diabetes ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Treating individuals with admission A1C >9% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m>75\u001b[0m\n",
              "\u001b[32mmmol/ mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m with insulin iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Implementing a transitional care model iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Proactively planning for care transitions \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mincluding scheduling home health visits and timely follow-up care\u001b[0m\u001b[32m)\u001b[0m\u001b[32m'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Management of Diabetes in Pregnancy'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs\u001b[0m\n",
              "\u001b[32mof pregnant women with diabetes or those at risk of gestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Preconception counseling \u001b[0m\n",
              "\u001b[32mis crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy \u001b[0m\n",
              "\u001b[32mcomplications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with\u001b[0m\n",
              "\u001b[32mtargets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the \u001b[0m\n",
              "\u001b[32msecond half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, \u001b[0m\n",
              "\u001b[32mwhile oral medications are generally avoided due to safety concerns. Postpartum care includes psychological \u001b[0m\n",
              "\u001b[32msupport, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity \u001b[0m\n",
              "\u001b[32mafter delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting \u001b[0m\n",
              "\u001b[32mbreastfeeding and regular diabetes screening postpartum.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Management of Diabetes in Pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Preconception Counseling: • Incorporate preconception \u001b[0m\n",
              "\u001b[32mcounseling into diabetes care starting at puberty and continuing in all people with diabetes and childbearing \u001b[0m\n",
              "\u001b[32mpotential. • Discuss family planning and prescribe effective contraception to be used until A1C is optimized for \u001b[0m\n",
              "\u001b[32mpregnancy. • Address the importance of achieving glucose levels as close to normal as is safely possible, ideally \u001b[0m\n",
              "\u001b[32mA1C <6.5% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<48 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m to reduce the risk of congenital anomalies, preeclampsia, macrosomia, preterm birth, and \u001b[0m\n",
              "\u001b[32mother complications. • Focus on nutrition, diabetes education, and screening for diabetes comorbidities and \u001b[0m\n",
              "\u001b[32mcomplications, in addition to achieving glycemic targets. • Counsel on the risk of development and/or progression \u001b[0m\n",
              "\u001b[32mof diabetic retinopathy. A dilated eye examination should occur before pregnancy or in the first trimester, with \u001b[0m\n",
              "\u001b[32mcontinued monitoring every trimester and for 1 year postpartum based on findings. The preconception care of people \u001b[0m\n",
              "\u001b[32mwith diabetes is detailed in Table 15.1 in the complete ADA Standards of Care in Diabetes—2024.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Management of Diabetes in Pregnancy'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs\u001b[0m\n",
              "\u001b[32mof pregnant women with diabetes or those at risk of gestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Preconception counseling \u001b[0m\n",
              "\u001b[32mis crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy \u001b[0m\n",
              "\u001b[32mcomplications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with\u001b[0m\n",
              "\u001b[32mtargets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the \u001b[0m\n",
              "\u001b[32msecond half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, \u001b[0m\n",
              "\u001b[32mwhile oral medications are generally avoided due to safety concerns. Postpartum care includes psychological \u001b[0m\n",
              "\u001b[32msupport, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity \u001b[0m\n",
              "\u001b[32mafter delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting \u001b[0m\n",
              "\u001b[32mbreastfeeding and regular diabetes screening postpartum.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glycemic Management and Goals in Pregnancy i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Perform fasting, preprandial, and \u001b[0m\n",
              "\u001b[32mpostprandial blood glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mBGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Glucose goals are fasting plasma glucose <95 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<5.3 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mand either 1-h postprandial glucose <140 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<7.8 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or 2-h postprandial glucose <120 mg/dL \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<6.7 mmol/L\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. \u001b[0m\n",
              "\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Ideally, the A1C goal in pregnancy is <6% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<42 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m if this can be achieved without significant \u001b[0m\n",
              "\u001b[32mhypoglycemia; the goal may be relaxed to <7% \u001b[0m\u001b[32m(\u001b[0m\u001b[32m<53 mmol/mol\u001b[0m\u001b[32m)\u001b[0m\u001b[32m to prevent hypoglycemia. iv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When used in addition to \u001b[0m\n",
              "\u001b[32mpre- and postprandial BGM, continuous glucose monitoring can help to achieve the A1C goal in diabetes and \u001b[0m\n",
              "\u001b[32mpregnancy. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mC\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Management of Gestational Diabetes Mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m GDM refers specifically to diabetes diagnosed \u001b[0m\n",
              "\u001b[32mafter the first trimester of pregnancy in individuals who did not have diabetes before pregnancy. Diabetes detected\u001b[0m\n",
              "\u001b[32mbefore or in early pregnancy is usually considered to be preexisting type 2 diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13_cont_3'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Management of Diabetes in Pregnancy'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs\u001b[0m\n",
              "\u001b[32mof pregnant women with diabetes or those at risk of gestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Preconception counseling \u001b[0m\n",
              "\u001b[32mis crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy \u001b[0m\n",
              "\u001b[32mcomplications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with\u001b[0m\n",
              "\u001b[32mtargets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the \u001b[0m\n",
              "\u001b[32msecond half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, \u001b[0m\n",
              "\u001b[32mwhile oral medications are generally avoided due to safety concerns. Postpartum care includes psychological \u001b[0m\n",
              "\u001b[32msupport, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity \u001b[0m\n",
              "\u001b[32mafter delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting \u001b[0m\n",
              "\u001b[32mbreastfeeding and regular diabetes screening postpartum.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'• Individuals without diabetes before or early in pregnancy should be screened for GDM at 24 to\u001b[0m\n",
              "\u001b[32m28 weeks of pregnancy. • Lifestyle behavior change is an essential component of GDM management. • Insulin is the \u001b[0m\n",
              "\u001b[32mpreferred medication for treating hyperglycemia in GDM. • Metformin and glyburide should not be used as first-line \u001b[0m\n",
              "\u001b[32magents in GDM. Other oral and noninsulin injectable glucose- lowering medications lack long-term safety data for \u001b[0m\n",
              "\u001b[32muse in GDM. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Additional Drug Considerations During Pregnancy i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Initiate or titrate blood pressure medication at\u001b[0m\n",
              "\u001b[32ma threshold of 140/90 mmHg. A target of 110–135/84 mmHg is suggested. Therapy should be reduced if blood pressure \u001b[0m\n",
              "\u001b[32mis <90/60 mmHg. ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Stop potentially harmful medications in pregnancy \u001b[0m\u001b[32m(\u001b[0m\u001b[32mi.e., ACE inhibitors, angiotensin receptor \u001b[0m\n",
              "\u001b[32mblockers, and statins\u001b[0m\u001b[32m)\u001b[0m\u001b[32m prior to conception and avoid in sexually active individuals of childbearing potential who \u001b[0m\n",
              "\u001b[32mare not using reliable contraception. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mE\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Postpartum Care i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Postpartum care should include psychosocial assessment\u001b[0m\n",
              "\u001b[32mand support for self-care.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_13_cont_4'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Management of Diabetes in Pregnancy'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs\u001b[0m\n",
              "\u001b[32mof pregnant women with diabetes or those at risk of gestational diabetes mellitus \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGDM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Preconception counseling \u001b[0m\n",
              "\u001b[32mis crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy \u001b[0m\n",
              "\u001b[32mcomplications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with\u001b[0m\n",
              "\u001b[32mtargets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the \u001b[0m\n",
              "\u001b[32msecond half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, \u001b[0m\n",
              "\u001b[32mwhile oral medications are generally avoided due to safety concerns. Postpartum care includes psychological \u001b[0m\n",
              "\u001b[32msupport, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity \u001b[0m\n",
              "\u001b[32mafter delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting \u001b[0m\n",
              "\u001b[32mbreastfeeding and regular diabetes screening postpartum.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'\u001b[0m\u001b[32m(\u001b[0m\u001b[32ma\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Contraception: Discuss and implement a contraception plan with all individuals with \u001b[0m\n",
              "\u001b[32mdiabetes of childbearing potential. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mb\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Lactation: Promote breastfeeding, which has been shown to reduce the risk \u001b[0m\n",
              "\u001b[32mof type 2 diabetes later in life. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Postpartum Care of Individuals With GDM: • Screen for diabetes at 4–12 weeks \u001b[0m\n",
              "\u001b[32mpostpartum with a 75-g oral glucose tolerance test using nonpregnancy criteria. • Lifelong diabetes screening \u001b[0m\n",
              "\u001b[32mshould occur every 1–3 years. • For those with overweight/obesity and prediabetes, implement intensive lifestyle \u001b[0m\n",
              "\u001b[32minterventions and/or metformin therapy. \u001b[0m\u001b[32m(\u001b[0m\u001b[32md\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Postpartum Care for Individuals With Preexisting Diabetes: Insulin \u001b[0m\n",
              "\u001b[32mresistance decreases dramatically immediately after delivery. Evaluate insulin requirements, adjust doses, and \u001b[0m\n",
              "\u001b[32mmonitor for hypoglycemia.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_14'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_14_cont_1'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Pharmacologic Approaches to Glycemic Treatment \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Ways to Address or Prevent Therapeutic \u001b[0m\n",
              "\u001b[32mInertia for People With Type 1 or Type 2 Diabetes i\u001b[0m\u001b[32m)\u001b[0m\u001b[32m EMPOWER PATIENTS: BE A BARRIER BUSTER Schedule diabetes-only \u001b[0m\n",
              "\u001b[32mvisits. Set and track shared goals and time frames. Integrate screening for social/emotional barriers and identify \u001b[0m\n",
              "\u001b[32msupport. Prescribed thoughtfully. Refer to diabetes self-management education and support \u001b[0m\u001b[32m(\u001b[0m\u001b[32mDSMES\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. Do your patients\u001b[0m\n",
              "\u001b[32mknow you are their champion? ii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m OPTIMIZE CARE AND TREATMENT: ACT NOW Conduct practice-based screening for likely \u001b[0m\n",
              "\u001b[32mtherapeutic inertia. Make personalized diabetes care plans. Implement a team-based approach to increase the \u001b[0m\n",
              "\u001b[32mfrequency and quality of engagement. Utilize A1C and glucose data to drive rapid-cycle treatment intensification. \u001b[0m\n",
              "\u001b[32mStratify follow-up based on A1C/glucose data and changes in therapy. Have you done everything in your control to \u001b[0m\n",
              "\u001b[32moptimize therapy and support during, after, and in between visits? iii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m IMPROVE DECISION-MAKING Follow a diabetes \u001b[0m\n",
              "\u001b[32mtreatment algorithm. Create and use a patient registry. Integrate decision support into the workflow. Utilize \u001b[0m\n",
              "\u001b[32mtechnology to enhance communication with people with diabetes.'\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m}\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m    \u001b[0m\u001b[1;39m{\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_14'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content_id'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'd_14_cont_2'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'doc_name'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'summary'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m\u001b[39m,\u001b[0m\n",
              "\u001b[39m        \u001b[0m\u001b[32m'content'\u001b[0m\u001b[39m: \u001b[0m\u001b[32m'Disseminate unblinded quality metrics. Have you enabled everyone in your practice to make \u001b[0m\n",
              "\u001b[32mhigh-quality treatment decisions quickly and consistently? \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When to Use Injectable Therapy in Type 2 Diabetes \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mi\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Which therapy should I start first? Treatment with a glucagon-like peptide 1 \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGLP-1\u001b[0m\u001b[32m)\u001b[0m\u001b[32m receptor agonist or a dual\u001b[0m\n",
              "\u001b[32mglucose-dependent insulinotropic polypeptide \u001b[0m\u001b[32m(\u001b[0m\u001b[32mGIP\u001b[0m\u001b[32m)\u001b[0m\u001b[32m/ GLP-1 receptor agonist is preferred before insulin therapy \u001b[0m\n",
              "\u001b[32mbecause of its ability to achieve both glycemic and weight management goals. Some GLP-1 receptor agonists also \u001b[0m\n",
              "\u001b[32mprovide cardiovascular benefit. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When should I start insulin first? If there is evidence of catabolism \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., \u001b[0m\n",
              "\u001b[32munexpected weight loss\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When A1C or blood glucose levels are very high \u001b[0m\u001b[32m(\u001b[0m\u001b[32mA1C >10% \u001b[0m\u001b[32m[\u001b[0m\u001b[32m>\u001b[0m\u001b[32m86 mmol/mol\u001b[0m\u001b[32m]\u001b[0m\u001b[32m or blood glucose \u001b[0m\n",
              "\u001b[32m≥300 mg/dL \u001b[0m\u001b[32m[\u001b[0m\u001b[32m≥16.7 mmol/L\u001b[0m\u001b[32m]\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\u001b[32m(\u001b[0m\u001b[32miii\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Can I use combination insulin and non insulin injectable therapy? Yes; combination\u001b[0m\n",
              "\u001b[32mtherapy with insulin and a noninsulin injectable is recommended forgreater glycemic effectiveness and beneficial \u001b[0m\n",
              "\u001b[32meffects on weight andypoglycemia risk.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_14'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_14_cont_3'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'If insulin is already being used, insulin dosing should be reassessed upon addition or dose \u001b[0m\n",
              "\u001b[32mescalation of a GLP-1 or dual GIP and GLP-1 receptor agonist. \u001b[0m\u001b[32m(\u001b[0m\u001b[32miv\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When would I use combination insulin and \u001b[0m\n",
              "\u001b[32mnoninsulin injectable therapy? Consider combination insulin and GLP-1 or dual GIP/GLP-1 receptor agonist therapy \u001b[0m\n",
              "\u001b[32mwhen individualized goals are not met using either one separately. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mV\u001b[0m\u001b[32m)\u001b[0m\u001b[32m When should I modify a patient’s injectable \u001b[0m\n",
              "\u001b[32mtherapy? Intensify or deintensify therapy when an individual is not meeting treatment goals, including management \u001b[0m\n",
              "\u001b[32mof hyperglycemia and weight and avoidance of hypoglycemia. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mB\u001b[0m\u001b[32m)\u001b[0m\u001b[32m GOALS: Cardiovascular Risk Reduction in High-Risk \u001b[0m\n",
              "\u001b[32mIndividuals with Type 2 Diabetes: Achieved alongside comprehensive cardiovascular risk management. Achievement and \u001b[0m\n",
              "\u001b[32mMaintenance of Glycemic and Weight Management Goals: Set individualized weight management goals. Choose glycemic \u001b[0m\n",
              "\u001b[32mmanagement approaches that balance efficacy and risk. Consider metabolic surgery for eligible patients.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_14'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_14_cont_4'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'Initial Treatment Decisions: Assessment of Cardiovascular Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Risk: For patients with\u001b[0m\n",
              "\u001b[32matherosclerotic cardiovascular disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mASCVD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m or indicators of high risk \u001b[0m\u001b[32m(\u001b[0m\u001b[32mvarying conditions like myocardial \u001b[0m\n",
              "\u001b[32minfarction, stable angina, or asymptomatic coronary artery disease\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, consider medications like GLP-1 RA with proven\u001b[0m\n",
              "\u001b[32mCVD benefit or SGLT2i with proven CVD benefit. Heart Failure \u001b[0m\u001b[32m(\u001b[0m\u001b[32mHF\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and Chronic Kidney Disease \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCKD\u001b[0m\u001b[32m)\u001b[0m\u001b[32m Considerations: \u001b[0m\n",
              "\u001b[32mFor patients with HF or prior HF symptoms, consider SGLT2i with proven HF benefit. For CKD patients \u001b[0m\u001b[32m(\u001b[0m\u001b[32meGFR <60 \u001b[0m\n",
              "\u001b[32mmL/min\u001b[0m\u001b[32m)\u001b[0m\u001b[32m, the decision hinges on the severity, typically recommending continuation of SGLT2i until initiation of \u001b[0m\n",
              "\u001b[32mdialysis or contraindication. Follow-Up Treatment Adjustments Based on A1C Levels: If A1C Above Target: For \u001b[0m\n",
              "\u001b[32mpatients on a GLP-1 RA, consider adding an SGLT2i with proven CVD benefit, or vice versa. Reassess therapeutic \u001b[0m\n",
              "\u001b[32minertia and modify treatment based on DSME/S support and technological tools like continuous glucose monitoring \u001b[0m\n",
              "\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m to identify gaps.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_14'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_14_cont_5'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m\"Additional Considerations for Glycemic Lowering: If more substantial cardiovascular risk \u001b[0m\n",
              "\u001b[32mreduction or further glycemic control is needed, consider additional drugs or therapy adjustments, based on the \u001b[0m\n",
              "\u001b[32mindividual's response and tolerability. Medication Efficacy for Glycemic and Weight Control: Efficacy for Glucose \u001b[0m\n",
              "\u001b[32mLowering: High efficacy medications include GLP-1 RA and SGLT2i. Moderate efficacy options are DPP-4 inhibitors and\u001b[0m\n",
              "\u001b[32mMetformin. Efficacy for Weight Loss: Very high: Semaglutide, Tirzepatide. High: Dulaglutide, Liraglutide. \u001b[0m\n",
              "\u001b[32mIntermediate: Not listed above; generally includes other GLP-1 RAs and SGLT2i. Neutral: DPP-4i, Metformin. \u001b[0m\u001b[32m(\u001b[0m\u001b[32mc\u001b[0m\u001b[32m)\u001b[0m\u001b[32m \u001b[0m\n",
              "\u001b[32mTo-Do List for Clinicians Treating People With Insulin Therapy Provide or refer patients for education about \u001b[0m\n",
              "\u001b[32minjection technique and timing and problem-solving for issues related to insulin therapy \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., hypoglycemia, \u001b[0m\n",
              "\u001b[32mmissed or incorrect doses, and dose adjustments\u001b[0m\u001b[32m)\u001b[0m\u001b[32m. .\"\u001b[0m\n",
              "    \u001b[1m}\u001b[0m,\n",
              "    \u001b[1m{\u001b[0m\n",
              "        \u001b[32m'doc_id'\u001b[0m: \u001b[32m'd_14'\u001b[0m,\n",
              "        \u001b[32m'content_id'\u001b[0m: \u001b[32m'd_14_cont_6'\u001b[0m,\n",
              "        \u001b[32m'doc_name'\u001b[0m: \u001b[32m'Pharmacologic Approaches to Glycemic Treatment'\u001b[0m,\n",
              "        \u001b[32m'summary'\u001b[0m: \u001b[32m'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and \u001b[0m\n",
              "\u001b[32mpatient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering \u001b[0m\n",
              "\u001b[32mpatients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional \u001b[0m\n",
              "\u001b[32mbarriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of\u001b[0m\n",
              "\u001b[32mtherapy based on continuous glucose monitoring \u001b[0m\u001b[32m(\u001b[0m\u001b[32mCGM\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and A1C data. For Type 2 diabetes, injectable therapies like \u001b[0m\n",
              "\u001b[32mGLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their \u001b[0m\n",
              "\u001b[32mbenefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases \u001b[0m\n",
              "\u001b[32mof significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The \u001b[0m\n",
              "\u001b[32mapproach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual \u001b[0m\n",
              "\u001b[32mhealth status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated\u001b[0m\n",
              "\u001b[32mcare model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient \u001b[0m\n",
              "\u001b[32mwell-being.'\u001b[0m,\n",
              "        \u001b[32m'content'\u001b[0m: \u001b[32m'Ensure that individuals have all supplies necessary for injections \u001b[0m\u001b[32m(\u001b[0m\u001b[32me.g., pen needles for \u001b[0m\n",
              "\u001b[32minsulin pens or appropriate syringes for insulin dose size or concentration\u001b[0m\u001b[32m)\u001b[0m\u001b[32m and glucose monitoring. . Evaluate \u001b[0m\n",
              "\u001b[32mindividuals with type 2 diabetes to determine whether they are candidates for GLP-1 or dual GIP/GLP-1 receptor \u001b[0m\n",
              "\u001b[32magonist therapy. . Evaluate all people on insulin therapy to determine whether they could benefit from continuous \u001b[0m\n",
              "\u001b[32mglucose monitoring. . Ensure that people on insulin therapy have the education and supplies needed to prevent and \u001b[0m\n",
              "\u001b[32mtreat hypoglycemia, including glucagon, glucose monitoring supplies, and appropriate sources of carbohydrates to \u001b[0m\n",
              "\u001b[32mtreat low glucose levels. . Schedule timely and routine follow-up visits to reassess patients and adjust care plans\u001b[0m\n",
              "\u001b[32mto avoid therapeutic inertia.'\u001b[0m\n",
              "    \u001b[1m}\u001b[0m\n",
              "\u001b[1m]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">[</span>\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes (A) Diagnostic Tests for Diabetes: i)A1C Prediabetes: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">5.7–6.4% (39–47 mmol/ mol) Diabetes: ≥6.5% (≥48 mmol/mol) ii) 2-hour glucose value during a 75-g oral glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tolerance test Prediabetes: 140–199 mg/dL (7.8–11.0 mmol/L) Diabetes: ≥200 mg/dL (≥11.1 mmol/L) iii)Fasting plasma </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose Prediabetes: 100–125 mg/dL (5.6–6.9 mmol/L) Diabetes: ≥126 mg/dL (≥7.0 mmol/L) iv)Random glucose value with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">classic hyperglycemia symptoms/ hyperglycemic crisis Diabetes: ≥200 mg/dL (≥11.1 mmol/L) • There is insufficient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">evidence to support the use of continuous glucose monitoring for screening or diagnosing prediabetes or diabetes.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_2'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'• In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis), diagnosis of type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes requires confirmatory testing, which can be a different test on the same day or the same test on a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">different day. • Marked discordance between A1C and repeated blood (B) Classification Classification of diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type is not always straightforward at presentation, and misdiagnosis is common. i)Type 1 diabetes (idiopathic or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">autoimmune β-cell destruction) ii)Type 2 diabetes (non-autoimmune progressive loss of adequate β-cell insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">secretion frequently on the background of insulin resistance and metabolic syndrome) iii)Gestational diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mellitus (GDM; detected at 24–28 weeks of gestation in individuals without previously identified diabetes or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">high-risk glucose metabolism) iv)Diabetes from other causes (e.g., monogenic diabetes syndromes, diseases of the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">exocrine pancreas, and drug- or chemical-induced diabetes) (C)Screening Criteria for Prediabetes and Type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Diabetes: Screening for prediabetes and type 2 diabetes should be performed in asymptomatic adults with an informal</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment of risk factors or a validated risk calculator.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_3'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'(D)Informal Risk Factor Assessment for Prediabetes and Type 2 Diabetes i) Everyone ≥35 years of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">age ii)People with prior GDM iii)History of prediabetes iv)People with HIV, exposure to high-risk medicines, or a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">history of pancreatitis. Adults (≥18 years of age) with overweight or obesity (BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">American individuals) who have one or more of the following risk factors: ʜ First-degree relative with diabetes ʜ </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">High-risk race/ethnicity ʜ History of cardiovascular disease ʜ Hypertension (≥130/80 mmHg or on therapy for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypertension) ʜ Polycystic ovary syndrome ʜ HDL cholestorol &lt;35 mg/dL (&lt;0.9 mmol/L) and/or trigylcerides &gt;250 mg/dL</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(&gt;2.8 mmol/L) ʜ Physical inactivity ʜ Other clinical conditions associated with insulin resistance (E) Clinical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Notes i) If results are normal, repeat screening at least every 3 years (annually for those with prediabetes), or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">sooner with symptoms or changes in risk.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'ii) Risk-based screening for prediabetes or type 2 diabetes should be considered after the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">onset of puberty or after 10 years of age, whichever occurs earlier, in children and adolescents with overweight </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(BMI ≥85th percentile) or obesity (BMI ≥95th percentile) who have one or more risk factors for diabetes. (F) i) (a)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: An altered relationship between A1C and glycemia (b) clinical tips: A mismatch between A1C and glycemia </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">could be caused by some hemoglobin variants, pregnancy (second and third trimesters and the postpartum period), </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss or transfusion, anemia, or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">erythropoietin therapy. People with HIV should be screened for diabetes and prediabetes before and 3–6 months after</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">starting or changing antiretroviral therapy and annually if initial results are normal. (c) best test:Fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasmaglucose ii) (a) condition: Acute pancreatitis (b) clinical tips: Screen for diabetes 3-6 months after an </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">episode of acute pancreatitis and annually thereafter.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test: Any standard test for diagnosing diabetes iii) (a) condition: Cystic fibrosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(b) clinical tips: Annual screening should begin by the age of 10 years in all people with cystic fibrosis not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">previously diagnosed with cystic fibrosis-related diabetes (c) best test: Oral glucose tolerance test iv) (a) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">condition: Posttransplantation status (b) clinical tips: Screen for hyperglycemia after organ transplantation. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Posttransplantation diabetes mellitus should be diagnosed when the individual is stable on immunosuppressive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy and free of acute infections. (c) best test: Oral glucose tolerance test v) (a) condition: Possible </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monogenic diabetes (b) clinical tips: Suspect monogenic diabetes in people diagnosed with diabetes in the first 6 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">months of life and in children and young adults with atypical characteristics of type 1 or type 2 diabetes, who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">often have a family history of diabetes in successive generations (suggestive of an autosomal dominant pattern of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inheritance).'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_1_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diagnosis and Classification of Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The document outlines the diagnostic criteria and classification for diabetes, emphasizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">various tests such as the A1C, where a level of ≥6.5% indicates diabetes; the 2-hour glucose value during an oral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose tolerance test with a threshold of ≥200 mg/dL for diabetes; fasting plasma glucose, where diabetes is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosed at ≥126 mg/dL; and random glucose testing, which diagnoses diabetes at ≥200 mg/dL in the presence of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">symptoms. It notes the limitations of continuous glucose monitoring in diagnosing prediabetes and diabetes, and the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">necessity for confirmatory testing in ambiguous cases. The classification section details different types of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes including Type 1, Type 2, gestational, and other causes such as genetic syndromes. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended for adults based on risk factors, with specific guidelines for assessing risks such as age, prior </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes, and other health conditions. Clinical notes suggest repeat screening every three years for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">normal results, and more frequently for those with prediabetes or changing symptoms. Special circumstances, like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hemoglobin variants or post-transplant status, may alter screening methods, with various specific tests recommended</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on the individual's condition and risk factors.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(c) best test:Any standard test for diagnosing diabetes plus appropriate genetic testing vi) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(a) condition: Therapy with certain medications (b) clinical tips: Consider screening people for prediabetes or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes if they are on certain medications known to increase diabetes risk, such as glucocorticoids, statins, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">thiazide diuretics, some HIV medications, and second-generation antipsychotic medications. (c) best test:Any </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">standard test test for diagnosing diabetes'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities (A) Screening for Type 2 Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(i) Why Screen? • Lab testing is safe and cost- effective. • Screening presents an opportunity to address </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk factors (e.g., hypertension and dyslipidemia). (ii) 2. How to Screen • Conduct an informal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment of risk factors. –or– • Use an assessment tool such as the ADA risk test. • Consider diagnostic testing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on assessment results. (iii) When to Screen • Monitor people with prediabetes at least annually. • In those </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">without prediabetes who have normal results, repeat screening at least every 3 years. • Screen after the onset of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">puberty or after the age of 10 years in children and adolescents with overweight (BMI ≥85th percentile) or obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(BMI ≥95th percentile) who have at least one risk factor.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Symptoms suggestive of diabetes or changes in risk (B) Diet and Physical Activity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Recommendations for Adults at Risk for Type 2 Diabetes (i) Follow a Healthy Eating Pattern • Emphasize whole </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">grains, legumes, nuts, fruits, and vegetables and minimize refined and processed foods • A variety of healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating patterns include: » Mediterranean-style » Low-carbohydrate » Vegetarian or plant-based » DASH (Dietary </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Approaches to Stop Hypertension) (ii) Get Regular Physical Activity • ≥150 min/week of moderate-intensity physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, such as brisk walking • May include resistance or strength training • Break up prolonged sedentary time </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(iii) Where to Refer: • Refer adults with overweight or obesity who are at high risk for type 2 diabetes to a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recognized diabetes prevention lifestyle change program (cdc.gov/diabetes/prevention/find-a-program.html). (iv) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">What is the Diabetes Prevention Program? • The Diabetes Prevention Program (DPP) study demonstrated that intensive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">lifestyle intervention could reduce the risk of type diabetes by 58% over 3 years.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The two major goals of the DPP intensive lifestyle intervention were to achieve and maintain </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥7% weight loss and ≥150 min of moderate-intensity physical activity, such as brisk walking, per week. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Technology-assisted programs using smartphones, web apps, and telehealth platforms can effectively deliver the DPP </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">lifestyle change program, overcoming barriers, especially for low-income and rural individuals. (C) Person-Centered</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Care Goals for Individuals at Risk of Type 2 Diabetes (i) It is important to weight the individualized risks and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits of interventions. (1) Facilitate weight management in those with overweight/obesity. (2) Minimize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">progression of hyperglycemia. (3) Reduce cardiovascular risk. (ii) Consider more intensive approaches for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals at high risk of progression to diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(1) BMI ≥35 kg/m2 (2) Higher glucose levels (e.g., fasting plasma glucose 110–125 mg/dL </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">[6.1–6.9 mmol/L], 2–h post-challenge glucose 173 199 mg/dL [9.6–11 mmol/L], and A1C ≥6.0% [42 mmol/mol]) (3) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">History of gestational diabetes mellitus What medications can be prescribed to adults to prevent type 2 diabetes? </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">The U.S. Food and Drug Administration has not approved any drugs for diabetes prevention. Metformin has the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">strongest evidence base for diabetes prevention. Who should be considered for metformin therapy to prevent type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes? i) Adults aged 25–59 years with a BMI ≥35 kg/m2 ii) Individuals with higher fasting plasma glucose (e.g.,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥110 mg/dL [≥ 6 mmol/L]) iii) Those with higher A1C (e.g., ≥6.0% [≥42 mmol/mol]) iv) Individuals with a history of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gestational diabetes mellitus What parameters should be monitoring in people on metformin therapy?'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'i) Vitamin B12 should be measured periodically, especially in those with anemia or peripheral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">neuropathy. Screening for type 1 diabetes? 1. Screen using autoantibodies 2. In people with preclinical type 1 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes, monitor for disease progression using A1C approximately every 6 months and 75-g oral glucose tolerance </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">test (i.e., fasting and 2-h plasma glucose) annually; modify frequency of monitoring based on individual risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment based on age, number and type of autoantibodies, and glycemic metrics. Medication to delay the onset of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 1 diabetes Teplizumab-mzwv infusion to delay the onset of symptomatic type 1 diabetes should be considered in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">selected individuals who are ≥8 years of age and have stage 2 type 1 diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Staging of type 1 diabetes (i) Stage 1 (1) Characteristics: • Autoimmunity • Normoglycemia • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Presymptomatic (2) Diagnostic criteria : • Multiple islet autoantibodies • No IGT or IFG (ii) Stage 2 (1) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Characteristics: • Autoimmunity • Dysglycemia • Presymptomatic (2) Diagnostic criteria : • Islet autoantibodies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(usually multiple) • Dysglycemia: IFG and/or IGT • FPG 100–125 mg/dl (5.6–6.9 mmol/L) • 2-h PG 140–199 mg/dl </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(7.8–11.0 mmol/L) • A1C 5.7–6.4% (39–47 mmol/mol) or ≥10% increase in A1C (iii) Stage 3 (1) Characteristics: • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Autoimmunity • Overt hyperglycemia • Symptomatic (2) Diagnostic criteria : • Autoantibodies may become absent • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Diabetes by Does statin therapy increase the risk of developing type 2 diabetes?'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_2_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Prevention or Delay of Diabetes and Associated Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'This text outlines strategies for the prevention and management of diabetes and associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities, focusing on Type 2 diabetes screening, diet, physical activity, and medication. Screening is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommended to be done safely and cost-effectively, targeting individuals with prediabetes annually and others </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">every three years, beginning from puberty or age 10 in at-risk youths. Diet recommendations promote a healthy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating pattern that includes whole grains, fruits, vegetables, and minimal processed foods, with various diet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">styles like Mediterranean and DASH highlighted. Physical activity should be moderate and regular, aiming for at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">least 150 minutes per week. High-risk adults should be referred to recognized diabetes prevention programs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin is noted as the most supported pharmacological prevention for high-risk individuals, although not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">FDA-approved for this purpose. Screening for Type 1 diabetes involves monitoring autoantibodies and glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metrics. Teplizumab-mzwv is mentioned for delaying Type 1 diabetes in specific stages. The text also addresses the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use of statins and pioglitazone, noting their benefits and risks in diabetes and cardiovascular disease contexts.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Statin therapy may slightly elevate type 2 diabetes risk in high-risk individuals. • In </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">primary and secondary prevention of cardiovascular disease, statin benefits outweigh diabetes risk. • Discontinuing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">statins based on concerns about increased diabetes risk is not advised. Does pioglitazone have a role in secondary </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular prevention in people at risk for type 2 diabetes? Pioglitazone could reduce stroke and myocardial </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">infarction risks in people with a history of stroke and evidence of insulin resistance or prediabetes. However, the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefit must be weighed against potential weight gain, edema, and increased fracture risk. Lower doses may lessen </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">these adverse effects.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and Adolescents'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">developmentally appropriate diabetes self-management education for children and adolescents, which should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">training to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">youth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">retinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and adolescents with diabetes and their parents/caregivers should receive culturally </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">sensitive and developmentally appropriate individualized diabetes self-management education and support according </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to national standards at diagnosis and routinely thereafter. Recommendations for managing Type 1 diabetes are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comprehensively addressed in the ADA Standards of Care in Diabetes—2024 document. (A) School and Child Care (i) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Youth spend significant time in school/day care, necessitating personnel training for optimal diabetes care. (ii) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Proper care ensures optimal diabetes management and safe access to all school- or day care– sponsored </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">opportunities. (iii) Federal and state laws require schools, day care facilities, and other entities to provide </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needed diabetes care to enable the children to safely access the school or day care environment. (B) Type 2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Diabetes in Youth and Adolescents (i) Screening • Risk-based screening should be considered after the onset of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">puberty or ≥10 years of age, whichever occurs earlier, in youth with overweight (BMI ≥85th percentile) or obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(BMI ≥95th percentile) and who have one or more additional risk factors for diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and Adolescents'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">developmentally appropriate diabetes self-management education for children and adolescents, which should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">training to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">youth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">retinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(ii) Diagnosis • Fasting plasma glucose, 2-h plasma glucose during a 75-g oral glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tolerance test, and A1C can be used to diagnose prediabetes or diabetes in children and adolescents. • In those in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">whom a diagnosis of type 2 diabetes is being considered, a panel of pancreatic autoantibodies should be tested to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">exclude the possibility of autoimmune type 1 diabetes. (iii) Treatment • Treatment of type 2 diabetes in youth may </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">include: metformin, insulin, a glucaogon-like peptide 1 (GLP-1) receptor agonist approved for use in youth with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes, and/or the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin. (See figure on the next</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">page.) (iv) Complications • Blood pressure should be measured at every clinic visit and treated if found to be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">elevated on three separate measurements. • Urine albumin-to-creatinine ratio and estimated glomerular filtration </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rate should be obtained at the time of diagnosis then annually. • Neuropathy screening by foot exam should be done </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">at diagnosis and then annually.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and Adolescents'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">developmentally appropriate diabetes self-management education for children and adolescents, which should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">training to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">youth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">retinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Retinopathy screening by dilated fundoscopy should be done at diagnosis and then annually. • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Evaluation for nonalcoholic fatty liver disease (by measuring AST and ALT) should be done at diagnosis and then </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">annually. • Screening for symptoms of obstructive sleep apnea should be done at each visit. • Evaluate for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">polycystic ovary syndrome in female adolescents when indicated. • Lipid screening should be done after optimizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glycemia and then annually. (C) Addressing Probable New Cases of Type 2 Diabetes in Youth New-Onset Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Management in Youth With Overweight or Obesity and Suspected Type 2 Diabetes Initial Management: Initiate lifestyle</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management and diabetes education for all new cases. Determine Hemoglobin A1C Levels: If A1C &lt; 8.5% (with no </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis): Start treatment with Metformin, titrating up to 2,000 mg per day as tolerated. If A1C ≥ 8.5% </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(with no acidosis or ketosis): Begin treatment with Metformin, titrating up to 2,000 mg per day as tolerated.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and Adolescents'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">developmentally appropriate diabetes self-management education for children and adolescents, which should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">training to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">youth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">retinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Add long-acting insulin, starting at 0.5 units/kg/day, with titration every 2-3 days based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood glucose monitoring (BGM). For Acidosis or DKA (Diabetic Ketoacidosis) or HHNK (Hyperglycemic Hyperosmolar </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Nonketotic Syndrome): Manage with intravenous (IV) insulin until acidosis resolves. Transition to subcutaneous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">insulin following resolution, adjusting treatment as identified by the type of diabetes once antibodies are known. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Pancreatic Autoantibodies Testing: Negative Result: Continue or start Metformin. If using insulin, titrate dosage </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on glucose values. If A1C goals are not met: Continue Metformin. Consider adding a GLP-1 receptor agonist or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">an SGLT2 inhibitor approved for youth with type 2 diabetes. Initiate or adjust insulin therapy. If using </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">long-acting insulin only and glycemic targets are not met with escalating doses, consider adding prandial insulin. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Total daily insulin dose may exceed 1 unit/kg/day. Positive Result: Continue or initiate multiple daily injections </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(MDI) of insulin or pump therapy, as appropriate for type 1 diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_3_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Children and Adolescents'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The ADA Standards of Care in Diabetes—2024 emphasize the need for culturally sensitive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">developmentally appropriate diabetes self-management education for children and adolescents, which should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provided at diagnosis and routinely thereafter. Schools and daycare facilities play a crucial role, requiring staff</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">training to ensure safe and effective diabetes management under federal and state laws. For Type 2 diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">youth, risk-based screening is advised post-puberty or from age 10, with diagnostic criteria including fasting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plasma glucose, oral glucose tolerance tests, and A1C levels, alongside testing for pancreatic autoantibodies to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">rule out Type 1 diabetes. Treatment options may include metformin, insulin, GLP-1 receptor agonists, and SGLT2 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors like empagliflozin. Regular monitoring for complications such as hypertension, nephropathy, neuropathy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">retinopathy, nonalcoholic fatty liver disease, obstructive sleep apnea, polycystic ovary syndrome, and dyslipidemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial. New-onset Type 2 diabetes management involves lifestyle changes, diabetes education, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacological treatments based on A1C levels, with specific adjustments for those presenting with or without </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">acidosis or ketosis.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Discontinue Metformin.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes A holistic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach to obesity management is essential, encompassing nutrition counseling, regular exercise, behavioral </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">strategies, and diabetes self-management education to ensure effective and sustainable results. i) Management of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Overweight and Obesity In people with type 2 diabetes and overweight or obesity, weight management should represent</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">a primary goal of treatment along with glycemic management. ii) Weight management is crucially important because </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">it: • Delays progression from prediabetes to type 2 diabetes • Is highly beneficial in treating type 2 diabetes • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Improves glycemia and reduces the need for glucose-lowering medications • Reduces cardiovascular risk factors, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">lowering long-term cardiovascular and mortality risks • Reduces other obesity-related health risks iii) When </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">addressing weight management: • Use person-centered, nonjudgmental, person-first language (e.g., “person with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes” rather than diabetic person” and “person with obesity” rather than “obese person”). • Calculate BMI and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">perform measures body fat distribution (e.g., waist circumference, waist-to-hip ratio, and/or waist-to-height </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ratio). • Monitor obesity-related parameters at least annually to guide treatment decisions.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'LIFESTYLE MODIFICATIONS plus ANTI-OBESITY MEDICATION / METABOLIC SURGERY is PERSON-CENTERED </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">APPROACH (iv) Person-Centered Treatment Options for Overweight and Obesity in Type 2 Diabetes BMI Categories: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">25.0-26.9 kg/m² (or 23.0-24.9)* 27.0-29.9 kg/m² (or 25.0-27.4)* ≥30.0 kg/m² (or ≥27.5)* Treatment Options: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Intensive Behavioral Counseling: Recommended for individuals with a BMI of: 25.0-26.9 kg/m² 27.0-29.9 kg/m² ≥30.0 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">kg/m² Obesity Pharmacotherapy: Recommended for individuals with a BMI of: 27.0-29.9 kg/m² ≥30.0 kg/m² Metabolic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Surgery: Recommended for individuals with a BMI of ≥30.0 kg/m². Notes: The alternative BMI thresholds (in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">parentheses) indicate adjusted values for specific populations or conditions, suggesting a more tailored approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to treatment.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The table visually indicates these recommendations with green checkmarks, confirming the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriateness of each treatment option for each BMI category. (v) Recommendations Nutrition, physical activity, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and behavioral therapy to achieve and maintain ≥5% weight loss are recommended for people with type 2 diabetes and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">overweight or obesity. Frequent counseling (≥16 sessions in 6 months) focusing on nutrition, exercise, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">behavioral strategies to achieve a 500–750 kcal/day energy deficit, is beneficial for weight loss and recommended </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">if available. Long-term (≥1 year) weight maintenance programs are advised for those meeting weight loss goals, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">offering monthly support, weekly body weight monitoring, self-monitoring strategies, and regular physical activity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(200–300 min/week). Short-term, structured very-low-calorie diets (800–1,000 kcal/day) should be reserved for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">select individuals, prescribed by trained practitioners in medical settings with close monitoring, and include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">counseling for long-term weight maintenance. When developing a plan of care, consider systemic, structural, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">socioeconomic factors that may affect nutrition patterns and food choices, such as food insecurity and hunger, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">access to healthful food options, cultural circumstances, and other social determinants of health.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(vi)Drugs Approved for the Treatment of Obesity 1. Medication: Phentermine (Symphathomimetic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">amine anorectic) Duration: Short-term treatment (12 weeks) Common Side Effects: Dry mouth, insomnia, dizziness, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">irritability, increased blood pressure, and elevated heart rate. Possible Safety Concerns/Considerations: • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Contraindicated for use in combination with monoamine oxidase inhibitors 2. Medication: Orlistat (Lipase inhibitor)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Duration: Long-term treatment (52 or 56 weeks) Common Side Effects: Abdominal pain, flatulence, and fecal urgency. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Possible Safety Concerns/Considerations: • Potential malabsorption of fat-soluble vitamins (A, D, E and K) and of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">certain medications (e.g., cyclosporine, thyroid hormone, and anticonvulsants) • Rare cases of severe liver injury </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reported • Cholelithiasis • Nephrolithiasis 3.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Medication: Phentermine / Topiramate ER (Symphathomimetic amine anorectic/antiepileptic) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Duration: Long-term treatment (52 or 56 weeks) Common Side Effects: Constipation, paresthesia, insomnia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nasopharyngitis, xerostomia, and increased blood pressure Possible Safety Concerns/Considerations: \\ue08c </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Contraindicated for use in combination with monoamine oxidase inhibitors \\ue08c Birth defects \\ue08c Cognitive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">impairment \\ue08c Acute angle-closure glaucoma \\ue08c Nephrolithiasis 4.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Medication: Naltrexone/bupropion ER (Opioid antagonist/antidepressant combination) Duration: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Long-term treatment (52 or 56 weeks) Common Side Effects:Constipation, nausea, headache,xerostomia, insomnia, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">elevated heart rate and blood pressure Possible Safety Concerns/Considerations: • Contraindicated in people with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">unmanaged hypertension and/or seizure disorders • Contraindicated for use with chronic opioid therapy • Acute </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">angle-closure glaucoma \\ue08c BLACK BOX WARNING: Risk of suicidal behavior/ideation in people &lt;24 years of age who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">have depression 5. Medication: Liraglutide (Glucagon-like peptide 1 receptor agonist) Duration: Long-term treatment</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(52 or 56 weeks) Common Side Effects: Possible Safety Concerns/Consideration: 6.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Medication:Semaglutide (Glucagon-like peptide 1 receptor agonist) Duration: Long-term treatment</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(52 or 56 weeks) Common Side Effects:Gastrointestinal side effects (nausea, vomiting, diarrhea, and esophageal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reflux), injection site reactions, elevated heart rate, hypoglycemia Possible Safety Concerns/Consideration: • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Pancreatitis has been reported in clinical trials, but causality has not been established. Discontinue if </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pancreatitis is suspected. • Use caution in people with kidney disease when initiating or increasing dose due to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">potential risk of acute kidney injury. • May cause cholelithiasis and gallstone-related complications • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Gastrointestinal disorders (severe constipation and small bowel obstruction/ileus progression) • Monitor for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">potential consequences of delayed absorption of oral medications. \\ue08c BLACK BOX WARNING: Risk of thyroid C-cell </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tumors in rodents; human relevance not determined 7.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Medication: Tirzepatide (Dual glucose-dependent insulinotropic polypeptide and glucagon-like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">peptide 1 receptor agonist) Duration: Long-term treatment (52 or 56 weeks) Common Side Effects: Gastrointestinal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">side effects (nausea, vomiting, diarrhea, and esophageal reflux), injection site reactions, elevated heart rate, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypoglycemia Possible Safety Concerns/Consideration: • Pancreatitis has been reported in clinical trials, but </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">causality has not been established. Discontinue if pancreatitis is suspected. • Use caution in people with kidney </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">disease when initiating or increasing dose due to potential risk of acute kidney injury. • May cause cholelithiasis</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and gallstone-related complications. • Gastrointestinal disorders (severe constipation and small bowel </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obstruction/ileus progression) • Monitor effects of oral medications with narrow therapeutic index (warfarin) or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">whose efficacy is dependent on threshold concentration. • Advise those using oral hormonal contraception to use or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">add a nonoral contraception method for 4 weeks after initiation and dose escalations.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_4_cont_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The comprehensive approach to managing obesity in individuals with Type 2 diabetes includes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">nutrition counseling, exercise, behavioral strategies, and diabetes education. Emphasizing weight management is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pivotal not only for delaying the progression from prediabetes to diabetes but also for enhancing glycemic control,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reducing the need for medications, and diminishing cardiovascular risks. A person-centered, nonjudgmental approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is advocated, utilizing measurements like BMI and waist circumference to guide treatment. Treatment options are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tailored according to BMI categories, with recommendations for intensive behavioral counseling, obesity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pharmacotherapy, and metabolic surgery for specific thresholds. Additionally, frequent counseling sessions are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advised to maintain a significant calorie deficit, leading to sustained weight loss. Approved medications for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity management include phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists like liraglutide and semaglutide, each with specific guidelines based on efficacy, side effects, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">safety concerns. The effectiveness of obesity pharmacotherapy is monitored by weight loss milestones, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments are made based on efficacy and tolerability.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'\\ue08c BLACK BOX WARNING: Risk of thyroid C-cell tumors in rodents; human relevance not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">determined (vii) Weight Loss Efficacy of Glucose-Lowering Medications (1) VERY HIGH: Semaglutide (injectable), </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tirzepatide (2) INTERMEDIATE : Dulaglutide, liraglutide (3) NEUTRAL : Dipeptidyl peptidase 4 inhibitors, metformin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(vii) Glucose-Lowering Medications • Consider weight when choosing glucose-lowering medications for individuals </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with type 2 diabetes and overweight or obesity.  When possible, avoid prescribing medications that cause weight </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gain to treat comorbid conditions.  Obesity pharmacotherapy should be considered for people with diabetes and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">overweight or obesity along with lifestyle changes. Potential benefits and risks must be considered. • Continue </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">obesity pharmacotherapy if it is effective (&gt;5% weight loss after 3 months). • Consider changing or stopping </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treatment if weight loss is &lt;5% after 3 months or if significant safety/tolerability issues arise'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Retinopathy, Neuropathy, and Foot Care'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">loss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">from annually to every 1-3 months for those at highest risk.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Retinopathy, Neuropathy, and Foot Care Optimizing the management of glycemia, blood pressure, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and lipids can reduce or slow the progression of microvascular complications of diabetes. i) Optimize Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Control ii) Optimize Blood Pressure iii) Control Optimize Lipid Control (A) Diabetic Retinopathy (DR) Screening </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Recommended DR screenings can allow for timely treatment to prevent or reverse vision loss. 1. How: Dilated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comprehensive eye exam: This type of eye examination involves dilating the pupils to better examine the retina and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">other eye structures for signs of damage. Retinal photography: This process captures detailed images of the retina </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to detect changes over time and monitor the progression of diabetic retinopathy. 2. When: For individuals with Type</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">1 diabetes, a dilated comprehensive eye exam is recommended within five years after the onset of diabetes. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals with Type 2 diabetes, it is advised to undergo retinal photography at the time of diabetes diagnosis. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Follow-Up Eye Exam Schedule: 3. Annual exams are recommended for patients with any level of retinopathy.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Retinopathy, Neuropathy, and Foot Care'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">loss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">from annually to every 1-3 months for those at highest risk.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Exams should be conducted every 1-2 years for those without retinopathy and who have had one or</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">more annual exams showing well-managed glycemia. Patients with progressing or sight-threatening retinopathy need </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">more frequent examinations to monitor and manage their condition effectively. (B) Neuropathy i) Screening All </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">people with diabetes should be assessed for diabetic peripheral neuropathy (DPN): Қ Starting at the diagnosis of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes Қ 5 years after the diagnosis of type 1 diabetes Қ At least annually thereafter Symptoms and signs </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of autonomic neuropathy should be assessed: Қ Starting at the diagnosis of type 2 diabetes Қ 5 years after the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnosis of type 1 diabetes Қ At least annually thereafter Қ With evidence of other microvascular complications, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly kidney disease and DPN Treatment • Various drugs may reduce pain from DPN, and both drug and non-drug </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">strategies may ease symptoms of DPN and autonomic neuropathy. • The safest and most evidence-based pharmacologic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">options for DPN include gabapentinoids, serotonin- norepinephrine reuptake inhibitors, tricyclic antidepressants, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and sodium channel blockers.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Retinopathy, Neuropathy, and Foot Care'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">loss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">from annually to every 1-3 months for those at highest risk.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Refer to a neurologist or pain specialist when pain control is not achieved within the scope </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of practice of the treating clinician. (C) Foot Care Initial treatment recommendations should include: • Daily foot</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inspection • Use of moisturizers for dry, scaly skin and avoidance of self-care of ingrown nails and calluses • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Well-fitted athletic or walking shoes with customized pressure-relieving orthoses for people with increased plantar</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pressures (e.g., with plantar calluses). (D) Risk Stratification and Screening Frequency Category 0: Very Low Ulcer</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Risk Characteristics: No loss of protective sensation (LOPS) and no peripheral arterial disease (PAD). Examination </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Frequency: Annually. Category 1: Low Ulcer Risk Characteristics: Either LOPS or PAD. Examination Frequency: Every </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">6–12 months. Category 2: Moderate Ulcer Risk Characteristics: Either LOPS and PAD, or LOPS/PAD combined with foot </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">deformity. Examination Frequency: Every 3–6 months. Category 3: High Ulcer Risk Characteristics: LOPS or PAD, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">one or more of the following: History of foot ulcer. Amputation (minor or major). End-stage renal disease.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_5_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Retinopathy, Neuropathy, and Foot Care'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Optimal management of glycemia, blood pressure, and lipids is crucial for preventing or slowing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the progression of microvascular complications in diabetes, including retinopathy, neuropathy, and foot issues. For</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic retinopathy, early and regular screenings using dilated eye exams and retinal photography are advised, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with more frequent checks for those showing signs of the disease. Neuropathy assessments should start at diagnosis </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for Type 2 diabetes and five years post-diagnosis for Type 1, with annual follow-ups. Effective treatments for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetic peripheral neuropathy include gabapentinoids and serotonin-norepinephrine reuptake inhibitors. Foot care </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recommendations emphasize daily inspections, proper moisturization, and the use of well-fitted shoes with orthoses </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent ulcers. Risk stratification for foot ulcers is categorized from very low to high based on factors like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">loss of protective sensation and peripheral arterial disease, dictating the frequency of foot examinations ranging </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">from annually to every 1-3 months for those at highest risk.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Examination Frequency: Every 1–3 months.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"Cardiovascular Disease and Risk Management Atherosclerotic cardiovascular disease (ASCVD), </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">encompassing coronary heart disease, cerebrovascular disease, and peripheral artery disease (PAD) presumed to be of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">atherosclerotic origin, is the primary cause of morbidity and mortality in individuals with diabetes, leading to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">significant health care costs. Managing multiple risk factors simultaneously can prevent or slow the progression of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ASCVD. Heart failure is another major cause of morbidity and mortality from cardiovascular disease. (A) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Recommendations for the Treatment of Confirmed Hypertension in Nonpregnant People With Diabetes management of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">confirmed hypertension in nonpregnant people with diabetes. It offers guidelines based on initial blood pressure </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">readings and the presence of albuminuria or coronary artery disease (CAD). Here's a structured text description </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining the correct flow and context: Initial Assessment and Treatment Decision Based on Blood Pressure (BP) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Levels: Initial BP &gt;130/80 &amp; &lt;150/90 mmHg: Treatment Initiation: Start one agent.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Assess for Albuminuria or CAD: No: Start one drug from ACEi (Angiotensin-Converting Enzyme </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors), ARB (Angiotensin II Receptor Blockers), or CCB (Calcium Channel Blockers), or Diuretic. Yes: Start one</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">drug, either ACEi or ARB. Follow-up: If treatment is tolerated and target BP is achieved, continue therapy. If </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">target is not met on two agents, continue therapy if treatment is tolerated. Initial BP ≥150/90 mmHg: Treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initiation: Start two agents. Assess for Albuminuria or CAD: No: Start drugs from two of three options: ACEi, ARB, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">CCB, or Diuretic. Yes: Start both ACEi or ARB, and either CCB or Diuretic. Follow-up: If adverse effects occur, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">consider switching to an alternative medication (ACEi, ARB, CCB, Diuretic). If BP not meeting target or adverse </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effects occur using a drug from each of the three classes, consider the addition of a mineralocorticoid receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">antagonist and refer to a specialist with expertise in BP management.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Ongoing Management: Assess BP Control and Adverse Effects Regularly: Adjust treatment based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">efficacy and tolerance. Addition of Complementary Drug Class: If the target is not met, add an agent from a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complementary drug class. (B) Screening for Asymptomatic Cardiovascular Disease (CVD) 1. Coronary Artery Disease </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(CAD) Who to Screen: Routine screening is not recommended for asymptomatic individuals. Additional Guidelines: If </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">atypical cardiac symptoms, signs or symptoms of associated vascular disease, or electrocardiogram abnormalities are</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">present, screening should be conducted using routine methods. 2. Heart Failure (HF) Who to Screen: All adults with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes, as diabetes increases risks for asymptomatic (stage B) and symptomatic (stage) HF. Screening Methods: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Measure B-type natriuretic peptide (BNP) or N-terminal pro-BNP. Echocardiography is recommended for those with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">abnormal BNP levels. 3. Peripheral Artery Disease (PAD) Who to Screen: Individuals with diabetes aged ≥50 years, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">those with any microvascular disease, foot complications, or end-stage organ damage from diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Duration Consideration: Consider screening anyone with a diabetes duration of ≥10 years. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Screening Method: Ankle-brachial index testing. Treatment of Stage B HF in People With Diabetes 1. General </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Treatment Recommendation Risk Reduction: To reduce the risk of progression to stage C HF, treatment with ACE </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inhibitors (ACEi) or Angiotensin II Receptor Blockers (ARB) and a beta-blocker is recommended. 2. Treatment Based </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">on Specific Risks If high risk for or established CVD: Use SGLT2 inhibitors (canagliflozin, dapagliflozin, or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">empagliflozin) to reduce the risk of HF hospitalization. If diabetic kidney disease: Consider using finerenone. If </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">specific SGLT2i consideration: Use SGLT2i like sotagliflozin. (C) How often should you check lipids? • For people </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with prediabetes or diabetes not on lipid-lowering therapy, check at diagnosis and at least annually thereafter. • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Check lipids at initiation of lipid- lowering therapy, 4–12 weeks after initiation or dose changes, and annually </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">thereafter.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'High-intensity Statin Therapy Objective: Lowers LDL cholesterol by ≥50% Medications and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Dosages: Atorvastatin: 40-80 mg Rosuvastatin: 20-40 mg Moderate-intensity Statin Therapy Objective: Lowers LDL </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cholesterol by 30-49% Medications and Dosages: Atorvastatin: 10-20 mg Rosuvastatin: 5-10 mg Simvastatin: 20-40 mg </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Pravastatin: 40-80 mg Lovastatin: 40 mg Fluvastatin XL: 80 mg (extended release) Pitavastatin: 1-4 mg Additional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Information: Administration: All listed statins are taken once daily. Fluvastatin XL is specified as an </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">extended-release formulation, which may offer benefits in terms of steady medication levels throughout the day. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">This list provides a detailed guide for prescribing statins, helping healthcare providers to choose the appropriate</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">intensity of statin therapy based on individual patient needs and treatment goals. (D) Lipid Management for Primary</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prevention of ASCVD Events in People with Diabetes 1. Age Group 20-39 Years Treatment Strategy: Lifestyle therapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is recommended.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Additional Measures: Consider statin therapy if there are additional ASCVD risk factors. 2. Age</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Group 40-75 Years Treatment Strategy: Lifestyle therapy. Statin Usage: Use a moderate-intensity statin in those </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">without ASCVD. Use a high-intensity statin in those with ≥1 ASCVD risk factor, aiming for an LDL cholesterol &lt;70 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mg/dL (&lt;1.8 mmol/L). 3. Age Group &gt;75 Years Treatment Strategy: Lifestyle therapy. Statin Usage: Continue current </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">statin therapy or consider initiating a moderate-intensity statin after weighing benefits and risks. Lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Management for Secondary Prevention of ASCVD Events in People With Diabetes of All Ages 1. Treatment Strategy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Statin Usage: Use high-intensity statin therapy to reduce LDL cholesterol by ≥50% from baseline to a target of &lt;55 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mg/dL (&lt;1.4 mmol/L). Additional Medications: Add ezetimibe or a PCSK9 inhibitor if LDL cholesterol goals are not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">met on maximum tolerated statin therapy. Alternatives for Statin Intolerance: Use bempedoic acid for those who are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">statin intolerant.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_6_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Cardiovascular Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The guidelines emphasize comprehensive management strategies for individuals with diabetes to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mitigate the risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, and other cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Effective management involves stringent control of blood pressure, lipids, and glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Initial treatment for confirmed hypertension in nonpregnant diabetics includes using ACE inhibitors, ARBs, or other</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suitable drugs based on the presence of albuminuria or coronary artery disease, with adjustments made based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood pressure response. Screening for asymptomatic cardiovascular conditions like coronary artery disease, heart </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure, and peripheral artery disease involves specific indicators such as B-type natriuretic peptide levels and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ankle-brachial index testing, with subsequent interventions tailored to disease stage and risk factors. For lipid </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management, statins are prescribed based on intensity needs, aiming to significantly lower LDL cholesterol, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complemented by lifestyle modifications. For patients intolerant to statins, alternatives like bempedoic acid or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">PCSK9 inhibitors are suggested to achieve lipid goals and prevent ASCVD events.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'It may be reasonable to add ezetimibe or a PCSK9 inhibitor to maximum tolerated statin therapy.</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">For severe statin intolerance, consider alternative lipid-lowering treatments such as PCSK9 inhibitor with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monoclonal antibody treatment, bempedoic acid, or PCSK9 inhibitor with siRNA inclisiran.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Screening for Chronic Kidney Disease (CKD) Who? Everyone with type 2 diabetes Everyone with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 1 diabetes for ≥5 years How? Urinary albumin-to-creatinine ratio (UACR) Estimated glomerular filtration rate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(eGFR) How often? Annually Monitoring Established CKD How? UACR and eGFR. Use the CKD Epidemiology Collaboration’s </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">CKD-EPI Refit equation, which eliminates race as a variable, for all individuals. How often? One to four times per </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">year, depending on the stage of the disease (A) Classification of Chronic Kidney Disease (CKD) CKD is classified </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on: Cause (C) GFR (G) Albuminuria (A) GFR Categories: G1: Normal or high; GFR ≥90 mL/min/1.73 m² - Low risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(if no other markers of kidney disease, no CKD) G2: Mildly decreased; GFR 60-89 mL/min/1.73 m² - Low risk G3a: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Mildly to moderately decreased; GFR 45-59 mL/min/1.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'73 m² - Moderately increased risk G3b: Moderately to severely decreased; GFR 30-44 mL/min/1.73 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">m² - High risk G4: Severely decreased; GFR 15-29 mL/min/1.73 m² - Very high risk G5: Kidney failure; GFR &lt;15 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mL/min/1.73 m² - Very high risk Albuminuria Categories: A1: Normal to mildly increased; &lt;30 mg/g (&lt;3 mg/mmol) A2: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Moderately increased; 30-299 mg/g (3-29 mg/mmol) A3: Severely increased; ≥300 mg/g (≥30 mg/mmol) Recommended </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Actions Based on GFR and Albuminuria Levels: For G1-G2: A1: Screen 1 A2: Screen 1;'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Treat 1 A3: Treat and refer 3 For G3a: A1: Treat 1 A2: Treat 1 A3: Treat and refer 3 For G3b: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">A1: Treat 2 A2: Treat and refer 3 A3: Treat and refer 3 For G4: A1: Treat and refer 3 A2: Treat and refer 3 A3: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Treat and refer 4+ For G5: A1: Treat and refer 4+ A2: Treat and refer 4+ A3: Treat and refer 4+ Risk Levels Low </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risk: Indicates GFR categories G1 and G2 when there are no other markers of kidney disease. Moderately increased </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risk: Assigned to G3a, suggesting more attention is needed. High risk: Associated with G3b, indicating advanced and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">noticeable decline in kidney function. Very high risk: Applies to G4 and G5, highlighting severe impairment or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">failure of kidney function. Why Manage CKD?'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'i) Decreases risk of CKD progression ii) Reduces cardiovascular risk (B) Holistic Approach to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Improving Outcomes in People With Diabetes and CKD Lifestyle Modifications: Healthy Diet Physical Activity Smoking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Cessation Weight Management First-line Drug Therapy: SGLT2i: Initiate if eGFR ≥20; continue until dialysis or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">transplant. Metformin: Initiate if eGFR ≥30. RAS Inhibitor: Use at maximum tolerated dose if hypertension is </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">present. Regular Reassessment Every 3-6 Months: Assess glycemia, albuminuria, blood pressure (BP), cardiovascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">disease (CVD) risk, and lipids. Additional Risk-based Therapy: GLP-1 RA: If needed to achieve individualized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glycemic targets. Nonsteroidal MRA: If albuminuria (ACR ≥30 mg/g) and normal potassium levels. Dihydropyridine CCB </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and/or Diuretic: If needed to achieve individualized BP targets. Steroidal MRA: For resistant hypertension if eGFR </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥45. Antiplatelet Agents: For clinical atherosclerotic cardiovascular disease (ASCVD).'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Ezetimibe, PCSK9i, or Icosapent Ethyl: If indicated based on ASCVD risk and lipids. Moderate- </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or High-intensity Statin Therapy: Depending on individual risk factors and overall health. Further Interventions: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Other Glucose-lowering Drugs: If needed to further achieve individualized glycemic targets. Color-coded Key Green: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Indicates therapies and actions applicable to all patients (both type 1 and type 2 diabetes). Blue: Indicates </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">actions or therapies specifically for type 2 diabetes (T2D) only. This flowchart provides a comprehensive guide for</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">managing diabetes and CKD, emphasizing a multi-faceted approach involving lifestyle changes, medication, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular monitoring to adapt treatment as needed based on individual patient risk factors and disease progression. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(C) Clinical Tips Periodically check serum creatinine and potassium levels when ACE inhibitor, angiotensin receptor</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blocker (ARB), or nonsteroidal mineralcorticoid receptor antagonist is used. Do not discontinue ACE inhibitor or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ARB therapy for increases ≤30% increases in serum creatinine in the absence of volume depletion.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_7_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Chronic Kidney Disease and Risk Management'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The guidelines for managing chronic kidney disease (CKD) in individuals with diabetes emphasize</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening and monitoring to slow disease progression and mitigate cardiovascular risks. Screening involves </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measuring the urinary albumin-to-creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR), using</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tools that eliminate racial bias in calculations. CKD is classified into five stages based on GFR and three levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of albuminuria, each dictating specific management strategies from routine screening to immediate referral for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care. Management includes lifestyle modifications such as diet and exercise, alongside pharmacotherapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with drugs like SGLT2 inhibitors, metformin, and RAS inhibitors, tailored to the patient's stage of CKD and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk. Additionally, regular reassessment of various health markers is crucial, with interventions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjusted based on these evaluations to optimize outcomes. The approach is holistic, incorporating both lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and medical therapies to address the multifactorial aspects of diabetes and CKD management.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Aim for a urinary albumin reduction ≥30% in people with CKD and urinary albumin ≥300 mg/g to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">slow CKD progression.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities Diabetes treatment goals aim </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to prevent or delay complications and optimize quality of life. These goals should be developed collaboratively </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with people with diabetes to honor their preferences and values. Comprehensive diabetes care should be provided by </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">an interprofessional team which may include but is not limited to diabetes care and education specialists, primary </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care and subspecialty clinicians, nurses, registered dietitian nutritionists, exercise specialists, pharmacists, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dentists, podiatrists, behavioral health professionals, and community partners such as community health workers and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">community paramedics. Ongoing treatment necessitates regular follow-up and the active engagement of people with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes and their care partners. Comprehensive medical evaluations (described in the table below) and the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provision of all recommended vaccinations (cdc.gov/vaccines) are essential components of ongoing diabetes care. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessment of Comorbidities Q) What autoimmune conditions should people with type 1 diabetes be screened for?'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Ans: People with type 1 diabetes should be screened soon after diagnosis and periodically </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">thereafter for: Autoimmune thyroid disease Other autoimmune conditions, if suggestive signs and symptoms are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">present Autoimmune Conditions Associated With Type 1 Diabetes Celiac disease Autoimmune liver disease Collagen </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">vascular diseases Autoimmune thyroid disease Pernicious anemia Primary adrenal insufficiency Myasthenia gravis Q) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">How does diabetes affect bone health? Ans: People with type 1 or type 2 diabetes have a higher fracture risk than </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">those without diabetes. This risk escalates with longer diabetes duration and poor glycemic control. People with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">type 2 diabetes on thiazolidinediones, insulin, or a sulfonylurea have an even higher fracture risk. Optimizing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Bone Health in People With Diabetes i) Screening: In older adults (&gt;65 years of age) and high-risk young adults </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Dual-energy X-ray absorptiometry every 2–3 years ii) Nutrition and Activity : Calcium and vitamin D Aerobic and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">weight-bearing physical activity Fall precautions iv) Pharmacotherapy Choose glucose-lowering medications with safe</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">profiles for bone health and low hypoglycemia risk to prevent falls.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Consider antiresorptive and osteo-anabolic agents for those with aT-score ≤−2.0 or previous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">fragility fractures. Question: Are people with diabetes at increased risk for cancer? Ans: Diabetes is associated </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with increased risk of cancers of the liver, pancreas, endometrium, colon/rectum, breast, and bladder. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Nevertheless, cancer screening recommendations are the same for people with diabetes as for those without diabetes.</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Question: How prevalent is nonalcoholic fatty liver disease (NAFLD)? Who should be screened for it and how? Ans: i)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Prevalence Approximately 70% of people with type 2 diabetes have NAFLD.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'ii) Screening Goals To identify individuals at risk for complications from nonalcoholic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">steatohepatitis (NASH), such as cirrhosis and hepatocellular carcinoma To prevent death from liver disease iii) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">High-Risk individuals People with central obesity and cardiometabolic risks or insulin resistance Individuals &gt;50 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">years of age Those with persistent high plasma aminotransferase levels (AST/ALT &gt;30 units/L for &gt;6 months) iv) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Screening Tool (C) Proposed Algorithm for Risk Stratification in Individuals with NAFLD or NASH. Noninvasive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Testing for Fibrosis (FIB-4) Initial Step: Perform FIB-4 test to assess the risk of fibrosis. Risk Categories: Low </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Risk: Individuals categorized under low risk following the FIB-4 test. Indeterminate Risk: Individuals whose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">results do not clearly categorize them as either low or high risk. High Risk: Individuals identified as high risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for fibrosis based on the FIB-4 results. Subsequent Actions: Low Risk: Follow-up: Repeat the FIB-4 test in 2-3 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">years to monitor any changes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Indeterminate Risk: Further Testing: Proceed with vibration-controlled transient elastography </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">or an ELF (Enhanced Liver Fibrosis) blood test to refine the risk assessment. After further testing: Low Risk: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Continue to monitor with a repeat of the test in 2-3 years. High Risk: Refer to a gastroenterologist or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hepatologist for further evaluation and management. High Risk: Immediate Referral: Refer directly to a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">gastroenterologist or hepatologist for advanced management and intervention. This flowchart provides a guideline on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">how to proceed with fibrosis risk assessment in patients using initial noninvasive testing and determining the need</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for further evaluation or routine monitoring based on risk levels. Management Weight loss with intensive lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy and/or metabolic surgery, as appropriate, is recommended. Pioglitazone and glucagon-like peptide 1 receptor</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonists are the preferred agents for treatment of hyperglycemia in adults with type 2 diabetes and NASH, unless </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">decompensated cirrhosis is present. People with type 2 diabetes and decompensated cirrhosis from NASH should be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treated with insulin. Statin therapy is safe in the setting of NAFLD.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Use with caution and close monitoring in people with decompensated cirrhosis. (D) Components of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the Comprehensive Diabetes Medical Evaluation Initial Visit, Every Follow-Up Visit, and Annual Visit Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">History Characteristics at onset (e.g., age, symptoms). Review of previous treatment plans and response. Assess </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">frequency/cause/severity of past hospitalizations. Family History Family history of diabetes in a first-degree </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">relative. Family history of autoimmune disorder. Personal History of Complications and Common Comorbidities Common </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">comorbidities (e.g., obesity, OSA, NAFLD). High blood pressure or abnormal lipids. Macrovascular and microvascular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Hypoglycemia: awareness/frequency/causes/timing of episodes. Presence of hemoglobinopathies or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">anemias. Last dental visit. Last dilated eye exam. Visits to specialists. Disability assessment and use of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assistive devices. Personal history of autoimmune disease. Interval History Changes in medical/family history since</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">last visit. Eating patterns and weight history. Assess familiarity with carbohydrate counting. Physical activity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and sleep behaviors. Tobacco, alcohol, and substance use.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Medications and Vaccinations Current medication plan. Medication-taking behavior. Medication </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">intolerance or side effects. Complementary and alternative medicine use. Vaccination history and needs. Technology </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Use Access use of health apps/online education. Glucose monitoring (meter/CGM) results and data use. Review insulin</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pump settings and use. Social Life Assessment Identify existing social supports. Identify surrogate decision maker,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">advanced care plan. Identify social determinants of health. Assess daily routine and environment. Physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Examination Height, weight, and BMI. Blood pressure determination. Orthostatic blood pressure measures. Fundoscopic</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">examination. Thyroid palpation. Skin examination. Comprehensive foot examination. Screen for PAD (pedal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pulses—refer for ABI if diminished). Screen for depression, anxiety, diabetes distress. Consider assessment for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive performance. Consider assessment for functional performance. Consider assessment for bone pain. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Laboratory Evaluation Lipid profile, liver function tests, spot urinary albumin-to-creatinine ratio. Serum </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">creatinine and estimated glomerular filtration rate. Thyroid-stimulating hormone in people with type 1 diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_8_cont_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Comprehensive Medical Evaluation and Assessment of Comorbidities'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"The comprehensive medical evaluation for diabetes management involves a holistic approach that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes collaborative goal setting tailored to individual preferences and values. An interprofessional team </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including specialists from various medical and community fields supports ongoing care. Key components include </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">regular screening for common and serious comorbidities, such as autoimmune disorders and chronic kidney disease, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">particularly focusing on diabetes-related complications like nephropathy. For instance, people with type 1 diabetes</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are screened for autoimmune thyroid disease and other conditions soon after diagnosis, while both type 1 and type 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes patients undergo regular assessments for bone health, cardiovascular risks, and liver disease. Effective </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management incorporates lifestyle interventions, pharmacotherapy aligned with specific health risks, and regular </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitoring of treatment efficacy and safety. The approach also includes a detailed review of the patient's medical,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">family, and social history, physical examinations, laboratory evaluations, and vaccinations, ensuring a thorough </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessment and optimal management of diabetes and its associated conditions.\"</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Vitamin B12 if on metformin. Complete Blood Count (CBC) with platelets. Serum potassium levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">in people with diabetes on ACE inhibitors, ARBs, or diuretics. Calcium, vitamin D, phosphorus for appropriate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients. This comprehensive checklist ensures that all significant aspects of diabetes management are reviewed and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assessed regularly to provide the best possible care and outcomes for individuals with diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes Building </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">positive health behaviors and maintaining psychological well-being are foundational for achieving diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management goals and maximizing quality of life. Essential tasks to help people with diabetes achieve their health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals: Refer for diabetes self-management education andsupport (DSMES) Counsel on and support cessation of tobacco </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">products and vaping Refer for medical nutrition therapy (MNT) Counsel on health behaviors Counsel on routine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">physical activity Support and refer to behavior health professionals for psychosocial care (A) DSMES Is Critical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">People Who Benefit • All people with diabetes Advantages • Ensures informed decision-making • Promotes self-care </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">behaviors • Facilitates problem-solving • Improved collaboration with the health care team • Imparts knowledge and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">self-care skills • Incorporates needs, goals, and life experiences Times to Refer • Annually • At diagnosis • When </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">not meeting treatment goals • When complicating factors develop • When transitions in life and care occur </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Appropriate Settings • Group or individual visits • In-person, telehealth, or digital platforms Essential </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Components • Provide culturally appropriate content • Be responsive to individual preferences, needs, and values • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Use positive, strength-based language that puts people first.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Consider social determinants of health with a focus on health equity. Proven Outcomes • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Improved diabetes knowledge, self-care, and quality of life • Lower A1C and self-reported weight reductions • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Reduced all-cause mortality risk, acute care and hospital services utilization, and lower health care costs • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Increased use of primary care and preventive services • Positive coping behavior (B) Psychosocial Care for All </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">People With Diabetes: Considerations and Recommendations (i) Screening ✓ Clinically significant mental health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diagnoses are considerably more prevalent in people with diabetes than in those without. ✓ Clinicians should </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">implement psychosocial screening protocols, including for diabetes distress. ✓ People with diabetes, caregivers, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and family members should be screened at least annually or when changes in disease, treatment, or life </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">circumstances occur. ✓ Address both clinical and subclinical psychological symptoms,which can affect the ability to</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">carry out self-management, short-term glycemic stability, as well as mortality risk. (ii) Interventions ✓ </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Interventions should be collaborative, person-centered, and culturally informed. ✓ Refer to behavioral health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">professionals or other trained health care professionals, ideally with experience in diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'✓ Consider individuals’ treatment burden, confidence and self-efficacy in management, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">social and family support Diabetes Distress The ongoing demands of diabetes self-care and the possibility or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reality of disease progression are directly linked to reported diabetes distress. High levels of distress: i) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Significantly affect medication-taking behavior ii) Are linked to higher A1C, lower self-efficacy, and less-optimal</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating) and exercise behavior (C) Medical Nutrition Therapy (MNT) for Diabetes Management General Principles of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">MNT: Flexible, Realistic, and Sustainable: Successful MNT programs adapt to individual lifestyles and are designed </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to be maintained over the long term. Provided by a Registered Dietitian Nutritionist: Expert guidance ensures that </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dietary plans are tailored to meet the unique needs of each individual. Available to All: MNT is recommended for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals with type 1 or type 2 diabetes, prediabetes, and gestational diabetes mellitus.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"Key Nutrition Principles: Include: Nonstarchy vegetables Whole grains Nuts/seeds Low-fat dairy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">products Whole fruits Legumes Minimize: Meat Sugar-sweetened beverages Sweets Refined grains Ultra-processed foods </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Screening Recommendations: Screen for disordered eating, food insecurity, and a history of dieting to better tailor</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dietary interventions and support. Support for Positive Health Behavior: Motivational Interviewing: Engaging in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">conversations that strengthen an individual's motivation and commitment to change. Problem-solving: Developing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">strategies to address barriers to healthy eating. Patient Activation: Empowering patients to take active roles in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">managing their health. Goal-setting and Action-planning: Establishing clear, achievable goals and steps to meet </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">them. Encouragement of Self-Monitoring: Promoting regular monitoring of health behaviors, with or without clinician</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">feedback. Social Support: Identifying and utilizing social resources to support dietary changes. Specific </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Advisories to Stop: Cigarettes E-cigarettes/vapes All tobacco products This includes recommendations for counseling</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and/or pharmacologic treatment to support cessation. Additional Notes: Data do not support a specific distribution </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of macronutrients; instead, individuals with diabetes are encouraged to adopt healthy eating patterns tailored to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">their personal needs and preferences.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"This MNT framework provides a holistic approach to diabetes management through diet, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing flexibility, personalized care, and comprehensive support strategies to foster long-term health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">improvements. (D) 24-Hour Physical Behaviors for Type 2 Diabetes 1. Sitting/Breaking Up Prolonged Sitting: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Recommendation: Limit sitting by breaking up prolonged sitting every 30 minutes with short regular bouts of slow </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">walking/simple resistance exercises to improve glucose metabolism. 2. Stepping: Benefits: An increase of only 500 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">steps/day is associated with a 2-9% decreased risk of cardiovascular morbidity and all-cause mortality. A 5- to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">6-minute brisk, intense walk per day equates to ~4 years' greater life expectancy. 3. Sweating </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(Moderate-to-Vigorous Activity): Recommendation: Encourage ≥150 minutes/week of moderate-intensity physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity (e.g., use large muscle groups, rhythmic in nature) or 75 minutes/week of vigorous-intensity spread over 2</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to 3 days/week, with no more than 2 consecutive days of inactivity. Supplement with two to three sessions involving</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">resistance, flexibility, and/or balance. 4.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"Strengthening: Activities: Resistance exercise (e.g., any activity that uses the person's own </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">body weight or works against a resistance) also improves insulin sensitivity and glucose levels; activities like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">tai chi and yoga also enhance elements of flexibility and balance. 5. Physical Function/Frailty/Sarcopenia: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Concern: The frailty phenotype in Type 2 diabetes is unique, often encompassing obesity alongside physical frailty </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">at an earlier age. The ability to undertake simple functional exercises in middle age is similar to that in those </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">over a decade older. 6. Sleep: Quality and Quantity: Aim for consistent, uninterrupted sleep, even on weekends. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Long (&gt;8h) and short (&lt;6h) sleep durations negatively impact A1C. Chronotype: Evening chronotypes (i.e., night owl;</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">go to bed late and get up late) may be more susceptible to poor glycemic levels vs. morning chronotypes (i.e., </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">early bird; go to bed early and get up early).\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_9_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes emphasizes fostering positive health behaviors and psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being to enhance health outcomes and quality of life. Key strategies include diabetes self-management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">education and support (DSMES), medical nutrition therapy (MNT), cessation of smoking and vaping, regular physical </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">activity, and psychosocial care. DSMES is critical for empowering patients through informed decision-making and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effective self-care, improving clinical outcomes such as glycemic control and reducing healthcare costs. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Psychosocial care addresses the mental health challenges associated with diabetes, ensuring annual screenings and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">appropriate interventions. MNT, delivered by registered dietitians, focuses on creating sustainable, personalized </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">eating plans rich in nutrients and low in processed foods. Physical activity recommendations advocate for breaking </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">up prolonged sitting, engaging in moderate to vigorous exercise, and incorporating resistance and balance exercises</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to improve metabolic health and reduce the risk of cardiovascular events. Together, these comprehensive strategies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are designed to support individuals with diabetes in achieving better health and managing the condition </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effectively.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Impact of Physical Behaviors on Cardiometabolic Health in Type 2 Diabetes Impact Table: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Different physical behaviors such as sitting, stepping, moderate-to-vigorous activity, strengthening, sleep </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">duration, sleep quality, and consistent timing (chronotype) have various effects on glucose/insulin levels, blood </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pressure, A1C, lipids, physical function, depression, and quality of life. The table categorizes the impact as: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Green arrows: strong evidence of higher levels/improvement. Yellow arrows: medium strength evidence. Red arrows: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">limited evidence. Circle: no data available. This approach underscores a holistic view of managing Type 2 diabetes,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">suggesting that balanced daily physical activities and regulated sleep patterns are crucial for maintaining overall</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health and managing the disease effectively.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Assessment of Glycemic Status How to Assess A1C measurement Continuous glucose monitoring (CGM)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">using appropriate metrics (e.g., time in range [TIR] and/or glucose management indicator [GMI]) When to Assess How </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">frequently? In those meeting treatment goals = At least two times per year For individuals not meeting treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals, with frequent or severe hypo- or hyperglycemia, changing health status, or growth and development in youth =</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">At least quarterly or more frequently as appropriate clinically Clinical Notes Limitations: Accuracy can be </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">affected by conditions that affect red blood cell turnover (e.g., hemolytic and other anemias, glucose-6-phosphate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dehydrogenase deficiency, recent blood transfusion, use of drugs that stimulate erythropoiesis, end‐stage kidney </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">disease, and pregnancy). Some hemoglobin variants can interfere with some A1C assays, although this problem has </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">been minimized with newer assays. A1C does not assess glycemic variability or hypoglycemia. Consider alternative </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">measures, such as fructosamine and glycated albumin, when necessary. Assess glycemic variability using a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">combination of results from blood glucose monitoring/CGM and A1C.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glucose Assessment via CGM: The Ambulatory Glucose Profile (AGP) Report 1. Ensure sufficient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">data for analysis; CGM active at least 70% of the time over 14 days is recommended. 2. Discuss individuals’ daily </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">self-management routine. 3. Ask individuals to identify and explain what they observe on the report. 4. Check </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">overall CGM metrics: i) Time below range (TBR): percentage of readings and time with glucose &lt;70 mg/dL (&lt;3.9 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/L) {AGP Report: Continuous Glucose Monitoring Overview 1. Time in Ranges: Very High (&gt;250 mg/dL): 20% of the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">time (Goal: &lt;5%) High (180-250 mg/dL): 24% of the time (Goal: &lt;25%) Target (70-180 mg/dL): 46% of the time (Goal: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">&gt;70%); notes that each 5% increase is clinically beneficial Low (&lt;70 mg/dL): 10% of the time (Goal: &lt;4%) Very Low </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(&lt;54 mg/dL): 5% of the time (Goal: &lt;1%) 2.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Test Patient Information: DOB: January 1, 1970 Testing Period: 14 Days, from August 8 to August</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">21, 2021 CGM Activation: 100% active during the testing period, ensuring reliable data collection. 3. Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metrics: Average Glucose: 175 mg/dL (Goal: &lt;154 mg/dL) Glucose Management Indicator (GMI): 7.5% (Goal: &lt;7%) Glucose</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Variability: 45.5% (Goal: &lt;36%); defined as the percentage coefficient of variation, indicating the extent of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">fluctuations in glucose levels. Key Insights and Recommendations: Time in Target Range: The patient spent 46% of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the time within the target glucose range, which is below the goal of &gt;70%. Efforts should be made to increase time </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">within this range to improve overall glucose management. High and Very High Levels: Significant time was spent with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose levels higher than recommended, suggesting a need for adjustments in treatment or lifestyle to better </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">manage glucose peaks. Low and Very Low Levels: The percentages here also exceed the goals, indicating potential </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risks of hypoglycemia. This might require reevaluation of medication doses or meal planning.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glucose Variability: High variability indicates that glucose levels are fluctuating more than </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">desired, which can be a concern for overall metabolic stability. } ii) TIR: percentage of readings and time with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose 70–180 mg/dL (3.9–10.0 mmol/L) iii) Time above range (TAR): percentage of readings and time &gt;250 mg/dL </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(&gt;13.9 mmol/L) iv) Mean glucose v) Glucose management indicator (GMI): an estimate of A1C vi) Glycemic variability:</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">expressed as percent coefficient of variation; target ≤36% 5) Identify any hypoglycemia first, and then look for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia patterns. Review the time spent in these patterns on the overall profile and daily graphs. {Overview </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of the Ambulatory Glucose Profile (AGP) Graph 1. Graph Layout: The graph displays glucose levels over a 24-hour </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">period, beginning and ending at midnight. It uses different colored bands to indicate the range of glucose values, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">from the 5th percentile to the 95th percentile. 2.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glucose Level Ranges: Red Line: Represents the median (50th percentile) glucose level, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">providing a central trend line of the glucose readings throughout the day. Green Band: This area represents the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">target glucose range (70 to 180 mg/dL), where glucose levels are considered well-managed. Orange and Yellow Bands: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">These bands show higher glucose levels, up to the 75th and 95th percentiles, respectively. Light Green and Light </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Orange Bands: Represent the lower (25th percentile) and higher glucose ranges, respectively. 3. Key Points in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Glucose Fluctuations: Overnight and Early Morning: The graph generally shows lower glucose levels, with the median </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">line within or close to the target range. Postprandial Peaks: Noticeable increases in glucose levels can be seen </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">during typical meal times (breakfast, lunch, and dinner), indicating postprandial glucose responses. Late Evening: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Glucose levels tend to rise in the late evening, possibly due to dinner intake or lessened physical activity. 4. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Significance of Different Percentiles: 5% to 25% Percentiles (Light Green): Show the lower fluctuations of glucose,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">indicating times when glucose levels might drop too low.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_6'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'75% to 95% Percentiles (Orange to Yellow): Highlight times when glucose levels are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">significantly above the target, suggesting hyperglycemia risks. Clinical Implications Target Range Maintenance: The</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">aim is to have the median line within the green band as much as possible, indicating good glucose control. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Management of Peaks: High peaks suggest a need for adjustments in diet, medication, or both to better manage </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose spikes. Addressing Hypoglycemia: Any part of the median line dipping below the target range especially if </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reaching the light green area, needs attention to prevent hypoglycemia. } 6) Discuss identified patterns and ask </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals to reflect on potential causes and possible solutions. {Overview of Daily Glucose Profiles Graph </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Details: Each graph is labeled with the days of the week, from Sunday through Saturday. The glucose levels are </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plotted against time, marked at 12pm for clarity, showing the midday point. Glucose Level Guidelines: Target Range:</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">The target glucose range (70 to 180 mg/dL) is highlighted by a green band that spans across each graph.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_7'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"Glucose Readings: The daily glucose readings are represented by a line that varies in height, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">indicating the fluctuations in glucose levels throughout each day. Analysis of the Daily Glucose Profiles General </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Observations: Variability: There's noticeable variability in glucose levels across the days. Some days show more </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">stability with glucose levels staying within or near the target range, while other days exhibit significant spikes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and drops. Patterns: Common patterns can be observed, such as potential spikes around typical meal times </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(breakfast, lunch, and dinner). These spikes might suggest postprandial glucose responses. Specific Days Analysis: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Days like Sunday and Wednesday show relatively good control with the glucose levels mostly staying within the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">target range. Other days, like Tuesday and Friday, exhibit more fluctuations with notable spikes that exceed 180 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mg/dL and brief dips potentially going below 70 mg/dL. Clinical Implications Consistency and Control: The graph for</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">each day provides insights into how well glucose levels are managed and how consistent the control is across </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">different days. Days with less fluctuation are indicative of more stable glucose control.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_8'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Adjustments Needed: Identifying days with high variability can help in targeting specific times</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for intervention, such as adjusting meal plans, medication timing, or physical activity. Utility for Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Management: These daily profiles are crucial for patients and healthcare providers to assess and adjust diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management plans. Understanding daily patterns helps in making informed decisions to optimize glucose control, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">potentially adjusting dietary intake, medication dosages, or lifestyle changes to achieve better glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">outcomes.} 7) If you use CGM metrics to assess glycemia, goals for nonpregnant adults or those with frailty will </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">vary; set glycemic goals based on the general guidelines below. 8) Use shared decision-making to develop an action </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">plan. Correlation Between A1C and Estimated Average Glucose (eAG) A calculator for converting A1C results into eAG,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">in either mg/dL or mmol/L, is available at professional.diabetes.org/eAG. Data in parentheses are a 95% CI.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_9'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'A1C (%) mg/dL mmol/L 5 97 (76–120) 5.4 (4.2–6.7) 6 126 (100–152) 7.0 (5.5–8.5) 7 154 (123–185) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">8.6 (6.8–10.3) 8 183 (147–217) 10.2 (8.1–12.1) 9 212 (170–249) 11.8 (9.4–13.9) 10 240 (193–282) 13.4 (10.7–15.7) 11</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">269 (217–314) 14.9 (12.0–17.5) 12 298 (240–347) 16.5 (13.3–19.3) Setting and Modifying Glycemic Goals Glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals should be individualized and periodically reevaluated. 1. Individualize based on key characteristics of the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">person with diabetes. 2. Individualize in the context of shared decision-making (to address needs and preferences).</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">3.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Follow these general guidelines: Recommended glycemic goals for many nonpregnant adults with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes without significant hypoglycemia: A1C &lt;7.0% (&lt;53 mmol/mol) Preprandial capillary plasma glucose: 80–130 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mg/dL (4.4–7.2 mmol/L) Peak postprandial capillary plasma glucose: &lt;180 mg/dL (&lt;10.0 mmol/L) CGM metrics: TIR &gt;70% </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with TBR &lt;4% and &lt;1% of time with glucose &lt;54 mg/dL A lower A1C goal may be acceptable and even beneficial if it </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">can be achieved safely without significant hypoglycemia or other adverse effects of treatment. A higher A1C goal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(such as &lt;8% [64 mmol/mol]) may be appropriate for individuals with limited life expectancy or when the harms of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treatment are greater than the benefits. TIR &gt;50% with &lt;1% TBR is appropriate in those with frailty or at high risk</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of hypoglycemia. Deintensify glucose-lowering medications for those at high hypoglycemia risk or when treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risks or burdens outweigh the benefits.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Overview of the Table: Patient/Disease Features and A1C Target Stringency The table uses a </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">color gradient to indicate the appropriateness of more stringent (toward a lower A1C target, &lt;7%) versus less </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">stringent A1C targets based on specific patient or disease characteristics: 1. Risks Potentially Associated with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Hypoglycemia and Other Drug-Related Adverse Effects More Stringent: Low risk of adverse effects favors a more </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">stringent A1C target. Less Stringent: High risk of adverse effects favors a less stringent A1C target. 2. Disease </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Duration More Stringent: Newly diagnosed patients may benefit more from stringent targets to potentially reverse </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">disease progression. Less Stringent: Long-standing diabetes where more stringent targets might not significantly </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">alter disease outcomes. 3. Life Expectancy More Stringent: Longer life expectancy supports aiming for a stricter </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">A1C to reduce long-term complications. Less Stringent: Shorter life expectancy may prioritize comfort and quality </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of life over strict glucose control. 4. Important Comorbidities More Stringent: Absence of severe comorbidities </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">might allow for tighter glucose control without significant risks.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_12'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"Less Stringent: Presence of severe comorbidities where strict control may exacerbate or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complicate conditions. 5. Established Vascular Complications More Stringent: Few or mild complications might </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">encourage tighter control to prevent progression. Less Stringent: Severe complications may mean that the risks of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">stringent control outweigh the benefits. 6. Individual Needs and Preference More Stringent: Patients who are highly</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">motivated and have excellent self-care capabilities. Less Stringent: Patients who prefer less burdensome therapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">due to personal preferences or ability to manage complex regimens. 7. Resources and Support System More Stringent: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Readily available resources and support systems enable stricter A1C targets. Less Stringent: Limited resources and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support may necessitate a less stringent approach to avoid overwhelming the patient. Summary This table effectively</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">guides healthcare providers in personalizing diabetes treatment goals based on individual patient factors. It </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizes the importance of tailoring A1C targets to balance effective diabetes management with the patient's </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">overall health status, lifestyle, and preferences, ensuring both safety and quality of life. Person and disease </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">factors used to determine optimal glycemic targets.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_13'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Characteristics and predicaments toward the left justify more stringent efforts to lower A1C; </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">those toward the right suggest less stringent efforts. A1C 7% = 53 mmol/mol. Hypoglycemia Assessment, Prevention, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and Treatment Hypoglycemia is categorized into three levels based on blood glucose concentrations and symptom </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">severity. Level 1 is glucose &lt;70 mg/dL (&lt;3.9 mmol/L) but ≥54 mg/dL (≥3.0 mmol/L). Level 2 is glucose &lt;54 mg/dL </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(&lt;3.0 mmol/L). Level 3 is a severe event characterized by altered mental and/or physical status requiring </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">assistance for treatment of hypoglycemia, irrespective of glucose level. Assessment and medication selection i) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Review hypoglycemia history at every clinical encounter in all at-risk individuals. ii) Screen for impaired </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypoglycemia awareness in all at-risk individuals. iii) Consider hypoglycemia risk when selecting diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications and setting glycemic goals. Prevention and management of hypoglycemia i) Use CGM for individuals at </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">high risk for hypoglycemia.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_10_cont_14'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic Goals and Hypoglycemia'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Glycemic status in diabetes management is assessed using A1C measurements and continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring (CGM), which includes metrics like Time in Range (TIR) and Glucose Management Indicator (GMI). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Assessments should occur at least twice a year for those meeting treatment goals and quarterly for those not </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">meeting goals or experiencing variable glycemic control. A1C tests have limitations due to conditions affecting red</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood cell turnover and may not reflect glycemic variability, prompting the use of alternatives like fructosamine </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for more immediate reflection of glycemic status. CGM provides a comprehensive view through the Ambulatory Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Profile (AGP), offering insights into daily glucose fluctuations and helping to identify periods of hypo- or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia for better diabetes management. Regular reviews of CGM data help tailor treatment to individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needs, using shared decision-making to set realistic and personalized glycemic goals. This approach helps in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimizing diabetes management by addressing both short-term fluctuations and long-term health goals'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'ii) Glucose is the preferred treatment for hypoglycemia in conscious individuals with glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">levels &lt;70 mg/dL (&lt;39 mmol/L), although any form of fast-acting carbohydrate can be used. Re-test and re-treat, if </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">needed, after 15 minutes. iii)Ensure that glucagon is prescribed for all those taking insulin and those at high </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risk for hypoglycemia, with education provided on its use and proper storage. iv) Offer structured education on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypoglycemia prevention and treatment to all individuals taking insulin and those at high risk for hypoglycemia. v)</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Upon occurrence of one or more episodes of level 2 or level 3 hypoglycemia, promptly reevaluate the treatment plan,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">including considering whether to deintensify or switch medications. v) Refer individuals with impaired hypoglycemia</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">awareness to a trained health care professional for evidence-based interventions to help reestablish awareness of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypoglycemia symptoms. vi) Conduct ongoing assessments of cognitive function, ensuring extra caution and support </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">for hypoglycemia if impaired or declining cognition is identified.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Older Adults'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The approach to managing diabetes in older adults is differentiated by their health status, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">healthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive impairments aim for less stringent targets like &lt;8.0%. Treatment in skilled nursing facilities focuses on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">situations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Individualization of Treatment Goals and Medication Plans for Older Adults With Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Central Panel: Patient Characteristics and Health Status i) Healthy Individuals: (1) Characteristics: Few </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">coexisting chronic illnesses and intact cognitive and functional status. (2) Treatment Goal: A1C &lt;7-7.5% (53-58 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/mol). ii) Complex/Intermediate Health: (1) Characteristics: Multiple coexisting chronic illnesses or two or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">more instrumental activities of daily living (IADL) impairments or mild to moderate cognitive impairments. (2) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Treatment Goal: A1C &lt;8.0% (&lt;64 mmol/mol). iii) Community-dwelling Individuals in Skilled Nursing Facilities: (1) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Characteristics: Receiving care in a skilled nursing facility for short-term rehabilitation. (2) Treatment Goal: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Focus on glucose goals of 100–200 mg/dL (5.55–11.1 mmol/L) rather than strict A1C targets. iv) Very Complex/Poor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Health: (1) Characteristics: Long-term care or end-stage chronic illnesses or moderate to severe cognitive </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">impairment or more ADL impairments.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Older Adults'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The approach to managing diabetes in older adults is differentiated by their health status, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">healthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive impairments aim for less stringent targets like &lt;8.0%. Treatment in skilled nursing facilities focuses on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">situations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(2)Treatment Goal: Avoid reliance on A1C; focus on avoiding hypoglycemia and symptomatic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hyperglycemia. v) At the End of Life: (2) Treatment Goal: Avoid hypoglycemia and symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">focusing on comfort. Left Panel: Medication Strategies for Maintenance Stay the Course if the person: Can </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">manage/perform tasks required. Has infrequent acute illnesses. Has support available, if needed. Right Panel: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Medication Strategies for Simplification Deintensify or Simplify the Plan if the person: Has had severe or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">recurrent hypoglycemia. Has experienced deterioration in health, cognitive, or functional status. Has had recent or</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">frequent acute illnesses or hospitalization. Is experiencing wide glycemic excursions. Has had significant changes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">in social circumstances. Is dealingling with polypharmacy issues. Additional Considerations (Bottom Left) Consider </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">using continuous glucose monitoring and other technologies to reduce hypoglycemia. Include medications to reduce </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cardiovascular risk, irrespective of glycemia. Use available resources to reduce cost-related barriers to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treatment.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Older Adults'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The approach to managing diabetes in older adults is differentiated by their health status, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">healthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive impairments aim for less stringent targets like &lt;8.0%. Treatment in skilled nursing facilities focuses on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">situations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Summary This diagram effectively maps out a patient-centered approach to managing diabetes in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">older adults, taking into account the complexity of their health status and the practicalities of their daily </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">lives. It emphasizes flexible treatment goals tailored to individual needs, capacities, and life stages, aiming to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">balance effective glycemic control with quality of life and minimizing treatment burdens. Simplification of Complex</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Insulin Therapy 1. Individual on Basal (Long- or Intermediate-acting) and/or Prandial (Short- or Rapid-acting) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Insulins: Basal Insulin Adjustments: Change timing from bedtime to morning. Titrate dose of basal insulin based on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">fasting finger-stick glucose test results over a week: If fasting goal is 90-150 mg/dL, consider adjusting goals </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">based on overall health and goals of care. If 50% of fasting values are above goal, increase dose by 2 units. If 2+</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">fasting values per week are &lt;80 mg/dL, decrease dose by 2 units. Prandial Insulin Adjustments: If prandial insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">&gt;10 units/dose, decrease dose by 50% and consider adding noninsulin agents.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Older Adults'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The approach to managing diabetes in older adults is differentiated by their health status, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">healthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive impairments aim for less stringent targets like &lt;8.0%. Treatment in skilled nursing facilities focuses on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">situations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Titrate prandial insulin doses down as noninsulin agent doses are increased with the aim to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">discontinue prandial insulin if feasible. 2. Individual on Premixed Insulin: Use 70% of the total dose as basal </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">insulin only in the morning. If mealtime insulin ≤10 units/dose: Discontinue prandial insulin and add noninsulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agent(s). Additional Pathways and Tips: Adding Noninsulin Agents: If eGFR is ≥45 mg/dL, start metformin 500 mg </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">daily and increase dose every 2 weeks as tolerated. If eGFR is &lt;45 mg/dL and patient is already taking metformin or</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">metformin is not tolerated, proceed to second-line agents. General Guidelines: Do not use rapid- and short-acting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">insulin at bedtime. Use a simplified sliding scale for adjusting prandial insulin based on premeal glucose levels. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Stop sliding scale when not needed daily. Additional Recommendations Based on Comprehensive Care Guidelines: Use </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individual and drug characteristics to guide decision-making.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_11_cont_5'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Older Adults'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The approach to managing diabetes in older adults is differentiated by their health status, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">ranging from healthy individuals to those at the end of life, with tailored A1C goals to match each scenario. For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">healthy older adults, the target A1C is below 7-7.5%, while more complex cases with multiple chronic illnesses or </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">cognitive impairments aim for less stringent targets like &lt;8.0%. Treatment in skilled nursing facilities focuses on</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining glucose levels between 100–200 mg/dL, avoiding strict A1C adherence. In very complex or poor health </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">situations, the focus shifts from A1C levels to preventing hypoglycemia and managing symptomatic hyperglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">emphasizing comfort. Medication strategies are adapted to the individual’s ability to manage diabetes, with options</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to simplify or intensify regimens based on changes in health status, hypoglycemia risk, and overall treatment </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">goals. Continuous glucose monitoring and other technologies are considered to reduce hypoglycemia, alongside </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications that address cardiovascular risks irrespective of glycemic control. This patient-centered approach </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">prioritizes flexible treatment goals to enhance quality of life and reduce treatment burdens in older adults.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Adjust insulin dose and/or add glucose-lowering agents based on finger-stick glucose testing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">before meals and bedtime: Target for pre-meal glucose is 90-150 mg/dL. Increase dose if more than two finger-stick </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">values per week are above the goal. Decrease dose if 2+ pre-meal finger-stick values/week are &lt;90 mg/dL. Summary </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">This guide effectively outlines how to simplify complex insulin regimens for individuals with varying levels of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blood glucose control and health statuses. It emphasizes personalized treatment adjustments to optimize efficacy, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">minimize hypoglycemia risks, and reduce the burden of diabetes management.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes Care in the Hospital'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">requires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">follow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with insulin and implementing transitional care models are employed to further decrease the likelihood of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">readmissions.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes Care in the Hospital (A) Glycemic Management During Hospitalization Carefully managing</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">people with diabetes during hospitalization can reduce the risk of hyperglycemia, hypoglycemia,or extreme glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">variability, which all lead to adverse outcomes, including death. Consult with a specialized diabetes or glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management team when possible. Hospital Care Delivery Standards Institute validated order sets for management of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dysglycemia in the hospital. State the type of diabetes on the initial evaluation when it is known. Perform an A1C </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">test on all hospitalized people with diabetes or hyperglycemia (random blood glucose &gt;140 mg/dL [7.8 mmol/L]) if no</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">A1C result is available from the prior 3 months. Assess diabetes self-management knowledge and behaviors on </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">admission and provide self-management education,if available, when needed.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes Care in the Hospital'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">requires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">follow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with insulin and implementing transitional care models are employed to further decrease the likelihood of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">readmissions.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">\"(B) Perioperative Care (i) A1C and glucose goals : • Elective surgery A1C goal: &lt;8% (63.9 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/L) • Blood glucose goal within 4 hours of surgery: 100–180 mg/dL (5.6–10.0 mmol/L) (ii) Medication </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">adjustments: • Hold metformin on the day of surgery. • Discontinue sodium–glucose cotransporter 2 inhibitors 3–4 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">days before surgery. • Hold other oral glucose-lowering agents the morning of the surgery or procedure. Then either</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">keep the next bullet or follow my suggestion and delete it, since I can't find it anywhere in the full SOC. • </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Individualize plan based on clinical scenario and procedure/surgery. (iii) Insulin therapy adjustments: • Give half</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of NPH dose or 75–80% of long-acting analog insulin or adjust insulin pump basal rates based on diabetes type and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">clinical judgment. (C) Transition From the Hospital to the Ambulatory Setting Tailor a structured discharge plan to</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">the individual with diabetes: (1) Provide diabetes self-management education before discharge. (2) Ensure </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medication reconciliation and access.\"</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'12_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes Care in the Hospital'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes care in the hospital setting focuses on meticulous glycemic management to minimize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">risks of hyperglycemia, hypoglycemia, and glucose variability, which can lead to severe outcomes including </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mortality. Effective management includes collaboration with specialized diabetes teams, using validated order sets,</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and assessing diabetes type and self-management capabilities upon admission. Perioperative care specifies </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">maintaining A1C below 8% and blood glucose between 100–180 mg/dL within four hours of surgery, with adjustments in </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">medications like metformin and SGLT2 inhibitors, and tailored insulin therapy. Transitioning from hospital to home </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">requires a structured discharge plan that encompasses diabetes education, medication reconciliation, and scheduling</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">follow-up visits to reduce readmissions and ensure continuity of care. Strategies such as treating high A1C levels </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with insulin and implementing transitional care models are employed to further decrease the likelihood of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">readmissions.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(3) Arrange virtual or in-person follow-up visits post-discharge: (a) Schedule a visit with the</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">primary care clinician, endocrinologist, or diabetes specialist within 1 month of discharge. (b) Schedule earlier </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">follow-up (1–2 weeks) if medications change or glucose targets not met at discharge. (D) Strategies To Reduce </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Readmissions i) Identifying people with ketosis-prone diabetes ii) Treating individuals with admission A1C &gt;9% (&gt;75</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mmol/ mol) with insulin iii) Implementing a transitional care model iv) Proactively planning for care transitions </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(including scheduling home health visits and timely follow-up care)'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Management of Diabetes in Pregnancy'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of pregnant women with diabetes or those at risk of gestational diabetes mellitus (GDM). Preconception counseling </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">targets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">while oral medications are generally avoided due to safety concerns. Postpartum care includes psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">breastfeeding and regular diabetes screening postpartum.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Management of Diabetes in Pregnancy (A) Preconception Counseling: • Incorporate preconception </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">counseling into diabetes care starting at puberty and continuing in all people with diabetes and childbearing </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">potential. • Discuss family planning and prescribe effective contraception to be used until A1C is optimized for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pregnancy. • Address the importance of achieving glucose levels as close to normal as is safely possible, ideally </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">A1C &lt;6.5% (&lt;48 mmol/mol) to reduce the risk of congenital anomalies, preeclampsia, macrosomia, preterm birth, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">other complications. • Focus on nutrition, diabetes education, and screening for diabetes comorbidities and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications, in addition to achieving glycemic targets. • Counsel on the risk of development and/or progression </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of diabetic retinopathy. A dilated eye examination should occur before pregnancy or in the first trimester, with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">continued monitoring every trimester and for 1 year postpartum based on findings. The preconception care of people </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">with diabetes is detailed in Table 15.1 in the complete ADA Standards of Care in Diabetes—2024.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Management of Diabetes in Pregnancy'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of pregnant women with diabetes or those at risk of gestational diabetes mellitus (GDM). Preconception counseling </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">targets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">while oral medications are generally avoided due to safety concerns. Postpartum care includes psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">breastfeeding and regular diabetes screening postpartum.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(B) Glycemic Management and Goals in Pregnancy i) Perform fasting, preprandial, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">postprandial blood glucose monitoring (BGM). ii) Glucose goals are fasting plasma glucose &lt;95 mg/dL (&lt;5.3 mmol/L) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and either 1-h postprandial glucose &lt;140 mg/dL (&lt;7.8 mmol/L) or 2-h postprandial glucose &lt;120 mg/dL (&lt;6.7 mmol/L). </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">iii) Ideally, the A1C goal in pregnancy is &lt;6% (&lt;42 mmol/mol) if this can be achieved without significant </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">hypoglycemia; the goal may be relaxed to &lt;7% (&lt;53 mmol/mol) to prevent hypoglycemia. iv) When used in addition to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pre- and postprandial BGM, continuous glucose monitoring can help to achieve the A1C goal in diabetes and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">pregnancy. (C) Management of Gestational Diabetes Mellitus (GDM) GDM refers specifically to diabetes diagnosed </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after the first trimester of pregnancy in individuals who did not have diabetes before pregnancy. Diabetes detected</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">before or in early pregnancy is usually considered to be preexisting type 2 diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13_cont_3'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Management of Diabetes in Pregnancy'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of pregnant women with diabetes or those at risk of gestational diabetes mellitus (GDM). Preconception counseling </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">targets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">while oral medications are generally avoided due to safety concerns. Postpartum care includes psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">breastfeeding and regular diabetes screening postpartum.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'• Individuals without diabetes before or early in pregnancy should be screened for GDM at 24 to</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">28 weeks of pregnancy. • Lifestyle behavior change is an essential component of GDM management. • Insulin is the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">preferred medication for treating hyperglycemia in GDM. • Metformin and glyburide should not be used as first-line </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agents in GDM. Other oral and noninsulin injectable glucose- lowering medications lack long-term safety data for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">use in GDM. (D) Additional Drug Considerations During Pregnancy i) Initiate or titrate blood pressure medication at</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">a threshold of 140/90 mmHg. A target of 110–135/84 mmHg is suggested. Therapy should be reduced if blood pressure </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is &lt;90/60 mmHg. ii) Stop potentially harmful medications in pregnancy (i.e., ACE inhibitors, angiotensin receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">blockers, and statins) prior to conception and avoid in sexually active individuals of childbearing potential who </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">are not using reliable contraception. (E) Postpartum Care i) Postpartum care should include psychosocial assessment</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">and support for self-care.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_13_cont_4'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Management of Diabetes in Pregnancy'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Diabetes management in pregnancy involves comprehensive strategies tailored to the unique needs</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of pregnant women with diabetes or those at risk of gestational diabetes mellitus (GDM). Preconception counseling </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">is crucial, starting at puberty and focusing on achieving optimal A1C levels below 6.5% to minimize pregnancy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">complications. Continuous glucose monitoring and frequent blood glucose measurements guide glycemic management with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">targets set to reduce hyperglycemia without risking significant hypoglycemia. For GDM, identified typically in the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">second half of pregnancy in previously non-diabetic individuals, lifestyle changes and insulin are recommended, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">while oral medications are generally avoided due to safety concerns. Postpartum care includes psychological </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support, screening for diabetes, and adjusting diabetes therapies to account for changes in insulin sensitivity </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">after delivery. The approach emphasizes both immediate and long-term health goals for mother and child, promoting </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">breastfeeding and regular diabetes screening postpartum.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'(a) Contraception: Discuss and implement a contraception plan with all individuals with </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">diabetes of childbearing potential. (b) Lactation: Promote breastfeeding, which has been shown to reduce the risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of type 2 diabetes later in life. (c) Postpartum Care of Individuals With GDM: • Screen for diabetes at 4–12 weeks </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">postpartum with a 75-g oral glucose tolerance test using nonpregnancy criteria. • Lifelong diabetes screening </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">should occur every 1–3 years. • For those with overweight/obesity and prediabetes, implement intensive lifestyle </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">interventions and/or metformin therapy. (d) Postpartum Care for Individuals With Preexisting Diabetes: Insulin </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">resistance decreases dramatically immediately after delivery. Evaluate insulin requirements, adjust doses, and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">monitor for hypoglycemia.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_1'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment (A) Ways to Address or Prevent Therapeutic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Inertia for People With Type 1 or Type 2 Diabetes i) EMPOWER PATIENTS: BE A BARRIER BUSTER Schedule diabetes-only </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">visits. Set and track shared goals and time frames. Integrate screening for social/emotional barriers and identify </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">support. Prescribed thoughtfully. Refer to diabetes self-management education and support (DSMES). Do your patients</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">know you are their champion? ii) OPTIMIZE CARE AND TREATMENT: ACT NOW Conduct practice-based screening for likely </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapeutic inertia. Make personalized diabetes care plans. Implement a team-based approach to increase the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">frequency and quality of engagement. Utilize A1C and glucose data to drive rapid-cycle treatment intensification. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Stratify follow-up based on A1C/glucose data and changes in therapy. Have you done everything in your control to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">optimize therapy and support during, after, and in between visits? iii) IMPROVE DECISION-MAKING Follow a diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treatment algorithm. Create and use a patient registry. Integrate decision support into the workflow. Utilize </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">technology to enhance communication with people with diabetes.'</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">}</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">    </span><span style=\"color: #000000; text-decoration-color: #000000; font-weight: bold\">{</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_2'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span><span style=\"color: #000000; text-decoration-color: #000000\">,</span>\n",
              "<span style=\"color: #000000; text-decoration-color: #000000\">        </span><span style=\"color: #008000; text-decoration-color: #008000\">'content'</span><span style=\"color: #000000; text-decoration-color: #000000\">: </span><span style=\"color: #008000; text-decoration-color: #008000\">'Disseminate unblinded quality metrics. Have you enabled everyone in your practice to make </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">high-quality treatment decisions quickly and consistently? (B) When to Use Injectable Therapy in Type 2 Diabetes </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(i) Which therapy should I start first? Treatment with a glucagon-like peptide 1 (GLP-1) receptor agonist or a dual</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose-dependent insulinotropic polypeptide (GIP)/ GLP-1 receptor agonist is preferred before insulin therapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">because of its ability to achieve both glycemic and weight management goals. Some GLP-1 receptor agonists also </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">provide cardiovascular benefit. (ii) When should I start insulin first? If there is evidence of catabolism (e.g., </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">unexpected weight loss) When A1C or blood glucose levels are very high (A1C &gt;10% [&gt;86 mmol/mol] or blood glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">≥300 mg/dL [≥16.7 mmol/L]) (iii) Can I use combination insulin and non insulin injectable therapy? Yes; combination</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy with insulin and a noninsulin injectable is recommended forgreater glycemic effectiveness and beneficial </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">effects on weight andypoglycemia risk.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_3'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'If insulin is already being used, insulin dosing should be reassessed upon addition or dose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">escalation of a GLP-1 or dual GIP and GLP-1 receptor agonist. (iv) When would I use combination insulin and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">noninsulin injectable therapy? Consider combination insulin and GLP-1 or dual GIP/GLP-1 receptor agonist therapy </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">when individualized goals are not met using either one separately. (V) When should I modify a patient’s injectable </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy? Intensify or deintensify therapy when an individual is not meeting treatment goals, including management </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of hyperglycemia and weight and avoidance of hypoglycemia. (B) GOALS: Cardiovascular Risk Reduction in High-Risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Individuals with Type 2 Diabetes: Achieved alongside comprehensive cardiovascular risk management. Achievement and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Maintenance of Glycemic and Weight Management Goals: Set individualized weight management goals. Choose glycemic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">management approaches that balance efficacy and risk. Consider metabolic surgery for eligible patients.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_4'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Initial Treatment Decisions: Assessment of Cardiovascular Disease (CVD) Risk: For patients with</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">atherosclerotic cardiovascular disease (ASCVD) or indicators of high risk (varying conditions like myocardial </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">infarction, stable angina, or asymptomatic coronary artery disease), consider medications like GLP-1 RA with proven</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">CVD benefit or SGLT2i with proven CVD benefit. Heart Failure (HF) and Chronic Kidney Disease (CKD) Considerations: </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">For patients with HF or prior HF symptoms, consider SGLT2i with proven HF benefit. For CKD patients (eGFR &lt;60 </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">mL/min), the decision hinges on the severity, typically recommending continuation of SGLT2i until initiation of </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">dialysis or contraindication. Follow-Up Treatment Adjustments Based on A1C Levels: If A1C Above Target: For </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients on a GLP-1 RA, consider adding an SGLT2i with proven CVD benefit, or vice versa. Reassess therapeutic </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">inertia and modify treatment based on DSME/S support and technological tools like continuous glucose monitoring </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">(CGM) to identify gaps.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_5'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">\"Additional Considerations for Glycemic Lowering: If more substantial cardiovascular risk </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">reduction or further glycemic control is needed, consider additional drugs or therapy adjustments, based on the </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individual's response and tolerability. Medication Efficacy for Glycemic and Weight Control: Efficacy for Glucose </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Lowering: High efficacy medications include GLP-1 RA and SGLT2i. Moderate efficacy options are DPP-4 inhibitors and</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Metformin. Efficacy for Weight Loss: Very high: Semaglutide, Tirzepatide. High: Dulaglutide, Liraglutide. </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">Intermediate: Not listed above; generally includes other GLP-1 RAs and SGLT2i. Neutral: DPP-4i, Metformin. (c) </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">To-Do List for Clinicians Treating People With Insulin Therapy Provide or refer patients for education about </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">injection technique and timing and problem-solving for issues related to insulin therapy (e.g., hypoglycemia, </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">missed or incorrect doses, and dose adjustments). .\"</span>\n",
              "    <span style=\"font-weight: bold\">}</span>,\n",
              "    <span style=\"font-weight: bold\">{</span>\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content_id'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'d_14_cont_6'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'doc_name'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Pharmacologic Approaches to Glycemic Treatment'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'summary'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'The management of diabetes, particularly for Type 1 and Type 2, emphasizes proactive and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patient-centered strategies to prevent therapeutic inertia and optimize treatment outcomes. It involves empowering </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">patients through dedicated diabetes visits, setting and tracking shared goals, and addressing social and emotional </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">barriers. Treatment is tailored using a team-based approach that includes regular screening and rapid adjustment of</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">therapy based on continuous glucose monitoring (CGM) and A1C data. For Type 2 diabetes, injectable therapies like </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are preferred over insulin initially due to their </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">benefits on glycemic control, weight management, and cardiovascular risk. Insulin therapy is recommended in cases </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">of significant hyperglycemia or catabolic symptoms, and can be combined with GLP-1 for enhanced efficacy. The </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">approach also integrates comprehensive cardiovascular risk management, adjusting treatments based on individual </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">health status, and ensuring continuous education and support to manage insulin therapy effectively. This integrated</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">care model aims to achieve and maintain glycemic control, reduce cardiovascular risk, and enhance overall patient </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">well-being.'</span>,\n",
              "        <span style=\"color: #008000; text-decoration-color: #008000\">'content'</span>: <span style=\"color: #008000; text-decoration-color: #008000\">'Ensure that individuals have all supplies necessary for injections (e.g., pen needles for </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">insulin pens or appropriate syringes for insulin dose size or concentration) and glucose monitoring. . Evaluate </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">individuals with type 2 diabetes to determine whether they are candidates for GLP-1 or dual GIP/GLP-1 receptor </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">agonist therapy. . Evaluate all people on insulin therapy to determine whether they could benefit from continuous </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">glucose monitoring. . Ensure that people on insulin therapy have the education and supplies needed to prevent and </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treat hypoglycemia, including glucagon, glucose monitoring supplies, and appropriate sources of carbohydrates to </span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">treat low glucose levels. . Schedule timely and routine follow-up visits to reassess patients and adjust care plans</span>\n",
              "<span style=\"color: #008000; text-decoration-color: #008000\">to avoid therapeutic inertia.'</span>\n",
              "    <span style=\"font-weight: bold\">}</span>\n",
              "<span style=\"font-weight: bold\">]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(len(docs))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 33
        },
        "id": "PegnTeqx1ryR",
        "outputId": "d2f2d706-cfd9-49d7-8a6e-cdc26c81c35f"
      },
      "execution_count": 26,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1;36m91\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">91</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "\n",
        "with open('Split_Data_Med.json', 'w') as f:\n",
        "    json.dump(docs, f, indent=4, ensure_ascii=False)"
      ],
      "metadata": {
        "id": "nedPj5KL1UvY"
      },
      "execution_count": 32,
      "outputs": []
    }
  ]
}